



Awareness and enforcement of guidelines for publishing industry-sponsored medical research among publication professionals: the Global Publication Survey

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004780
Article Type:	Research
Date Submitted by the Author:	31-Dec-2013
Complete List of Authors:	Wager, Elizabeth; Sideview Woolley, Karen; ProScribe Medical Communications, Adshead, Viv; KnowledgePoint 360, Cairns, Angela; KnowledgePoint 360, Fullam, Josh; TGaS Advisors, Gonzalez, John; AstraZeneca, Grant, Tom; AstraZeneca, Tortell, Stephanie; KnowledgePoint 360,
Primary Subject Heading:	Medical publishing and peer review
Secondary Subject Heading:	Ethics
Keywords:	MEDICAL JOURNALISM, MEDICAL ETHICS, MEDICAL EDUCATION & TRAINING

SCHOLARONE™
Manuscripts

Only

1
2
3 **Awareness and enforcement of guidelines for publishing industry-sponsored medical**
4
5 **research among publication professionals: the Global Publication Survey**
6
7
8

9 Elizabeth Wager

10 Sideview, Princes Risborough, UK

11 Karen Woolley

12 ProScribe Medical Communications, Noosaville, Australia; Faculty of Health

13 Sciences, University of Queensland, Brisbane, Australia; Faculty of Science, Health,

14 Education and Engineering, Sunshine Coast, Australia

15 Viv Adshead

16 KnowledgePoint360 Group, Macclesfield, Cheshire, UK

17 Angela Cairns

18 KnowledgePoint360 Group, Macclesfield, Cheshire, UK

19 Josh Fullam

20 TGaS Advisors, East Norriton, Pennsylvania, USA

21 John Gonzalez

22 AstraZeneca, Alderley Park, Cheshire, UK

23 Tom Grant

24 AstraZeneca, Alderley Park, Cheshire, UK

25 Stephanie Tortell

26 Complete Medical Communications, Macclesfield, Cheshire, UK *

27 * now at: KnowledgePoint360 Group, Macclesfield, Cheshire, UK

1
2
3 **Corresponding author:** Dr Elizabeth Wager

4
5 Sideview, 19 Station Road, Princes Risborough, HP27 9DE, UK

6
7 email: liz@sideview.demon.co.uk

8
9 phone (+44) (0)1844 275814

10
11 fax (+44) (0)1844 275034

12
13
14
15
16 **Keywords**

17
18 publications, guidelines, drug industry, ethics, data reporting

19
20
21
22
23 **Word count**

24
25 5451 words (excluding abstract, refs, figures, and tables)

26
27
28
29
30 I, Dr Elizabeth Wager, the Corresponding Author of this article contained within the original
31 manuscript which includes any diagrams & photographs, other illustrative material, video,
32 film or any other material howsoever submitted by the Contributor(s) at any time and related
33 to the Contribution ("the Contribution") have the right to grant on behalf of all authors and do
34 grant on behalf of all authors, a licence to the BMJ Publishing Group Ltd and its licensees, to
35 permit this Contribution (if accepted) to be published in BMJ Open and any other BMJ Group
36 products and to exploit all subsidiary rights, as set out in the licence at:
37 http://group.bmj.com/products/journals/instructions-for-authors/BMJOpen_licence.pdf

Abstract

Objectives: To gather information about current practices and implementation of publication guidelines among publication professionals working in or for the pharmaceutical industry.

Design/ Setting: Web-based survey publicised to members of the International Society for Medical Publication Professionals (ISMPP) and other relevant organizations, November 2012 to February 2013.

Participants: 469 individuals involved in publishing industry-sponsored research in peer-reviewed journals, mainly working in pharmaceutical or device companies ('industry', n=144), communication agencies ('agency', n=238) or contract research organizations (CRO, n=15), or as freelancers (n=34). Most respondents (78%) had worked on medical publications for ≥ 5 years and 62% had a PhD/MD.

Results: Over 90% of industry, agency, and CRO respondents routinely refer to Good Publication Practice (GPP2) and the International Committee of Medical Journal Editors' Uniform Requirements. Most respondents (78% industry, 79% agency) received mandatory training on ethical publication practices. Over 90% of respondents' companies had publication guidelines or policies and required medical writing support to be acknowledged in publications (96% industry, 99% agency). Many industry respondents used publication management tools to monitor compliance with company guidelines and about half (46%) stated that their company had formal publication audits. Fewer agencies audited adherence to guidelines but 20% of agency respondents reported audits of employees and 6% audits of freelancers. Of concern, 37% of agency respondents reported requests from authors or sponsors that they believed were unethical, although 93% of these requests were withdrawn after respondents explained the need for compliance with guidelines. Most respondents'

1
2
3 departments (63% industry, 58% agency, 60% CRO) had been involved in publishing studies
4
5 with negative or inconclusive results.
6
7

8 **Conclusions:** Within this survey sample, publication professionals working in or for industry
9
10 were aware of, and applied, major publication guidelines. However, the survey also identified
11
12 specific areas where education and promotion of guidelines is needed to ensure ethical
13
14 publication practices.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article summary

Strengths of this study

- Large-scale, international survey of publication professionals (n=469)
- Focused on awareness and implementation of guidelines relating to responsible publication practice, providing insight into current industry practices
- Included publication professionals (e.g. writers, planners, and managers) working in pharmaceutical and medical device companies, medical communication agencies, contract research organizations, or as freelancers
- Survey allowed anonymous responses

Limitations of this study

- Limited response from freelancers (n=34), journal editors, publishers, and academics (n=38)
- Self-selection bias may mean that respondents were not representative of the total population if those with a particular interest in ethical publication practices were more likely to complete the survey than those with less knowledge or interest

INTRODUCTION

Misleading, inaccurate, or incomplete reporting of clinical trial findings can have serious consequences, since doctors and policy-makers rely on publications when developing treatment guidelines and making decisions affecting patients. The involvement of medical writers and other publication professionals, such as planners and managers, in developing peer-reviewed publications reporting clinical trials has been criticised by some,[1, 2] but defended by others.[3, 4] Similarly, while some studies have shown that publications funded by pharmaceutical companies are of equal or higher quality than publications from academia,[5-7] others have shown that they are more likely to be biased.[8, 9] Concern about irresponsible publication practices, from both within and outside the industry, has led to the creation and evolution of several guidelines.[4, 10-13] These guidelines seek to establish responsible publication practices, increase transparency, and prevent bias and commercial influence in reporting medical research. While many have welcomed such guidelines, critics of the pharmaceutical industry remain unconvinced, for example, commenting “Publicly, they insist that everything has changed.... But my concern is this. Having seen so many codes openly ignored and broken, it’s hard to take any set of voluntary ideals seriously.”[14] Given this concern about whether voluntary guidelines are effective, and because there was little evidence available to show whether continuing concerns about industry publication practices were justified, we sought to generate ‘real world’ evidence about current practices in the medical publications profession.

We therefore carried out a large-scale, international, survey (the Global Publication Survey) to obtain information about the ways in which medical writers and other publication professionals work and, in particular, their awareness of current publication guidelines. We also sought to learn about the processes adopted by pharmaceutical and communications

1
2
3 companies to encourage responsible practices and to implement published guidelines. The
4
5 aim of this survey was to identify areas in which guidelines were understood and enforced,
6
7 areas for improvement, and targets for education and training.
8
9

10 11 12 **METHODS**

13
14 The survey questionnaire (Appendix 1) was developed by an international team including
15
16 professional writers and publication managers with experience of working in pharmaceutical
17
18 and communications companies and in a freelance capacity. Several team members had been
19
20 involved in developing publication guidelines (see the author list and acknowledgements for
21
22 details). Question topics were based on results of a previous survey of members of the
23
24 International Society for Medical Publication Professionals (ISMPP). Question and answer
25
26 options were discussed, drafted, and refined by the team. Question types included multiple
27
28 choice (check one/check all), matrix table, rating (1-5 scale), ranking (top 3), dropdown
29
30 selection, and free text. Logic checks limited the number of questions respondents saw based
31
32 on 'skip logic' (i.e. some questions only appeared if the respondent answered 'yes' to an
33
34 earlier question). 'Not applicable', 'Don't know', and 'Other (specify)' responses were
35
36 offered to capture the full range of possible responses.
37
38
39

40
41
42 The questionnaire was transcribed to an online data capture tool hosted by Qualtrics
43
44 (www.qualtrics.com) survey technology. Pilot testing for question content, flow, and logic
45
46 was performed by team members, and the survey was revised as necessary.
47
48
49

50
51
52 Respondents saw a different selection of questions depending on their work sector
53
54 (categorised as: pharmaceutical or medical device company, agency, contract research
55
56 organization [CRO], freelance, journal editor, publisher, or academic) and their previous
57
58
59
60

1
2
3 answers. Respondents answered, on average, about 40 questions. A response was required for
4
5 each question before the next screen was displayed but users had the option to revisit
6
7 previously completed questions. Optional questions were included at the end of the core
8
9 survey allowing participants to offer additional comments.
10

11
12
13
14 The survey was announced on 28th November 2012 via email to all members of ISMPP
15
16 (n=1105). A link included in the email provided individual access to the survey (so each
17
18 recipient could respond only once and reminders could be sent to non-responders). ISMPP
19
20 members were also encouraged to share an unrestricted link to the survey with individual
21
22 colleagues or via their company intranet. The survey was also promoted via social media
23
24 (LinkedIn and Twitter). Several organizations and companies (including the American
25
26 Medical Writers Association, the European Medical Writers Association, the European
27
28 Association of Science Editors, the Committee on Publication Ethics, McCann Complete
29
30 Medical, and Excerpta Medica) publicised the survey to their members or on their websites
31
32 through December 2012. The survey closed on 18th February 2012.
33
34
35
36
37

38 Respondents could complete the survey anonymously but, to encourage participation, had the
39
40 option of supplying an email address to enter a draw for one of two iPad tablet computers.
41
42 Participants were informed that their personal information would not be shared beyond those
43
44 administering the survey. Respondent-level data was available only to TGaS Advisors who
45
46 were responsible for all aspects of survey administration and data aggregation, and was not
47
48 shared with the survey organizers or sponsors. Descriptive statistics using frequencies and
49
50 percentages were used. Funding for the incentive prizes was provided by ISMPP. The team
51
52 members who developed the questionnaire and executed the survey, interpreted the data, and
53
54
55
56
57
58
59
60

1
2
3 developed this publication, worked in their own time or during work time with permission
4
5 from their various employers but without specific funding or payment.
6
7

8
9
10 Research Ethics Committee (Internal Review Board) approval was not required for this
11
12 survey, as it did not relate to personal medical information, did not involve patients or
13
14 healthcare professionals (other than in their role as journal editors), was not carried out by an
15
16 academic institution, and participation was entirely voluntary.
17
18
19

20 21 **RESULTS**

22 23 **Respondents**

24
25 The survey reached the intended international target audience with responses from 23
26
27 countries. The largest responses came from the USA (44%) and UK (39%). Of the 490 who
28
29 opened the survey invitation, 469 confirmed that they were involved in publishing industry-
30
31 sponsored research in peer-reviewed medical journals and completed the survey (Table 1).
32
33 Most respondents (92%), worked in pharmaceutical or medical device companies (termed
34
35 'industry' respondents; 31%), medical communications agencies (termed 'agency'
36
37 respondents; 51%), or contract research organizations (CROs 3%) providing publication
38
39 services to drug and device manufacturers, or as freelancers (7%). The survey was also
40
41 completed by 5 journal editors, 17 publishers, 9 academics and 7 people working in other
42
43 roles – results from these categories (total = 8%) are not reported in the text due to the low
44
45 response rate and small numbers but may be viewed at QQQ. Because of the responsive
46
47 design, the numbers answering each question varied – the full data tables are available at
48
49 QQQ. Most respondents took 20-30 minutes to complete the survey.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Because of the methods used to promote the survey, it was not possible to calculate a
4
5 response rate. However, the membership of ISMPP at the time of the survey was 1105 and
6
7 the response rate from ISMPP members was 20% (i.e. 221 of the respondents responded via
8
9 the individual links sent out to ISMPP members).
10

11
12
13
14 Most respondents were highly educated (56% had a doctorate) and experienced (79% had
15
16 worked with medical publications for at least 5 years) (Table 1). Half of the respondents
17
18 worked in departments that had been involved with over 30 manuscripts in the last year.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Respondent characteristics

Characteristic	Number	Percentage
Workplace:		
industry ¹	144	31
agency or CRO ²	238	51
CRO ³	15	3
freelance	34	7
other	38	8
Experience of working with peer-reviewed publications:		
<2 years	36	8
2-4 years	66	14
5-9 years	111	24
10 years or more	256	55
Qualification: ⁴		
Masters degree	111	24
Doctorate	263	56
MD / medical qualification	26	6
Other	26	6
Certified Medical Publication	161	34
Professional (CMPP)		

¹Pharmaceutical, biotech or medical device company

² Communications company

³ Contract research organization

⁴ Respondents were asked to tick all that applied

Awareness of guidelines

Almost all industry and agency respondents were aware of international guidelines on responsible publication practices (Fig 1). Overall, 91% stated that they routinely referred to Good Publication Practice (GPP2) and 93% to the International Committee of Medical Journal Editors' Uniform Requirements for guidance on ethical practice. Other sources of guidance consulted routinely by respondents in all sectors included ISMPP (71%), medical writers associations (e.g. AMWA and EMWA: 39%), and the Committee on Publication Ethics (COPE: 34%).

Training

Regular training on ethical publication practices was compulsory for most respondents in industry and agencies. Mandatory training for employees was reported by 78% of industry, 79% of agency, and 93% of CRO respondents. In addition, 68% of agency respondents reported that their industry customers provided mandatory training for agency personnel. Training at least once a year was reported by 70%, 68% and 71% for industry, agency and CRO respondents respectively. Just over half the industry respondents (55%) reported that their companies provided training for agency staff or freelancers but only 17% of agency and 20% of CRO respondents reported that their organization provided training for freelancers (while 43% and 53% respectively didn't know if freelancers were trained). Similarly, 24% of the freelancers (5/21) reported that they received mandatory training from industry or agency customers.

Respondents kept up-to-date on current guidelines primarily via training provided by their organization (64%), from professional associations (68%), and monitoring the literature (70%).

Company codes of conduct and publication policies

In addition to their awareness of external guidelines on ethical publication practices (e.g., GPP2), most respondents were aware of internal guidelines governing publication practices. Overall, 78% of respondents worked in an organization that had a Code of Conduct governing ethical publication practices. Nearly all the industry (94%) and agency (94%) respondents and all the CRO respondents (15/15) stated that their company had guidelines or a policy on ethical publication practices (5 industry and 8 agency respondents stated their company did not have such a policy while 3 and 7, respectively, did not know) (Fig 1).

Most company guidelines and policies are not publicly available: only 38% of industry, 35% of agency, and 33% of CRO respondents reported that these documents were publicly accessible (e.g. posted online) (Figure 2).

Of the industry respondents, 67% stated that their company was committed to peer-reviewed publication of results of all studies in humans. Exceptions to this commitment were studies for which companies did not have control (e.g. investigator-initiated studies) (reported by 21) and Phase 1 studies (i.e. early-phase drug development) (reported by 14).

Public disclosure of trial results was reported, by those working within the industry, to be fulfilled by: posting results on a public register (92%), publishing in a peer-reviewed journal (73%), publishing a conference abstract (51%), posting results on a company website (28%), or a combination of these. When asked about the timing of journal publications, most industry respondents reported that their company policy was to submit a manuscript within 12 or 18 months of study completion (last subject, last visit) (43% and 18% respectively).

1
2
3 Nevertheless, 24% of industry respondents reported that their company did not have a target
4
5 deadline for submitting a manuscript after trial completion (Figure 2).
6
7

8
9
10 Similar proportions of industry and agency respondents (80% and 81% respectively) reported
11
12 that authorship obligations were set out in formal agreements before manuscript development
13
14 (Fig 1). Almost all industry (96%) and agency (99%) respondents, and 100% of CRO
15
16 respondents, reported that their department ensured that authors acknowledge professional
17
18 medical writing support in every publication (Fig 1). Only one respondent from each of the
19
20 industry and agency groups answered no to this question. However, 11% of respondents from
21
22 both industry and agency, and 13% from CROs, were aware of academic authors initially
23
24 refusing to acknowledge professional writing support in the last 12 months.
25
26
27
28

29 **Compliance with codes**

30
31 Respondents from industry, and to a lesser extent from agencies, had their publication
32
33 practices subjected to compliance checks. Of the industry respondents, 61% stated that their
34
35 company had a formal process for monitoring adherence to company standards and 66 of
36
37 these (46% of the total) carried out publication audits. A very similar response was obtained
38
39 from those working in CROs (60% and 47% respectively). However, of the agency
40
41 respondents, 44% reported that their company had formal compliance monitoring for internal
42
43 standards and only 20% carried out publication audits. In addition, about half the industry
44
45 respondents (47%) reported that their company had a formal process for monitoring third-
46
47 party providers' adherence with company standards and 75% of these reported that this
48
49 involved an audit. Agency and CRO respondents stated that some (43%, 47% respectively),
50
51 most (19%, 0%), or none (6%, 13%) of their customers had formal, regular processes such as
52
53 knowledge tests or audits for monitoring suppliers' adherence to the customer's standards,
54
55
56
57
58
59
60

1
2
3 while 27% of agency and 40% of CRO respondents did not know if their customers did this.
4
5 Agency and CRO respondents also reported that their customers used publication
6
7 management tools to assess compliance (only 6% and 13% respectively reported that no
8
9 customers did this).
10

11
12
13
14 Of the industry respondents, 52% worked in a company operating under a US Government
15
16 'Corporate Integrity Agreement' (CIA: see [https://oig.hhs.gov/compliance/corporate-](https://oig.hhs.gov/compliance/corporate-integrity-agreements/index.asp)
17
18 [integrity-agreements/index.asp](https://oig.hhs.gov/compliance/corporate-integrity-agreements/index.asp)), which typically requires formal compliance checking.
19
20

21 22 23 **Organization of publication activities**

24
25 Publication activities were primarily governed by medical departments; publications were
26
27 rarely funded, or approved, by commercial departments (Fig 1). According to the industry
28
29 respondents, the budget for peer-reviewed publications was usually held by the medical
30
31 affairs (72%) or clinical development (24%) departments. Nevertheless, seven respondents
32
33 (5%) stated that the publications budget was held by a commercial department (e.g. sales or
34
35 marketing) (Fig 2). Involvement of members of commercial departments in developing
36
37 publications varied, with industry respondents stating that they were: not involved (27%),
38
39 provided with information only (48%), members of the publication team (44%), allowed to
40
41 suggest target journals for author consideration (22%), involved in reviewing manuscripts for
42
43 accuracy (19%), or part of a formal approval process (5%).
44
45
46
47
48

49 50 **Agency response to requests for perceived unethical practices**

51
52 Respondents were often, but not always, successful in preventing publication practices they
53
54 considered unethical. Of the agency respondents, 38% were aware, in the past 12 months, of
55
56 their company being asked by an author or a sponsor to do something that they believed
57
58
59
60

1
2
3 contravened ethical practices (10% once and 28% more than once) while 2/15 CRO
4
5 respondents (13%) reported such requests. Respondents reported that their agency's response
6
7 was to explain the need for compliance, resulting in the request being withdrawn or amended
8
9 (92% and both CRO cases), or to refuse to accept the work (1%); however, 3% (3/90) stated
10
11 that the agency ultimately complied with the request.
12
13

14
15
16 Although a slightly higher proportion of freelancers (17/34, 50%) reported requests which
17
18 they believed constituted unethical practices, this should not be over-interpreted due to the
19
20 small group size; 12% (2/17) of freelancers accepted such work.
21
22

23 24 25 **Information provided to authors**

26
27 Authors were routinely provided with various documents and data sources to facilitate
28
29 manuscript preparation. These documents included (for agency and industry respondents
30
31 respectively): clinical study report (81%, 79%), study protocol (79%, 83%), summarized data
32
33 (67%, 66%), statistical report (58%, 62%), manuscript outline (58%, 56%), statistical
34
35 analysis plan (42%, 54%), and raw data/data tables (42%, 42%).
36
37
38
39

40 41 **Enforcement of authorship criteria**

42
43 Respondents actively enforced compliance with authorship criteria (Table 2).
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2

Responses to the question “In the last 12 months, to your knowledge, how often has your department recommended to the lead author the removal of a co-author from a manuscript or abstract that was in development?”

	Never	Once	More than once	Other	Don't know
Industry (n=144)	44% (64)	10% (15)	22% (32)	2% (3)	21% (30)
Agency (n=238)	24% (58)	11% (26)	35% (84)	3% (6)	27% (64)
CRO* (n=15)	27% (4)	33% (5)	7% (1)	7% (1)	27% (4)
Freelance (n=34)	74% (25)	9% (3)	15% (5)	3% (1)	0

*Contract Research Organization

Of the industry respondents, 33% were aware of an author being removed from a manuscript within the last 12 months and 94% stated that this was due to the individual not meeting authorship criteria. Other reasons for recommending removal of an author included individuals leaving the company (28%) or not agreeing to adhere to ethical publication practices (13%) (respondents could select more than one reason). Three respondents from industry and two from agencies reported authors being removed because they disagreed with

1
2
3 the interpretation of the data. Eight freelancers reported recommending the removal of an
4
5 author, in all cases because the individual did not meet authorship criteria.
6
7

8 9 10 **Publishing negative findings**

11 Most industry respondents' companies attempted to publish negative or inconclusive results.
12
13 Of the industry respondents, 63% reported that their department had supported the
14
15 publication of a study with negative or inconclusive results (17% stated that this had not
16
17 happened and 19% did not know). Only six respondents (4%) were aware of a negative or
18
19 inconclusive study for which publication was not planned, in three cases this was due to the
20
21 discontinuation of product development. Responses were similar in the agency (and CRO)
22
23 groups, with 58% (60%) aware of the publication of negative findings and 6% (13%) being
24
25 aware of negative findings for which publication was not planned. Of the freelancers, 38%
26
27 had been involved with the publication of negative findings in the last 12 months.
28
29
30
31
32
33

34 **Freelance responses**

35
36 Only 34 freelance publication professionals responded to the survey and some of these did
37
38 not answer all questions, therefore the results may not be representative and should not be
39
40 over-interpreted. However, the following findings were noteworthy: 12/34 (35%) did not
41
42 know whether their customers had publication guidelines; 15/21 (71%) stated that they did
43
44 not receive mandatory training; and 21/34 (62%) stated that their clients did not have formal,
45
46 regular processes to monitor their adherence to standards. However, freelancers reported
47
48 routinely consulting published guidelines (100% for ICMJE, 91% for GPP2) on ethical
49
50 issues.
51
52
53
54
55
56
57
58
59
60

DISCUSSION

This is one of the largest, international surveys designed to capture information about current knowledge and implementation of publication guidelines within the pharmaceutical, medical device, and medical communications industries. Our survey showed high levels of knowledge of the various publication guidelines among publication professionals, with over 90% of respondents stating that they routinely referred to them. Although these published guidelines (such as GPP2) are not generally enforced by legislation, most companies have codes of conduct, policies, or internal guidelines that reflect and enforce them. Similarly, most companies (industry and agencies) provide mandatory training to internal staff, while many pharmaceutical and medical device companies also train agency personnel who develop publications on their behalf. The relatively low rates of training and auditing of freelancers suggested in this survey (albeit from a small number of respondents), however, may represent a problem that companies, agencies, and authors who work with freelancers should address.

Many pharmaceutical companies in the USA currently operate under Corporate Integrity Agreements (CIAs). For such companies, many aspects of good publication practice are legally enforced. An analysis of 12 such agreements issued from 2009 to mid-2012 showed that they included requirements for author agreements, publication plans, and the posting of study results.[15] The CIA requirements were consistent with GPP2 and the ICMJE guidelines and also mandated training and reporting. CIA requirements apply not only to the pharmaceutical company but also to their management of any third-party suppliers, therefore, they will also affect many agencies, freelancers, and CROs. Similarly, even companies without a CIA often require suppliers to follow their policies. Therefore, for many agencies and freelancers, failure to follow a customer's policy could mean loss of future business, thus the underlying guidelines are viewed as compulsory rather than optional.

1
2
3
4
5 The importance with which guidelines are viewed is reflected in the effort (and therefore time
6
7 and money) companies invest in monitoring compliance. Our survey found that many
8
9 pharmaceutical and device companies have formal monitoring processes including
10
11 publication audits. Since our survey may have included several respondents from the same
12
13 company, the results cannot indicate precisely what proportion of companies have such
14
15 processes but it is probably well over half. The fact that fewer agencies appear to audit to
16
17 their own internal standards is not surprising, since many reported being regularly audited by
18
19 their customers. However, rates of training and auditing of freelancers (by pharmaceutical
20
21 companies and agencies) is less reassuring and suggests room for improvement.
22
23
24
25
26

27 Many companies use specialist publication planning software (such as Datavision™ or
28
29 PubSTRAT™). Our survey shows that such tools are used not only for publication project
30
31 management but also to monitor and demonstrate compliance with company procedures, for
32
33 example, by ensuring that all authors have approved a manuscript outline, drafts, and the final
34
35 version.
36
37
38
39
40

41 Lack of transparency surrounding company involvement, non-disclosure of competing
42
43 interests, and misleading authorship have been causes for concern in industry-sponsored
44
45 publications in the past.[16] In particular, the occurrence of ‘ghost-writing’ (i.e.
46
47 unacknowledged use of medical writers) and guest or honorary authorship (i.e. named authors
48
49 not fulfilling journal authorship criteria) were spurs for the development of both general and
50
51 specific guidelines.[3, 4, 11, 17] It is therefore encouraging that 96-100% of respondents
52
53 (working in pharmaceutical and medical device companies, agencies, and CROs) stated that
54
55 their department ensured that medical writers were acknowledged (thus preventing the
56
57
58
59
60

1
2
3 medical writers from being 'ghost writers'). Of concern, however, is the fact that some
4
5 academic authors apparently continue to be reluctant to acknowledge writing support.
6

7
8 Although publication professionals can alert authors about the need for disclosure, academic
9
10 institutions clearly have an educational role to play.
11

12
13
14 The ICMJE authorship criteria (which are widely endorsed by medical journals and which
15
16 were revised after the survey) state that listed authors should have made substantial
17
18 contributions to both the research and its publication. Therefore authorship cannot be
19
20 determined until a publication is developed. Individuals involved with the research being
21
22 reported may be invited to become authors, but will not qualify unless they also take an
23
24 active role in the publication. It is therefore encouraging that our survey found that not only
25
26 industry sponsors of research, but also publication agencies and freelancers working for them,
27
28 actively enforce authorship criteria by suggesting that individuals should be removed from
29
30 author listings if they fail to meet the ICMJE or other agreed criteria (see Table 2). It can take
31
32 considerable courage for a freelancer or agency employee to suggest that a proposed author
33
34 has not contributed sufficiently to merit being listed, especially if that person is a senior
35
36 academic or well-known expert. Being the one to identify a guest author carries the risk of
37
38 damaging relationships and possibly work prospects. However, arguably there is an even
39
40 greater and more serious risk of damaged relations, reputations, and work prospects if a
41
42 publication professional fails to raise authorship concerns which are later raised by a journal.
43
44 Early clarification of authorship obligations should reduce the risk of guest authorship and it
45
46 was encouraging that most respondents reported that authorship agreements were confirmed
47
48 before manuscript preparation started.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 As we cannot tell how often proposed authors fail to contribute to publications, our survey
4 cannot show how often this is overlooked, but the fact that almost one-third of industry
5 respondents were aware of instances of authors being removed because they did not meet
6 authorship criteria suggests that guidelines are being enforced. However, this question also
7 revealed that three industry (2%) and two agency (0.8%) respondents were aware of authors
8 being removed from publications because they disagreed with the interpretation of the
9 findings. We cannot tell how many cases these represent, since several respondents may have
10 reported the same case, nor can we tell whether the disagreements about interpretation were
11 with the sponsor (which would be concerning) or between co-authors, but this issue needs
12 further scrutiny.
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 The difficulties of interpreting the ICMJE authorship criteria in some situations have been
28 examined in a study coordinated by the Medical Publishing Insights and Practices (MPIP)
29 Initiative.[18] Using vignettes presenting ‘challenging real-world authorship scenarios’ this
30 study found that journal editors, clinical investigators, medical writers, and publication
31 planners had different views about who qualified for authorship and suggested that additional
32 guidance might be helpful.
33
34
35
36
37
38
39
40
41
42

43 **Limitations**

44 We had originally hoped to compare or confirm responses from publication professionals
45 with those from journal editors and academic investigators, however, we were less successful
46 in promoting the survey among these groups than among publication professionals and
47 consider the response from these sectors too small to be reliable. The number of responses
48 from freelance publication professionals was also disappointing and it is therefore important
49 not to over-interpret the findings from this group. Care should also be taken in extrapolating
50
51
52
53
54
55
56
57
58
59
60

1
2
3 proportions of respondents to proportions of companies or agencies, since we had no way of
4
5 measuring the numbers of respondents per company.
6

7 We also recognise that our survey, like many others, carried the risk of self-selection bias.
8

9
10 Our survey was promoted mainly via professional organizations such as ISMPP and
11
12 AMWA/EMWA which promote ethical publication practices. Those choosing to respond to a
13
14 survey supported by these associations may be more likely to follow and report ethical
15
16 publication practices. Our respondents therefore may not be representative of all publication
17
18 professionals and may be better informed about the topics covered by this survey and more
19
20 aware of guidelines (e.g. from attending professional meetings or taking part in educational
21
22 activities). We also acknowledge that our respondents came primarily from higher-income
23
24 countries. Our findings may not be applicable to publication practices in lower-income
25
26 countries, particularly given the significant influence of country income on publication
27
28 practices. [5, 19]
29
30
31
32
33

34 **Comparison with other surveys**

35
36 Journal editors' awareness of various guidelines was measured in 2007 in an international
37
38 survey to which 111 editors of biomedical journals responded.[20] This survey noted that
39
40 "awareness and use of guidelines and other resources on publication ethics was generally
41
42 low". Over half the editors (55%) reported being unaware of the ICMJE Uniform
43
44 Requirements and two-thirds (67%) were unaware of the GPP guidelines, while the
45
46 proportion of editors reporting that they had used these guidelines were just 24% and 9%
47
48 respectively. This represents a marked contrast to the publication professionals responding to
49
50 our survey, over 90% of whom reported that they routinely referred to these two guidelines.
51
52
53
54
55
56
57
58
59
60

1
2
3 Another survey of 183 editors of high-impact medical journals in 2009 found that, although
4
5 76% had received training in medical editing, they performed poorly when answering
6
7 questions about: authorship (only 30% gave 'correct' answers, i.e. consistent with commonly
8
9 cited guidelines), plagiarism (17% correct), peer review (16% correct), and conflicts of
10
11 interest (15% correct).[21]
12
13

14
15
16 A 2012 survey of 294 healthcare professionals found that 42% were unaware of the GPP
17
18 guidelines.[22] This survey also found that the doctors (69% of whom were authors on peer-
19
20 reviewed articles) were unfamiliar with, or disagreed with, the ICMJE authorship criteria,
21
22 since a considerable proportion considered that data collection (51%) or general supervision
23
24 of a laboratory (33%) alone were criteria for authorship. Nevertheless, 66% of respondents in
25
26 the healthcare practitioners survey stated that they would be concerned about 'the
27
28 involvement of pharmaceutical employees as authors or reviewers of a draft manuscript'. A
29
30 smaller survey of surgeons in Croatia (in 2011) found that only 54% (31/57) were aware of
31
32 the ICMJE guidelines although 74% (43/58) of the respondents had worked on at least 2
33
34 manuscripts for publication in the last 2 years.[23]
35
36
37
38
39

40
41 A large-scale, repeated survey of medical writers (who were nearly all members of AMWA
42
43 or EMWA),[24] which attracted 746 responses in 2005, and 662 in 2008, found lower levels
44
45 of familiarity with guidelines than the current survey (carried out in 2012) but showed that
46
47 awareness had risen between 2005 and 2008. For example, the proportion of respondents
48
49 claiming to be familiar with ICMJE guidelines rose from 54% in 2005 to 75% in 2008. The
50
51 figures for GPP were 43% and 58%, and for the EMWA guidelines (published in 2005) 27%
52
53 and 46% respectively in 2005 and 2008. The AMWA/EMWA survey also asked writers
54
55 about their experience of being involved with unacknowledged writing work (i.e.
56
57
58
59
60

1
2
3 ghostwriting). In 2005, 39% stated that this practice had decreased in the last 5 years (52%
4 stated that it was unchanged and 8% that it had increased). In 2008, 63% considered that
5 ghostwriting had decreased, 30% stated that it was unchanged and 6% that it had increased in
6 the last 5 years. The proportion of professional writers reporting that they always requested
7 acknowledgement for a substantial contribution to a manuscript also rose from 25% in 2005
8 to 43% in 2008. The survey was repeated in 2011 (with 620 respondents)[25] and responses
9 showed a clear decrease in the proportion of manuscripts (not necessarily all for peer-
10 reviewed journals) with undisclosed contributions (i.e. ghostwriting) which fell from 62% in
11 2005, to 42% in 2008, and 33% in 2011.

12
13
14
15
16
17
18
19
20
21
22
23
24
25 Ghostwriting of review articles commissioned by pharmaceutical companies was a particular
26 concern when the first GPP guidelines were developed.[26] A survey of authors published in
27 six, high impact general medical journals found a decline in ghost authorship between 1996
28 and 2008, and a significant decrease (from 26% to 15%) in honorary authorship (which often
29 accompanies ghostwriting) for review articles and editorials (although not for other types of
30 article).[27]

31
32
33
34
35
36
37
38
39
40
41 Our survey did not get sufficient response from academics to draw any conclusions about
42 their understanding of their role as authors of medical publications. We hope that the full
43 report of the MPIP authorship project will cast more light on this.[18]

44 45 46 47 48 49 **RECOMMENDATIONS**

50
51 While many of our findings are heartening (Fig 1), some indicate a need for further action
52 (Fig 2). We hope that the professional organizations who were involved with this survey (in
53 particular, ISMPP, AMWA, and EMWA) along with pharmaceutical and medical device
54
55
56
57
58
59
60

1
2
3 companies will use the findings to identify topics for future training or discussion. We
4
5 suggest they might focus on the following areas.
6

- 7
8 • Although many companies and agencies had publication policies, it is disappointing
9 that so few of these policies were made public. We encourage companies to post their
10 publication policies on their websites. Companies might also consider publishing the
11 results of publication audits to indicate how closely they comply with guidelines (for
12 example, what proportion of clinical trials are published) and to help identify
13 obstacles to compliance.
14
- 15 • While our survey suggests that most pharmaceutical companies and agencies have a
16 code of conduct and provide mandatory training on responsible publication practices
17 to relevant staff, this is not always the case, and there is room for improvement,
18 especially for those that sub-contract work to freelancers. We therefore recommend
19 that companies, agencies, and professional groups (such as ISMPP, EMWA, and
20 AMWA) put renewed effort into ensuring that all publication professionals receive
21 effective training. Freelancers should be accountable for their own training, or ensure
22 they receive sufficient training from their customers. We also recommend that
23 individuals involved less directly in publications should be made aware of the relevant
24 guidelines.
25
- 26 • Although pharmaceutical companies generally provide invited authors with study
27 reports and protocols, this was not universal. Named authors should always have
28 access to study results to ensure they can understand and interpret the findings.
29
- 30 • The reported requests from authors or companies for agency staff to do something
31 that the publication professionals considered unethical warrants further investigation.
32 Our survey did not ask about reporting mechanisms for perceived unethical practices,
33 or how strongly these are communicated and used. We encourage agencies to develop
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 systems for handling such situations. Further education of authors and industry staff,
4
5 particularly those who are not familiar with the stringency of current guidelines,
6
7 should help reduce such requests.
8

- 9
10 • The number of freelancers responding to the survey was small (<50), but some of
11
12 their responses suggested differences from publication professionals working in
13
14 companies. We therefore hope a similar survey might be undertaken focusing on the
15
16 needs of this community and their publication practices to better understand areas
17
18 where they may need support.
19

20
21
22
23 These suggested actions focus primarily on pharmaceutical companies and communications
24
25 agencies. However, clinical trials and their publication involve many players, and other
26
27 surveys suggest that both healthcare professionals (investigators and academics) and journal
28
29 editors would benefit from greater knowledge of published guidelines and may, in fact, be
30
31 less familiar with such guidelines than publication professionals. Given the financial and
32
33 human resources required to ensure timely, accurate, and complete reporting of research
34
35 results,[28] it is likely that the demand for, and use of, publication professionals will increase.
36
37 Our survey findings indicate that further involvement of knowledgeable and experienced
38
39 medical publication professionals, who are familiar with guidelines on reporting clinical trials
40
41 and publication ethics, should be viewed as a positive step in achieving timely and reliable
42
43 reporting. Our survey findings also complement evidence which shows that manuscripts
44
45 prepared with professional writing or editing support are more likely to comply with
46
47 reporting requirements,[29] less likely to be retracted for misconduct,[5] and are accepted for
48
49 publication more quickly,[30] than those prepared without such support.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Authorship of research publications is not straightforward and the ICMJE criteria have
4
5 recently been revised. Our survey did not examine views on existing criteria or problems with
6
7 their implementation, although others have done so.[31, 32] We are aware of current
8
9 initiatives aimed at deepening understanding and developing consensus around authorship
10
11 and the transparency of contributions and we welcome these. We would also welcome
12
13 surveys that test how well non-industry authors and editors comply with voluntary guidelines
14
15 issued by their professional associations and how such compliance is checked.
16
17
18
19

20 21 **CONCLUSIONS**

22
23 Despite criticism that most publication guidelines are voluntary, our survey suggests that the
24
25 major guidelines are widely known and implemented by publication professionals working in
26
27 pharmaceutical and medical device companies, communication agencies, CROs, and as
28
29 freelancers. Many companies enforce these guidelines through policies, codes of conduct,
30
31 standard operating procedures, and audits. For companies operating under a CIA, many of the
32
33 GPP and ICMJE recommendations are mandated and audited by the Office of the Inspector
34
35 General via independent auditors. When the GPP guidelines were first developed (in the late
36
37 1990s), publication audits were unheard of, yet many companies now regularly audit their
38
39 practices against guidelines such as GPP2, and CIAs mean that many of the GPP
40
41 recommendations are now legally enforced and monitored.
42
43
44
45
46

47
48 While there is no room for complacency, and we make no claim that all problems with the
49
50 publication of industry-funded research have disappeared, this survey, taken together with
51
52 others showing improved acknowledgement of medical writers, and reductions in guest
53
54 authorship, suggest that guidelines such as GPP (published in 2003) and GPP2 (2010) have
55
56
57
58
59
60

1
2
3 had a definite, positive effect on publication practices and that most companies and individual
4
5 publication professionals are striving to do the right thing.
6
7

8 9 **Acknowledgements**

10 We thank the organizations and individuals that helped publicise and execute the survey, in
11
12 particular Mike Smith (Alphabiocom) and Fiona Steinkamp (NovoNordisk). We also thank
13
14 Dr Serina Stretton (ProScribe Medical Communications) for her assistance with the figures.
15
16
17
18
19

20 21 **Contributions**

22 All authors were involved in developing the questionnaire and analysing or interpreting the
23
24 data. All authors reviewed the manuscript and discussed it critically over several revisions,
25
26 and agreed to submit it for publication. In addition, EW wrote the first draft of the paper, JF
27
28 was responsible for data management and analysis, and KW presented initial findings at the
29
30 2013 ISMPP meeting and prepared the figures.
31
32
33
34
35
36
37
38
39
40
41
42

43 **Competing interests**

44 EW is an author of the original GPP guidelines, the anti-ghostwriting checklist, the EMWA
45
46 guidelines on the role of medical writers in publications, and several COPE guidelines. She
47
48 works as a freelance publications consultant and has provided training to many
49
50 pharmaceutical companies and communication agencies and receives fees and expenses for
51
52 talks and workshops on publication guidelines.

53 KW conducts and publishes research on ethical medical writing practices. She is actively
54
55 involved in not-for-profit associations that advocate for ethical publication practices. She is
56
57 paid to provide ethical medical writing training courses and services for not-for-profit and
58
59 for-profit clients, particularly in the Asia-Pacific region.

60 AC has served on the ISMPP Certification Board of Trustees.

1
2
3 ST is the chair of the ISMPP Advocacy and Outreach Committee.
4

5 AC, VA and ST are employed by a medical communications company that provides
6 publications services to authors and industry sponsors.
7

8 JG is on the Board of Trustees of ISMPP and is a steering committee member of the MPIP
9 (Medical Publications Insights and Practices) Initiative.
10

11 JG and TG are employees of AstraZeneca and own shares in the company.
12

13 JF is an employee of TGaS Advisors, a division of the KnowledgePoint360 Group.
14

15 All authors (except JF) are members of ISMPP. None of the authors received any specific
16 remuneration for working on this project.
17
18

19 **Funding**

20 Funding for the incentive prizes was provided by ISMPP. Data collection and analysis was
21 provided (free of charge) by KnowledgePoint360 via TGaS Advisors.
22
23

24 **Data sharing statement**

25 The full questionnaire is available at QQQ. Data aggregated by sector (industry, agency,
26 freelance) is available at XXX.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Sismondo S. Ghosts in the machine: publication planning in the medical sciences. *Social Studies of Science* 2009;**39**:171.
2. Fugh-Berman A. The haunting of medical journals: how ghostwriting sold "HRT". *PLoS ONE* 2010;**7**(9):e1000335.
3. WAME Policy Statement: Ghost writing initiated by commercial companies. <http://www.wame.org/resources/policies#ghost>
4. Jacobs A, Wager E. EMWA guidelines on the role of medical writers in developing peer-reviewed publications. *Curr Med Res Opin* 2005;**21**:317-321.
5. Woolley K, Lew R, Stretton S et al. Lack of involvement of medical writers and the pharmaceutical industry in publications retracted for misconduct: a systematic, controlled, retrospective study. *Current Medical Research & Opinion* 2011;**27**:1175-1182.
6. Kaiser K, Cofield S, Fontaine K et al. Is funding source related to study reporting quality in obesity or nutrition randomized control trials in top-tier medical journals? *Int J Obesity* 2013;**36**:977-981.
7. Smith SM, Wang AT, Katz NP et al. Adverse event assessment, analysis, and reporting in recent published analgesic trials: ACTION systematic review and recommendations. *Pain* 2013;**154**:997-1008.
8. Lundh A, Sismondo S, Lexchin J et al. Industry sponsorship and research outcome. *Cochrane Database Syst Rev* 2012;**12**:MR000033.

- 1
2
3 9. Als-Nielsen B, Chen W, Gluud C et al. Association of funding and conclusions in
4
5 randomized drug trials: a reflection of treatment effect or adverse events? JAMA
6
7 2003;**290**:981-988.
8
9
- 10 10. Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical
11
12 companies. *Curr Med Research Opinion* 2003;**19**:149-154.
13
14
- 15 11. Graf C, Battisti WP, Bridges D et al. Good publication practice for communicating
16
17 company sponsored medical research: the GPP2 guidelines. *BMJ* 2010;**339**:b4330.
18
19
- 20 12. Norris R, Bowman A, Fagan JM et al. International Society for Medical Publication
21
22 Professionals (ISMPP) position statement: the role of the professional medical writer.
23
24 *Curr Med Research Opinion* 2007;**23**:1837-1840.
25
26
- 27 13. AMWA Code of Ethics. http://www.amwa.org/amwa_ethics
28
29 http://www.amwa.org/amwa_ethics.
30
31
32
33
- 34 14. Goldacre B. *Bad Pharma*. London: Fourth Estate: 2012.
35
36
- 37 15. Rodino FJ. Corporate Integrity Agreements. What they say about publications,
38
39 publication planning, transparency, and ICMJE. *Therapeutic Innovation & Regulatory*
40
41 *Science* 2013;**47**(1):50-56.
42
43
44
- 45 16. Laine C, Mulrow CD. Exorcising ghosts and unwelcome guests. *Annals of Internal*
46
47 *Medicine* 2005;**143**:611-612.
48
49
- 50 17. Gøtzsche PC, Kassirer JP, Woolley KL et al. What should be done to tackle
51
52 ghostwriting in the medical literature? *PLoS Medicine* 2009;**6**(2):e1000023.
53
54
55
56
57
58
59
60

- 1
2
3 18. Marusic A, Hren D, Bhattacharya A et al. Deciding authorship: survey findings from
4 clinical investigators, journal editors, publication planners, and medical writers. 2013.
5
6 Chicago. 7th International Congress on Peer Review and Biomedical Publication. 8-9-
7
8 2013.
9
10
- 11
12 19. Stretton S, Bramich NJ, Keys J et al. Publication misconduct and plagiarism
13 retractions: a systematic, retrospective study. *Curr Med Res Opin* 2012;**28**:1575-1583.
14
15
- 16
17 20. Wager E, Fiack S, Graf C et al. Science journal editors' views on publication ethics:
18 results on an international survey. *Journal of Medical Ethics* 2009;**35**:348-353.
19
20
- 21
22 21. Wong V, Callahan ML. Medical journal editors lacked familiarity with scientific
23 publication issues despite training and regular exposure. *J Clin Epidemiol* 2012;**65**:247-
24
25 252.
26
27
- 28
29 22. Good Publication Practice: The awareness and views of healthcare professionals.
30
31 <http://www.epghealthmedia.com/industry-reports/HCP-views-on-GPP/>
32
33
- 34
35 23. De Faoite D, Bakota B, Staresinic M et al. Awareness, attitudes, and perceptions of
36 Croatian-based orthopedic and trauma surgeons toward scientific manuscripts,
37
38 publishing internationally and medical writing. Results of an online questionnaire. *Coll*
39
40 *Antropol* 2013;**1**:165-168.
41
42
- 43
44 24. Jacobs A, Hamilton CW. Decreased evidence of ghostwriting in a 2008 vs 2005
45 survey of medical writers. *The Write Stuff* 2009;**18**(2):118-123.
46
47
- 48
49 25. Hamilton CW, Jacobs A. Evidence of decreased ghostwriting in a series of three
50 surveys of medical communicators conducted between 2005 and 2011. *AMWA Journal*
51
52 2012;**27**:115.
53
54
55
56
57
58
59
60


- 1
2
3 26. Wager E. Publication ethics: the shift from philosophy to compliance. *Regulatory*
4 *Affairs Journal* 2011;(2 Feb 2011):18-19.
5
6
7
8 27. Wislar JS, Flanagan A, Fontanarosa PB et al. Honorary and ghost authorship in high
9 impact biomedical journals: a cross sectional survey. *BMJ* 2011;**343**:d6128.
10
11
12
13 28. Woolley KL, Gertel A, Hamilton C et al. Poor compliance with reporting research
14 results -- we know it's a problem ... how do we fix it? *Curr Med Research Opinion*
15 2012;**28**:1857-1860.
16
17
18
19 29. Jacobs A. Adherence to the CONSORT guideline in papers written by professional
20 medical writers. *The Write Stuff* 2010;**19**:196-200.
21
22
23
24 30. Bailey M. Science editing and its effect on manuscript acceptance time. *AMWA*
25 *Journal* 2011;**26**:147-152.
26
27
28
29 31. Pignatelli B, Maisonneuve H, Chapuis F. Authorship ignorance: views of researchers
30 in French clinical settings. *J Med Ethics* 2005;**31**:578-581.
31
32
33
34 32. Bhopal R, Rankin J, McColl E et al. The vexed question of authorship: views of
35 researchers in a British medical faculty. *BMJ* 1997;**314**:1009-1012.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



155x61mm (300 x 300 DPI)

Peer review only



161x61mm (300 x 300 DPI)

Peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The Global Publications Survey – Questionnaire Final Draft

MISSION

To identify educational needs in ethical medical publication practices and recommend how these should be addressed to advance the professions that support these practices, and to enhance transparency around peer-reviewed medical publications.

CONTENT

Section 1 – Demographics and core questions

Section 2 – INDUSTRY (Pharmaceutical, Biotech, Medical Devices, Diagnostics)

Section 3 – AGENCY (services include support of ethical medical publications)

Section 4 – CRO (services include support of ethical medical publications)

Section 5 – FREELANCER (Self-employed medical publications professional)

Section 6 – JOURNAL EDITOR

Section 7 – PUBLISHING COMPANY

Section 8 – ACADEMIC, RESEARCH and/or MEDICAL Institution or Association

GPS GLOSSARY (adapted from a glossary kindly provided by ISMPP)

Privacy Notice

In completing this survey you will be providing TGaS Advisors with some of your personal information. TGaS Advisors, based in the United States, is part of the KnowledgePoint360 Group LLC, which is a Safe Harbor Certified company. Your personal information will be used only for the purposes of administering the survey, and to allow stratification and analysis of the data. Your personal information will not be shared with any third parties who are not involved in the administration or analysis of the data. Any shared reports or publications arising from the survey will include only aggregated anonymized data.

Section 1 – DEMOGRAPHICS and CORE QUESTIONS

- [Q1] Does your role include or involve medical publications, defined in this survey as publishing research in peer-reviewed medical journals?
 - Yes
 - No (If no, it is not appropriate for you to complete this Survey. Thank you for your interest.)

- [Q2] How long have you been involved with peer-reviewed medical publications?
 - <2 years
 - 2 to <5 years
 - 5 to <10 years
 - ≥10 years

- [Q3] What academic qualifications do you hold (tick all that apply)?
 - Bachelors degree
 - Masters degree
 - PhD/PharmD or other doctoral degree
 - MD or other medical qualification
 - Other (please specify)

- [Q4] Are you a Certified Medical Publication Professional (CMPP)? Yes/No
 - If no, please describe why you have chosen not to undertake this certification? (tick all that apply)
 - Not relevant to my role
 - Not supported by my senior managers
 - Not sufficiently recognized
 - Not required by my clients
 - Cost is prohibitive
 - Not aware of CMPP
 - I have other professional certifications (please specify)
 - Other (please specify)

- [Q5] Where do you or your organization routinely go for current information on guidelines for ethical medical publication practises? (tick all that apply)
 - Good Publication Practice 2 (GPP2)
 - ICMJE uniform requirements
 - Enhancing the QUALity and Transparency Of health Research (EQUATOR)
 - Experts in-house (or external advisors)
 - International Society for Medical Publications Professionals (ISMPP)
 - Professional Medical Writers Association (eg. AMWA/EMWA)
 - Committee on Publication Ethics (COPE)
 - Council of Science Editors (CSE)
 - Association of Clinical Researchers and Educators (ACRE)
 - Medical Publishing Insights and Practices (MPIP)

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Social media/networking groups (please specify)
 - Other (please specify)
 - [Q6] How do you educate yourself on current guidelines and best practises? (tick all that apply)
 - Provided by the organization that I work for
 - Through industry/professional associations
 - Monitoring of the literature
 - Member of social networking groups
 - Undertaking professional qualifications
 - Informal interactions with colleagues
 - Other (please specify)
 - [Q7] In your opinion, how informed are each of the following professional groups with regard to guidelines for ethical publication practises e.g. GPP2 (using a scale of '1' to '5', where 1 = not well informed; 5 = very well informed; or 'Don't know')
 - Medical publications professionals in industry
 - Medical publication professionals in agency
 - Medical publications professionals in CRO
 - Freelancer/ independent medical publications professionals
 - Journal editors
 - Publishers
 - Academic researchers
 - Clinical investigators
 - R&D in industry
 - [Q8]. Is there a Code of Conduct governing ethical peer-reviewed medical publication practises in your organization? Yes/ No/ Don't know/Not relevant
 - If yes, please indicate if this code is:
 - internal to your organization
 - external to your organization
 - If no, would having a global Code of Conduct enhance adherence to current peer-reviewed medical publication standards? (i.e. a code that includes a formal process to enable complaints to be reviewed and disciplinary action to be taken against individuals or organizations that do not comply with the Code)?
 - Yes
 - No
 - Don't know
 - [Q9] Please indicate what types of professional association(s) you are a member of (tick all that apply)
 - A medical professional association
 - An association linked to the pharmaceutical/medical device industry
 - An association for medical writers

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- An association for academic researchers/scientists
 - An association for clinical researchers
 - An association for medical journal editors or publishers
 - Other (please specify)
 - Not a member of any professional associations
- [Q10] What type of organization do you currently work for? (tick one)
 - Pharmaceutical/biotech/medical device/diagnostics industry [TGaS: Go to Section 2]
 - Agency involved in peer-reviewed medical publications [TGaS: Go to Section 3]
 - CRO involved in peer-reviewed medical publications [TGaS: Go to Section 4]
 - Freelancer/independent medical publications professional involved in peer-reviewed medical publications [TGaS: Go to Section 5]
 - Medical journal [TGaS: Go to Section 6]
 - Publishing company involved in medical publications [TGaS: Go to Section 7]
 - Academic and/or medical institution or association [TGaS: Go to Section 8]
 - Other (please specify) [TGaS: Go to final questions]

Section 2 – INDUSTRY (Pharmaceutical, Biotech, Medical Devices, Diagnostics)

(Unless otherwise directed, please respond as a member of a department within a company, rather than your parent company)

- [Q1-IND] Please select the category that best describes the geographic remit of your role
 - Global HQ
 - Regional HQ
 - Please specify which region
 - National
 - Please specify which country [TGAS – please insert drop down list of countries]
 - Other (please specify)
- [Q2-IND] Please select the category that best describes your role in industry
 - Executive/Department or Function Head
 - Director/Team Leader
 - Publications Manager
 - Researcher (preclinical, clinical or medical)
 - Medical Writer/Editor
 - Other (please specify)
- [Q3-IND] Please indicate the primary focus of the company for which you work
 - Pharmaceutical
 - Biotech
 - Devices/diagnostics
 - Other (please specify)
- [Q4-1ND] To your knowledge, approximately how many peer-reviewed manuscripts has your department supported in the last 12 months?
 - None
 - If none, do you expect your department to support manuscripts in the next 12 months? Yes/No/Don't know
 - <10
 - 10 to <30
 - 30 to <100
 - ≥100
 - Don't know
- [Q5-IND] Is your department operating according to the requirements of a U.S. government Corporate Integrity Agreement (CIA), even if not located in the U.S.? Yes/No/Don't know
- [Q6-IND] Does your company have guidelines/SOP/policy or equivalent that drives ethical, peer-reviewed medical publications practises? Yes/No/Don't know
 - If yes

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Are these global standards? Yes/No/Don't know
 - Are any of these publicly disclosed? Yes/No/Don't know
 - Is mandatory training provided to the medical publications professionals in your company? Yes/ No/ Don't know
 - If yes, are training updates mandated at least annually?
Yes/No/Don't know
 - Is mandatory training provided to other employees involved in peer-reviewed medical publications, even if these are not the main focus of their role (e.g. an internal researcher who will be an author on a paper)?
Yes/No/Don't know
 - [Q6a-IND] Is there a formal, regular process to monitor internal adherence to your standards? Yes/No/Don't know
 - If yes (tick all that apply)
 - Testing knowledge, at least annually
 - Audits
 - Reports from publication management tools
 - Other (please specify)
 - Don't know
 - [Q6b-IND] Is training provided to third-party service providers involved in peer-reviewed medical publications (e.g. Agency and Freelancers/independent publications professionals)? Yes/No/Don't know
 - If yes, how frequently? (tick all that apply)
 - At least annually
 - At instigation of the relationship
 - *Ad hoc* updates provided as guidelines change
 - Other (please specify)
 - Don't know
 - [Q6c-IND] Is there a formal, regular process to monitor third-party service providers' adherence to your standards? Yes/No/Don't know
 - If yes (tick all that apply)
 - Testing knowledge, at least annually
 - Audits
 - Reports from publication management tools
 - Other (please specify)
 - Don't know
 - [Q7-IND] In your department, what public disclosure of clinical trial results is required to fulfil obligations of data transparency? (tick all that apply)
 - Posting summary results on public trial database/registry
 - Abstract publication
 - Peer-reviewed manuscript publication
 - Posting summary results on company website

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Posting full clinical study report (e.g. on company website)
 - Other (please specify)
 - Don't know

 - [Q8-IND] Does your department commit to peer-reviewed publication of results of all studies in humans)? Yes/No/Don't know
 - If yes, within what timeframe do you commit to submit manuscripts for peer review?
 - Within 12 months of last subject, last visit
 - Within 18 months of last subject, last visit
 - No timeframe mandated
 - Other (please specify)
 - Don't know
 - If no, what are the exceptions? (tick all that apply)
 - Phase I studies (in healthy volunteers and/or patients)
 - Studies for which the company does not have control
 - Studies controlled by development partners
 - Investigator Initiated Studies
 - Other (please specify)
 - Don't know

 - [Q9-IND] In the last 12 months, approximately what percentage of the peer-reviewed manuscripts that your department has supported were published in open access journals?
 - None
 - <5%
 - 5 to <10%
 - 10 to <20%
 - ≥20%
 - Don't know

 - [Q9a-IND] In your opinion, how do you think the level of open access publications that your department will support will change over the next 2 years?
 - Increase
 - Stay the same
 - Decrease
 - Don't know

 - [Q9b-IND] From the list below, please rate the following reasons to publish in open access journals (using a scale of '1' to '5', where 1 = weak rationale; 5 = strong rationale)
 - Wider access to data
 - Increased speed of publication
 - Copyright retained with authors or company
 - It's mandatory in my organization
 - Other (please specify)

- 1
2
3 ▪ Don't know
4
5
6 • [Q10-IND] In what circumstances does your department support review articles? (tick all that
7 apply)
8 ○ We do not support review articles
9 ○ Where a scientific/medical or educational need has been identified
10 ○ If proposed by a journal editor/publisher
11 ○ If proposed by external authors
12 ○ If it is a systematic review
13 ○ If it is a narrative review
14 ○ Other (please specify)
15 ○ Don't know
16
17 ○ [Q10a-IND] If your department supports review articles, please outline in what
18 capacity? (tick all that apply)
19 ▪ Company author
20 ▪ Review for scientific accuracy
21 ▪ Providing data
22 ▪ Financial support for professional medical writing/editing, statistical analysis
23 or other assistance
24 ▪ Other (please specify)
25
26 • [Q11-IND] In your company, which department directly manages the budget for peer-
27 reviewed medical publications? (tick all that apply)
28 ○ Medical Affairs
29 ○ Clinical Development
30 ○ Commercial (e.g. Sales and Marketing)
31 ○ Other (please specify)
32 ○ Don't know
33
34 • [Q12-IND] How are Commercial (e.g. Sales and Marketing) colleagues involved in peer-
35 reviewed medical publications? (tick all that apply)
36 ○ They are not involved
37 ○ They are provided with information only
38 ○ They are members of the Publication Planning Team
39 ○ They can suggest publications/journals for author consideration
40 ○ They can review draft manuscripts for accuracy
41 ○ They are part of the formal approval process
42 ○ Other (please specify)
43 ○ Don't know
44
45 • [Q13-IND] Thinking about phase III studies in particular, has your department
46 organized/implemented publication steering committees or plan to implement such a
47 committee within the next 6 months? Yes/No/Don't know
48 ○ If yes, how often is this happening compared with 2 years ago?
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- More often
 - About the same
 - Less often
 - Don't know
- [Q14-IND] In your department, what data are routinely shared with authors for development of peer-reviewed medical publications? (tick all that apply)
 - Study protocol
 - Statistical analysis plan
 - Statistical reports
 - Raw data/data tables
 - Clinical Study Report (CSR)
 - Summarized data
 - An outline or draft manuscript
 - Other (please specify)
 - Don't know
 - [Q15-IND] In the last 12 months, to your knowledge, how often has your department recommended to the lead author the removal of a co-author from a manuscript or abstract that was in development?
 - Never
 - Once
 - More than once
 - Other, please specify
 - Don't know
 - [15a-IND] If once or more, please state reasons (tick all that apply)
 - Author did not meet authorship criteria
 - Author did not agree to adhere to ethical publication practises
 - Author did not agree to disclose medical writing support
 - Author disagreed with the interpretation of the data
 - Author disagreed with the order of authorship
 - Internal author left the organization
 - Other (please specify)
 - Don't know
 - [Q16-IND] In your department, are authorship obligations covered under formal agreements prior to each manuscript development? Yes/No/Don't know
 - [Q17-IND] In your opinion, who should take responsibility for educating authors on ethical peer-reviewed publication practises? (rank top 3, where 1=primary responsibility)
 - Industry and its professional associations
 - Third party service providers
 - Medical professional associations
 - Academic institutions (universities or hospitals)

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Journal Editors and their professional associations
 - Medical writing and publication professionals associations
 - Government
 - Other (please specify)
 - Don't know

 - [Q18-IND] Does your department receive assistance from third party service providers in the development of publication plans? (tick all that apply)
 - No third party assistance
 - Agencies
 - CROs
 - Self-employed/ independent publications professionals
 - Other (please specify)
 - Don't know

 - [Q19IND] In your opinion, what percentage of peer-reviewed medical publications in your publication plan are provided with some level of support from professional medical writers?
 - <25%
 - 25 to <50%
 - ≥50%
 - Don't know

 - [Q20-IND] In your department, over the past 12 months, how often has an author refused an offer of professional medical writing support for their manuscript?
 - Never
 - Once
 - More than once
 - Don't know
 - [Q20a-IND] In your opinion, is refusal happening more or less frequently than 2 years ago?
 - More frequently
 - About the same
 - Less frequently
 - Don't know

 - [Q21-IND] Does your department ensure that authors acknowledge professional medical writing support within a peer-reviewed publication according to current guidelines?
Yes/No/Don't know
 - [Q21a-IND] In the last 12 months, have you had an author refuse to acknowledge professional writing support? Yes/No/Don't know
 - If yes, how frequently has this occurred in the last 12 months?
 - Once
 - More than once
 - Don't know

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- [Q21b-IND] In your opinion, is refusal happening more or less frequently than 2 years ago?
 - More frequently
 - About the same
 - Less frequently
 - Don't know

 - [Q22-IND] In the last 12 months, how frequently has your department made a specific payment to external authors for their time and commitment writing and reviewing a manuscript?
 - Never
 - Once
 - More than once
 - Don't know

 - [Q22a-IND] If payment has been made please describe the circumstances (tick all that apply)
 - For statistical review
 - For developing clinical manuscripts
 - For developing review papers
 - Other (please specify)
 - Don't know

 - [Q23-IND] In the past 12 months, how often do you think your department has experienced a journal rejecting a manuscript from a robust, well-designed clinical trial, on the grounds that it was associated with the pharmaceutical industry?
 - Never
 - Once
 - More than once
 - If once or more, please indicate which journal(s)
 - Don't know

 - [Q24-IND] In the peer-reviewed medical publications that your department has supported over the past 12 months, how often has a journal required a professional medical writer to be included as an author?
 - Never
 - Once
 - More than once
 - If once or more, please indicate which journal(s)
 - Don't know

 - [Q25-IND] In the past 12 months, to your knowledge, has your department supported development of a peer-reviewed publication for a study (or studies) that did not meet the primary endpoint or could otherwise be construed as inconclusive or negative? Yes/No/Don't know

- 1
2
3 ○ If yes, has the paper(s) been accepted or published in a peer-reviewed journal?

4 Yes/No/Don't know

- 5 ▪ If no (tick all that apply)

- 6 • The paper(s) has not yet been submitted for peer review
7 • The paper(s) was rejected
8 • The paper(s) was published, but not in a peer-reviewed journal
9 • Other (please specify)
10 • Don't know

- 11
12
13
14 • [Q26-IND] In the past 12 months, are you aware of any results from your company's study (or
15 studies) that did not meet the primary endpoint or could otherwise be construed as
16 inconclusive or negative for which publication is not planned? Yes/No/Don't know

- 17 ○ If yes, what reason is given for non-publication? (tick all that apply)

- 18 ▪ Study did not meet primary endpoint
19 ▪ Study was not conducted in humans
20 ▪ Drug development has been discontinued
21 ▪ Study was not well designed
22 ▪ Study did not complete
23 ▪ Additional studies are required to verify the findings
24 ▪ Company does not like the results
25 ▪ Other (please specify)
26 ▪ Don't know
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Section 3 – AGENCY

(Unless otherwise directed, please respond as an employee of an Agency, or a single division of a larger Agency network, rather than the parent company)

- [Q1-AG] Please select the category that best describes the geographic remit of your role
 - Global HQ
 - Regional
 - Please specify which region
 - National
 - Please specify which country *[TGAS – please insert drop down list of countries]*
 - Other (please specify)
- [Q2-AG] Please select the category that best describes your role in the Agency
 - Executive/Department or Function Head
 - Director/Team leader
 - Medical Writer/Editor
 - Account Manager/Client Services
 - Other (please specify)
- [Q3-AG] To your knowledge, approximately how many peer-reviewed manuscripts has your Agency supported in the last 12 months?
 - None
 - If none, do you expect your Agency to support manuscripts in the next 12 months? Yes/No/Don't know
 - <10
 - 10 to <30
 - 30 to <100
 - ≥100
 - Don't know
- [Q4-AG] What proportion of your Agency's business revenues were related to peer-reviewed medical publications in the last 12 months?
 - None
 - <10%
 - 10 to <25%
 - 25 to <50%
 - 50 to <75%
 - ≥75%
 - Don't know
- [Q5-AG] Does your Agency have guidelines/SOP/policy or equivalent that drives ethical peer-reviewed medical publications practises? Yes/No/Don't know
 - If yes

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Are these global standards? Yes/No/Don't know
 - Are any of these publicly disclosed? Yes/No/Don't know
 - Is mandatory training provided to the medical publications professionals in your company? Yes/No/Don't know
 - If yes, are training updates mandated at least annually? Yes/No/Don't know
 - [Q5a-AG] Is there a formal, regular process to monitor internal adherence to your standards? Yes/No/Don't know
 - If yes (tick all that apply)
 - Testing knowledge, at least annually
 - Audits
 - Reports from publication management tools
 - Other (please specify)
 - Don't know
 - [Q5b-AG] Is training provided to Freelancers (independent publications professionals) that work with your Agency? Yes/No/Don't know
 - If yes, How frequently does your agency provide training to freelancers?(tick all that apply)
 - At least annually
 - At instigation of the relationship
 - *Ad hoc* updates provided as guidelines change
 - Other (please specify)
 - Don't know
 - Not applicable
 - [Q5c-AG] Is there a formal, regular process to monitor Freelancers' adherence to your standards? Yes/No/Don't know
 - If yes (tick all that apply)
 - Testing knowledge, at least annually
 - Audits
 - Reports from publication management tools
 - Other (please specify)
 - Don't know
 - Not applicable
 - [Q6-AG] What proportion of your client companies have their own guidelines/SOPs/policies or equivalent that drive ethical peer-reviewed medical publications practises?
 - None
 - <10%
 - 10 to <50%
 - 50 to <90%
 - ≥90%
 - Don't know

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- [Q6a-AG] If clients do have guidelines/SOPs/policy:
 - Are these global standards? Most / Some / None / Don't know
 - If most or some, are any of these publically disclosed? Most / Some / None / Don't know
 - Is mandatory training provided to your Agency? Yes/No/Don't know
 - If yes, how frequently (tick all that apply)?
 - At least annually
 - At instigation of the relationship
 - *Ad hoc* updates provided as guidelines change
 - Other (please specify)
 - Don't know
 - [Q6b-AG] Do any of your clients have a formal, regular process to monitor Agency adherence to their standards? Most/some /None / Don't know
 - If yes, indicate what proportion of your clients use the following (where 0=none; 1=<50%; 2=50-99%; 3=100%)
 - Testing knowledge, at least annually
 - Audits
 - Reports from publication management tools
 - Don't know
 - [Q7-AG] What role(s) does your Agency play in peer-reviewed publications? (tick all that apply)?
 - Strategic services e.g. gap analyses to identify unmet educational needs?
 - Publication plan management, tracking all manuscripts within database systems
 - Medical writing services for authors
 - Editorial services for authors
 - Authorship, when criteria are met
 - Other, please specify
 - Don't know
 - [Q8-AG] In the last 12 months, approximately what percentage of peer-reviewed manuscripts that your Agency has supported were published in open access journals?
 - None
 - <5%
 - 5 to <10%
 - 10 to <20%
 - ≥20%
 - Don't know
 - [Q8a-AG] In your opinion, how do you think the level of open access publications that your Agency will support will change over the next 2 years?
 - Increase
 - Stay the same
 - Decrease

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Don't know
 - [Q8b-AG] From the list below, please rate each of the following reasons to publish in open access journals (using a scale of '1' to '5', where 1 = weak rationale ; 5 = strong rationale)
 - Wider access to data
 - Increased speed of publication
 - Copyright retained with authors or company
 - It's mandatory in the organizations with which we work
 - Don't know
 - [Q9-AG] What data do your clients routinely share with authors for development of peer-reviewed medical publications? (tick all that apply)
 - Study protocol
 - Statistical analysis plan
 - Statistical reports
 - Raw data/data tables
 - Clinical Study Report (CSR)
 - Summarized data
 - An outline or draft manuscript
 - Other (please specify)
 - Don't know
 - [Q10-AG] In the last 12 months, to your knowledge, how often has your Agency recommended to the lead author the removal of a co-author from a manuscript or abstract that was in development?
 - Never
 - Once
 - More than once
 - Other (please specify)
 - Don't know
 - [Q10a-AG] If once or more, please state reasons (tick all that apply)
 - Author did not meet authorship criteria
 - Author did not agree to adhere to ethical publication practises
 - Author did not agree to disclose medical writing support
 - Author disagreed with the interpretation of the data
 - Author disagreed with the order of authorship
 - Internal author left the client organization
 - Other (please specify)
 - Don't know
 - [Q11-AG] In your Agency, are authorship obligations covered under formal agreements between authors and client companies prior to each manuscript development? Yes/No/Don't know

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- [Q12-AG] In your opinion, who should take responsibility for educating authors on ethical peer-reviewed publication practises? (rank top 3, where 1=primary responsibility)
 - Industry and its professional associations
 - Third party service providers (such as agencies and independent publication professionals)
 - Medical professional associations
 - Academic institutions (universities or hospitals)
 - Journal Editors and their professional associations
 - Medical writing and publication professionals associations
 - Government
 - Other (please specify)
 - Don't know

 - [Q13-AG] In your Agency, over the past 12 months, how often has an author refused an offer of professional medical writing support for their manuscript?
 - Never
 - Once
 - More than once
 - Don't know
 - [Q13a-AG] In your opinion, is refusal happening more or less frequently than 2 years ago?
 - More frequently
 - About the same
 - Less frequently
 - Don't know

 - [Q14-AG] Does your Agency ensure that authors acknowledge professional medical writing support within a peer-reviewed publication according to current guidelines? Yes/No/Don't know
 - [Q14a-AG] in the last 12 months, have you had an author refuse to acknowledge professional writing support? Yes/No/Don't know
 - If yes, how frequently has this occurred in the last 12 months?
 - Once
 - More than once
 - Don't know
 - [Q14b-AG] In your opinion, is refusal happening more or less frequently than 2 years ago?
 - More frequently
 - About the same
 - Less frequently
 - Don't know

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- [Q15-AG] In the past 12 months, how often do you believe a journal has rejected a manuscript (from robust, well-designed clinical trials) that your Agency was involved with on the grounds that it was associated with the pharmaceutical industry?
 - Never
 - Once
 - More than once
 - If once or more, please indicate which journal(s)
 - Don't know

 - [Q16-AG] In the peer-reviewed medical publications that your Agency has supported over the past 12 months, how often has a journal requested a professional medical writer to be included as an author?
 - Never
 - Once
 - More than once
 - If once or more, please indicate which journal(s)
 - Don't know

 - [Q17-AG] In the past 12 months, to your knowledge, how frequently has your Agency been asked by a member of a client team or author to undertake a task that you understood may contravene ethical peer-reviewed publications practises?
 - Never
 - Once
 - More than once
 - Don't know

 - [Q17a-AG] If one or more times, how did your Agency respond?
 - Refused to accept the work
 - Explained the need for compliance, such that the request was withdrawn/amended appropriately
 - Accepted the work, even though it was not amended after discussion about compliance
 - Other (please specify)
 - Don't know

 - [Q18-AG] In the past 12 months, to your knowledge, has your Agency been involved in the development of a peer-reviewed publication for a study (or studies) that did not meet the primary endpoint or could otherwise be construed as inconclusive or negative? Yes/No/Don't know
 - If yes, has the paper(s) been accepted or published in a peer-reviewed journal?
Yes/No/Don't know
 - If no (tick all that apply)
 - The paper(s) has not yet been submitted for peer review
 - The paper(s) was rejected
 - The paper(s) was published, but not in a peer-reviewed journal

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- Other (please specify)
 - Don't know
-
- [Q19-AG] In the past 12 months, are you aware of any results from a client study (or studies) that did not meet the primary endpoint, or could otherwise be construed as inconclusive or negative, for which publication is not planned? Yes/No/Don't know
 - If yes, what reason is given for non-publication? (tick all that apply)
 - Study did not meet primary endpoint
 - Study was not conducted in humans
 - Drug development has been discontinued
 - Study was not well designed
 - Study did not complete
 - Additional studies are required to verify the findings
 - Company did not like the results
 - Other (please specify)
 - Don't know
-
- [Q20-AG] What proportion of your Agency's medical publications work is outsourced to freelancers (independent medical publications professionals)?
 - None
 - <5%
 - 5 to <10%
 - 10 to <20%
 - ≥20%
-
- [Q21-AG] If not "None" to Q20-AG When freelancers work with your Agency, do they? (tick all that apply)
 - Support development and/or management of publication plans?
 - Provide medical writing assistance in support of peer-reviewed publications?
 - Provide editorial assistance in support of peer-reviewed publications?
 - Manage publications databases
 - Other (please specify)
-
- [Q22-AG] If not "None" to Q20-AG Does your Agency draw up a formal contract with every freelancer prior to assigning any work? Yes/No/Don't know

Section 4 – CRO

(Unless otherwise directed, please respond as an employee of a department within a CRO, rather than the parent company)

- [Q1-CRO] Please select the category that best describes the geographic remit of your role
 - Global HQ
 - Regional
 - Please specify which region
 - National
 - Please specify which country [TGAS – please insert drop down list of countries]
 - Other (please specify)
- [Q2-CRO] Please select the category that best describes your role in the CRO
 - Executive/Department or Function Head
 - Director/Team Leader
 - Medical Writer/Editor
 - Account Manager/Client Services
 - Other (please specify)
- [Q3-CRO] To your knowledge, approximately how many manuscripts has your department supported during the last 12 months?
 - None
 - If none, do you expect your department to support manuscripts in the next 12 months? Yes/No/Don't know
 - <10
 - 10 to <30
 - 30 to <100
 - ≥100
 - Don't know
- [Q4-CRO] What proportion of your department's business revenues were related to peer-reviewed medical publications in the last 12 months?
 - None
 - <10%
 - 10 to <25%
 - 25 to <50%
 - 50 to <75%
 - ≥75%
 - Don't know
- [Q5-CRO] Does your department have guidelines/SOP/policy or equivalent that drives ethical peer-reviewed medical publications practices? Yes/No/Don't know
 - If yes

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Are these global standards? Yes/No/Don't know
 - Are any of these publicly disclosed? Yes/No/Don't know
 - Is mandatory training provided to the medical publications professionals in your company? Yes/No/Don't know
 - If yes, are training updates mandated at least annually? Yes/No/Don't know
 - [Q5a-CRO] Is there a formal, regular process to monitor internal adherence to your standards? Yes/No/Don't know
 - If yes (tick all that apply)
 - Testing knowledge, at least annually
 - Audits
 - Reports from publication management tools
 - Other (please specify)
 - Don't Know
 - [Q5b-CRO] Is training provided to freelancers (independent medical publications professionals) who work with your company? Yes/No/Don't know
 - If yes, how frequently? (tick all that apply)
 - At least annually
 - At instigation of the relationship
 - *Ad hoc* updates provided as guidelines change
 - Other (please specify)
 - Don't know
 - [Q5c-CRO] Is there a formal, regular process to monitor freelancers' adherence to your standards? Yes/No/Don't know
 - If yes (tick all that apply)
 - Testing knowledge, at least annually
 - Audits
 - Reports from publication management tools
 - Other (please specify)
 - Don't know
 - [Q6-CRO] What proportion of your client companies have their own guidelines/SOPs/policies or equivalent that drive ethical peer-reviewed medical publications practises?
 - None
 - <10%
 - 10 to <50%
 - 50 to <90%
 - ≥90%
 - Don't know
 - [Q6a-CRO] If clients do have guidelines/SOPs/policy

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Are these global standards? Most / Some / None / Don't know
 - Are any of these publically disclosed? Most / Some / None /Don't know
 - Is mandatory training provided to your department? Yes/No/Don't know
 - If yes, how frequently? (tick all that apply)
 - At least annually
 - At instigation of the relationship
 - *Ad hoc* updates provided as guidelines change
 - Other (please specify)
 - Don't know
 - [Q6b-CRO] Do any of your clients have a formal, regular process to monitor your adherence to their standards? Most / Some / None / Don't know
 - If Most / Some, indicate what proportion of your clients use the following (where 0=none; 1=<50%; 2=50-99%; 3=100%)
 - Testing knowledge, at least annually
 - Audits
 - Reports from publication management tools
 - Don't know
 - [Q7-CRO] What role(s) does your department play in peer-reviewed publications? (tick all that apply)
 - Strategic services e.g. gap analyses to identify unmet educational needs
 - Publication plan management, tracking all manuscripts within database systems
 - Medical writing assistance for authors
 - Editorial service for authors
 - Authorship, when criteria are met
 - Other (please specify)
 - Don't know
 - [Q8-CRO] What data do your clients routinely share with authors for development of peer-reviewed publications? (tick all that apply)
 - Study protocol
 - Statistical analysis plan
 - Statistical reports
 - Raw data/data tables
 - Clinical Study Report (CSR)
 - Summarized data
 - An outline or draft manuscript
 - Other (please specify)
 - Don't know
 - [Q9-CRO] In the last 12 months, to your knowledge, how often has your department recommended to the lead author the removal of a co-author from a manuscript or abstract that was in development?

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Never
 - Once
 - More than once
 - Other (please specify)
 - Don't know

 - [Q9a-CRO] If once or more, please state reasons (tick all that apply)
 - Author did not meet authorship criteria
 - Author did not agree to adhere to ethical publication practises
 - Author did not agree to disclose medical writing support
 - Author disagreed with the interpretation of the data
 - Author disagreed with the order of authorship
 - Internal author left the client organization
 - Other (please specify)
 - Don't know

 - [Q10-CRO] In your department, are authorship obligations covered under formal agreements between authors and client companies prior to each manuscript development? Yes/No/Don't know

 - [Q11-CRO] In your opinion, who should take responsibility for educating authors on ethical peer-reviewed publication practises? (rank top 3, where 1=primary responsibility)
 - Industry and its professional associations
 - Third party service providers (such as agencies, CROs and independent medical publication professionals)
 - Medical professional associations
 - Academic institutions (universities or hospitals)
 - Journal Editors and their professional associations
 - Medical writing and publication professionals associations
 - Government
 - Other (please specify)

 - [Q12-CRO] In your department, over the past 12 months, how often has an author refused an offer of professional medical writing support for their manuscript?
 - Never
 - Once
 - More than once
 - Don't know

 - [Q12a-CRO] In your opinion, is refusal happening more or less frequently than 2 years ago?
 - More frequently
 - About the same
 - Less frequently
 - Don't know

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- [Q13-CRO] Does your department ensure that authors acknowledge professional medical writing support within a peer-reviewed publication according to current guidelines?
Yes/No/Don't know
 - [Q13a-CRO] In the last 12 months, have you had an author refuse to acknowledge professional medical writing support? Yes/No/Don't know
 - If yes, how frequently has this occurred in the last 12 months?
 - Never
 - Once
 - More than once
 - Don't know
 - [Q13b-CRO] In your opinion, is refusal happening more or less frequently than 2 years ago?
 - More frequently
 - About the same
 - Less frequently
 - Don't know
 - [Q14-CRO] In the past 12 months, how often do you believe a journal has rejected a manuscript (from robust, well-designed clinical trials) that your department was involved with on the grounds that it was associated with the pharmaceutical industry?
 - Never
 - Once
 - More than once
 - If once or more, please indicate which journal(s)
 - Don't know
 - [Q15-CRO] In the peer-reviewed medical publications that your department has supported over the past 12 months, how often has a journal requested a professional medical writer to be included as an author?
 - Never
 - Once
 - More than once
 - If once or more, please indicate which journal(s)
 - Don't know
 - [Q16-CRO] In the past 12 months, to your knowledge, how frequently has your department been asked by a member of a client team or author to undertake a task which you understood may contravene ethical peer-reviewed publications practises?
 - Never
 - Once
 - More than once
 - Don't know

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- [Q16a-CRO] If one or more times, how did your department respond? (tick all that apply)
 - Refused to accept the work
 - Explained the need for compliance, such that the request was withdrawn/amended appropriately
 - Accepted the work even though it was not amended after discussion about compliance
 - Other (please specify)
 - Don't know
 - [Q17-CRO] In the past 12 months, to your knowledge, has your department been involved with the development of a peer-reviewed publication for a study (or studies) that did not meet the primary endpoint or could otherwise be construed as inconclusive or negative? Yes/No/Don't know
 - If yes, has the paper(s) been accepted or published in a peer-reviewed journal? Yes/No/Don't know
 - If no (tick all that apply)
 - The paper(s) has not yet been submitted for peer review
 - The paper(s) was rejected
 - The paper(s) was published, but not in a per-reviewed journal
 - Other (please specify)
 - Don't know
 - [Q18-CRO] In the past 12 months, are you aware of any results from a client study (or studies) that did not meet the primary endpoint, or could otherwise be construed as inconclusive or negative, for which publication is not planned? Yes/No/Don't know
 - If yes, what reason is given for non-publication? (tick all that apply)
 - Study did not meet primary endpoint
 - Study was not conducted in humans
 - Drug development has been discontinued
 - Study was not well designed
 - Study did not complete
 - Additional studies are required to verify the findings
 - Company did not like the results
 - Other (please specify)
 - Don't know
 - [Q19-CRO] What proportion of your department's medical publications work is outsourced to freelancers (independent medical publications professionals)?
 - None
 - <5%
 - 5 to <10%
 - 10 to <20%
 - ≥20%

- 1
- 2
- 3 • [Q20-CRO] When freelancers work with your department, do they? (tick all that apply)
- 4 ○ Support development and/or management of publication plans?
- 5 ○ Provide medical writing assistance in support of peer-reviewed publications?
- 6 ○ Provide editorial assistance in support of peer-reviewed publications?
- 7 ○ Manage publications databases
- 8 ○ Other (please specify)
- 9
- 10
- 11
- 12 • [Q21-CRO] Does your department draw up a formal contract with every freelancer prior to
- 13 assigning any work? Yes/No/Don't know
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

For peer review only

Section 5 – FREELANCER (independent medical publications professional)

- 1
2
3
4
5 • [Q1-FL] How long have you worked in medical publications in a freelance (independent)
6 capacity?
7
 - 8 ○ <2 years
 - 9 ○ 2 to <5 years
 - 10 ○ 5 to <10 years
 - 11 ○ ≥10 years
 - 12
 - 13
 - 14 ○ [Q1a-FL] If >5 years, in your opinion, how does freelance writers' adherence to
15 ethical peer-reviewed publication practise today compare with 5 years ago?
 - 16 • Today writers are more aware of good publication practice and
17 follow it stringently (1=strongly disagree to 5=strongly agree)
 - 18
 - 19
- 20 • [Q2-FL] Please rank which of the following most strongly influences your adherence to ethical
21 peer-reviewed publication practise (1= least influential to 6 = most influential)?
22
 - 23 ○ Author(s)
 - 24 ○ Client (Industry)
 - 25 ○ Client (Agency)
 - 26 ○ Peer network
 - 27 ○ Medical publication associations
 - 28 ○ Self-regulated, based on keeping up-to-date with guidelines
 - 29
 - 30
- 31 • [Q3-FL] What role(s) do you play in peer-reviewed publications? (tick all that apply)
32
 - 33 ○ Strategic services e.g. gap analyses to identify unmet educational needs
 - 34 ○ Publication plan management, tracking all manuscripts within database systems
 - 35 ○ Medical writing assistance for authors
 - 36 ○ Editorial services for authors
 - 37 ○ Authorship, when criteria are met
 - 38 ○ Other (please specify)
 - 39
 - 40
- 41 • [Q4-FL] What proportion of your client companies have their own guidelines/SOPs/policies or
42 equivalent that drive ethical peer-reviewed medical publications practises?
43
 - 44 ○ None
 - 45 ○ <10%
 - 46 ○ 10 to<50%
 - 47 ○ 50 to<90%
 - 48 ○ ≥90%
 - 49 ○ Don't know
 - 50
 - 51
 - 52 ○ [Q4a-FL] If clients do have guidelines/SOPs/policy
 - 53 ■ Are these global standards? Most / Some / None /Don't know
 - 54 ■ Are any of these publicly disclosed? Most / Some / None/Don't know
 - 55 ■ Is mandatory training provided to you? Yes/No/Don't know
 - 56
 - 57 • If yes, how frequently? (tick all that apply)
 - 58
 - 59
 - 60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- At least annually
 - At instigation of the relationship
 - Ad hoc* updates provided as guidelines change
 - Other (please specify)
 - Don't know

 - [Q4b-FL] Do any of your clients have a formal, regular process to monitor your adherence to their standards? Yes/No/Don't know
 - If yes, indicate what proportion of your clients use the following (where 0=none; 1=<50%; 2=50-99%; 3=100%)
 - Testing knowledge, at least annually
 - Audits
 - Reports from publication management tools
 - Don't know

 - [Q5-FL] In the past 12 months, how frequently have you been asked by a member of a client team to undertake a task that you understood may contravene ethical peer-reviewed publications practises?
 - Never
 - Once
 - More than once
 - Don't know

 - [Q5a-FL] If one or more times, how did you respond? (tick all that apply)
 - Refused to accept the work
 - Explained the need for compliance, such that the request was withdrawn/amended appropriately
 - Accepted the work even though it was not amended after discussion about compliance
 - Other (please specify)
 - Don't know

 - [Q6-FL] In your opinion, what level of independent support is available to you when dealing with client or author issues related to ethical peer-reviewed publication practises? None/insufficient/sufficient/plenty
 - If none or insufficient, in your opinion, how should this counsel be provided?
 - Professional association to provide compliance support services
 - Peer network
 - Social media
 - Other (please specify)

 - [Q7-FL] In the last 12 months, how often have you recommended to the lead author the removal of a co-author from a manuscript or abstract that was in development?
 - Never
 - Once

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- More than once
 - Other (please specify)
 - Don't know

 - [Q7a-FL] If once or more, please state reasons (tick all that apply)
 - Author did not meet authorship criteria
 - Author did not agree to adhere to ethical publication practises
 - Author did not agree to disclose medical writing support
 - Author disagreed with the interpretation of the data
 - Author disagreed with the order of authorship
 - Internal author left the client organization
 - Other (please specify)
 - Don't know

 - [Q8-FL] In your opinion, who should take responsibility for educating authors on ethical peer-reviewed publication practises? (rank top 3, where 1=primary responsibility)
 - Industry and its professional associations
 - Third party service providers (such as agencies and independent medical publication professionals)
 - Medical professional associations
 - Academic institutions (universities or hospitals)
 - Journal Editors and their professional associations
 - Medical writing and publication professionals associations
 - Government
 - Other (please specify)

 - [Q9-FL] In the past 12 months, how have you had an author refuse an offer of professional medical writing support for their manuscript?
 - Never
 - Once
 - More than once
 - Don't know
 - [Q9a-FL] In your opinion, is refusal happening more or less frequently than 2 years ago?
 - More frequently
 - About the same
 - Less frequently
 - Don't know

 - [Q10-FL] Do you feel that you are appropriately acknowledged for medical writing support that you provide?
 - Always
 - Sometimes
 - Never

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Don't know
 - [Q11-FL] In the peer-reviewed medical publications that you have supported over the past 12 months, has a journal requested that you be included as an author?
 - Never
 - Once
 - More than once.
 - Don't Know
 - [Q11a-FL] If once or more, please indicate which journal(s)
 - [Q12-FL] Over the past 12 months, how often do you believe a journal has rejected a manuscript (from robust, well-designed clinical trials) that you were involved with on the grounds that it was associated with the pharmaceutical industry?
 - Never
 - Once
 - More than once
 - If once or more, please indicate which journal(s)
 - Don't know
 - [Q13-FL] In the past 12 months, have you been involved with the development of a peer-reviewed publication for a study (or studies) that did not meet the primary endpoint or could otherwise be construed as inconclusive or negative? Yes/No/Don't know
 - If yes, has the paper(s) been accepted or published in a peer-reviewed journal? Yes/No/Don't know
 - If no, tick all that apply
 - The paper(s) has not yet been submitted for peer review
 - The paper(s) was rejected
 - The paper(s) was published, but not in a peer-reviewed journal
 - Other (please specify)
 - Don't know
 - [Q14-FL] In the past 12 months, are you aware of any results from a client study (or studies) that did not meet the primary endpoint, or could be construed as inconclusive or negative, for which publication is not planned? Yes/No/Don't know
 - If yes, what reason is given for non-publication? (tick all that apply)
 - Study did not meet primary endpoint
 - Study was not conducted in humans
 - Drug development has been discontinued
 - Study was not well designed
 - Study did not complete
 - Additional studies are required to verify the findings
 - Company did not like the results
 - Other (please specify)
 - Don't know

Section 6 – JOURNAL EDITOR – Please respond thinking of one Primary Healthcare journal you are responsible for

- [Q1-JE] Please select the category that best describes the geographic remit of your role
 - Global HQ
 - Regional HQ
 - Please specify which region
 - National
 - Please specify which country [TGAS – please insert drop down list of countries]
 - Other, please specify...
- [Q2-JE] Please select the category that best describes your role at the journal
 - Journal Editor
 - Managing Editor
 - Associate Editor
 - Administrative role
 - Other (please specify)
- [Q3-JE] Please describe the key elements of your role (tick all that apply)
 - Screening all submissions prior to peer-review
 - Selecting journal review panel
 - Writing editorials on key papers
 - Developing author guidelines
 - Soliciting content for the journal
 - Developing themed issues
 - Handling queries on manuscripts
 - Determining manuscripts for enhanced content
 - Handling disputes/retractions
 - Other (please specify)
- [Q4-JE] What medium does your journal publish in?
 - Print only
 - Online only
 - Both
- [Q5-JE] Please describe the importance of the following to your journal
 - Open Access content:
 - Very
 - Somewhat
 - Not relevant
 - Don't know
 - Enhanced content such as MOAs, videos, supplemental information:
 - Very
 - Somewhat

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Not relevant
 - Don't know

 - [Q5a-JE] If very or somewhat, do you charge a fee for these enhancements?
 - Yes
 - No
 - Don't know

 - [Q6-JE] Is your journal considered to be a general or specialty journal?
 - General medical
 - Speciality medical
 - Health economics
 - Epidemiology
 - Primary care
 - Other (please specify)

 - [Q7-JE] In the course of a 12-month period, roughly what proportion of accepted papers in your journal covers negative studies (i.e. studies that have not met the primary endpoint or are statistically non-significant/neutral/inconclusive)?
 - None
 - <10%
 - 10 to <25%
 - 25 to <50%
 - 50 to <75%
 - ≥75%
 - Don't know

 - [Q8-JE] In the past 12 months, has your journal had to print a retraction as a result of misconduct?
 - Yes
 - No
 - Don't know

 - [Q8a-JE] If yes, please specify if the research was
 - Industry-sponsored
 - Academic research
 - Other (please specify)
 - Don't know

 - [Q9-JE] Do you publicly name your peer-review panel on your website?
 - Yes
 - No
 - Other, please specify
 - Don't know

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- [Q9b-JE] Do you disclose which reviewers participated in the peer-review for individual papers?
 - Yes
 - No
 - Other, please specify
 - Don't know

 - [Q10-JE] When sending manuscripts out for peer-review, is this conducted in a blinded or open fashion?
 - We anonymize submissions prior to peer review
 - We do not anonymize submissions prior to peer review
 - Other (please specify)
 - Don't know

 - [Q11-JE] What authorship criteria does your journal apply?
 - ICMJE guidelines
 - Specific journal criteria (modified ICMJE)
 - Specific journal criteria
 - Contributor model
 - Other (please specify)
 - Don't know

 - [Q12-JE] In the last 12 months, has your journal refused to accept an author on a manuscript or abstract because he/she has not fulfilled your specified authorship criteria?
 - No
 - Yes
 - Was this as a result of your own review? Yes/No
 - Was this as a result of concerns raised by others? Yes/No
 - We don't check authorship criteria – authors are responsible for their own submissions
 - Other (please specify)
 - Don't know

 - [Q13-JE]: What conflict of interest guidelines are used at your journal?
 - ICMJE
 - Journal's own
 - Other (please specify)
 - Don't know
 - [Q13a-JE] Over what duration of time does your journal require authors to disclose COI information over?
 - Current relationships and activities

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Activities within the last 2 years
 - Activities within the last 4 years
 - Activities within the last 5 years
 - More than 5 years
 - [Q13b-JE] Do you require disclosures on
 - Solely in relation to drugs/devices that are the subject of the manuscript
 - All industry COI regardless of whether they are discussed in the manuscript
 - [Q14-JE] What is your journal's position on professional medical writing support? (tick all that apply)
 - Medical writers are acceptable as long as their contribution is appropriately acknowledged and they are authors if they fulfil the criteria for authorship
 - All medical writers involved in drafting a manuscript should be authors
 - We follow a contributor model
 - Only where the authors need help for language and grammar
 - We do not accept manuscripts that have had professional medical writing support
 - Other (please specify)
 - Don't know
 - [Q15-JE]. Do professional medical writers improve the quality of a manuscript?
 - Yes
 - Sometimes,
 - No,
 - Don't know
 - [Q16-JE] Do you ensure authors acknowledge medical writing support according to your journal's current guidelines?
 - Yes, in our guidance for authors, we provide relevant information (such as a checklist) on acknowledging contributions and support
 - No, this is the responsibility of the authors.
 - Don't know
 - Other (please specify)
 - [Q17-JE] Does your journal always publish the full acknowledgments submitted by the authors?
 - Yes – both online and in print
 - Yes – in print only
 - Yes – online only
 - No
 - Other (please specify)
 - Don't know

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- [Q18-JE] In the past 12 months, how often have you heard of an author refusing to acknowledge professional medical writing support on a manuscript they submitted to your journal?
 - Never
 - Once
 - More than once
 - Don't know

 - [Q18a-JE] In your opinion, is refusal happening more or less frequently than 2 years ago?
 - More frequently
 - About the same
 - Less frequently
 - Don't know

 - [Q19-JE] What is your journal's policy on review articles? (tick all that apply)
 - We review all submissions on merit, provided all appropriate acknowledgments and COIs are disclosed and journal guidelines are met
 - We only accept review articles from academia
 - We do not publish review articles
 - Other (please specify)
 - Don't know

 - [Q20 – JE] What is your journal's philosophy and/or policy on publishing pharmaceutical industry sponsored research? (tick all that apply)
 - We consider all well-conducted research regardless of the funding source
 - We accept industry sponsored research only if they allow full access to the original data
 - We accept industry sponsored research if they allow analysis of the data to be conducted by an independent academic statistician
 - We do a more rigorous review of industry sponsored research
 - We don't accept publications on industry sponsored research
 - Other (please specify)
 - Don't know

 - [Q21-JE] In the past 12 months, has your journal rejected a paper primarily because of you believed the content was biased because it was associated with the pharmaceutical industry?
 - No
 - We don't publish industry sponsored research
 - Yes, once
 - Yes, more than once
 - Don't know

 - [Q22-JE] Does your journal accept advertising from industry?

FINAL DRAFT

The Global Publications Survey

October 21 2012

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- Yes
- No
- Don't know
 - If yes, do you have an in-house or affiliated sales department that contacts industry regarding potential advertising?
 - Yes
 - No
 - Don't know
- [Q23-JE] Does your journal sell reprints of individual papers?
 - Yes
 - No
 - Don't know
 - If yes, do you have an in-house or affiliated sales department that contacts industry regarding potential reprints?
 - Yes
 - No
 - Don't know

For peer review only

Section 7 – PUBLISHING COMPANY

- [Q1-PC] Please select the category that best describes the geographic remit of your role
 - Global HQ
 - Regional
 - Please specify which region
 - National
 - Please specify which country [TGAS – please insert drop down list of countries]
 - Other (please specify)
- [Q2-PC] Please select the category that best describes your role in the journal
 - Executive
 - Journal Publisher
 - Managing Publisher
 - Associate Publisher
 - Business / Sales role
 - Administrative role
 - Other (please specify)
- [Q3-PC] Please describe the key elements of your role (tick all that apply)
 - Developing new publication channels applicable to medical publications
 - Determining manuscripts for enhanced content
 - Handling disputes/retractions
 - Managing journal production
 - Commissioning content
 - Other (please specify)
- [Q4-PC] What proportion of your company is focused on medical publishing?
 - <10%
 - 10 to <50%
 - 50 to <75%
 - ≥75%
- [Q5-PC] What proportion of your medical journals are supported by online content
 - None
 - 10 to <50%
 - 50 to <75%
 - ≥75%
- [Q6-PC] What is the primary business model for your medical journals? (tick all that apply)
 - Journal subscriptions
 - Advertising revenue
 - Open access fees
 - Other (please specify)

- 1
2
3 ○ Don't know
4
5
6 • [Q7-PC] Please describe the importance of the following to your medical journals
7 ○ Open access content
8 ▪ Very
9 ▪ Somewhat
10 ▪ Not relevant
11 ▪ Don't know
12
13 ○ Enhanced content such as MOAs, videos, supplemental information
14 ▪ Very
15 ▪ Somewhat
16 ▪ Not relevant
17 ▪ Don't know
18
19 ▪ [Q7a-PC] If very or somewhat, do you charge a fee for these enhancements?
20 • Yes
21 • No
22 • Don't know
23
24 ▪ [Q7b-PC] Who pays for enhanced content in your journals?
25 • There is no charge
26 • Either the industry or academic sponsor linked to that paper
27 • Paid for by unrestricted educational grants
28 • Paid for from the advertising budget
29 • Other (please specify)
30
31
32
33
34
35
36 • [Q8-PC] Are your medical journals primarily considered to be general or specialty journals?
37 Please tick all that apply
38 ○ General medical
39 ○ Speciality medical
40 ○ Health economics
41 ○ Epidemiology
42 ○ Primary care
43 ○ Other (please specify)
44
45
46
47 ○ [Q9-PC] In the course of a 12-month period, roughly what proportion of accepted papers in
48 your medical journals cover negative studies (i.e. studies that have not met the primary
49 endpoint or are statistically non-significant/neutral/inconclusive)?
50 ○ None
51 ○ <10%
52 ○ 10 to <25%
53 ○ 25 to <50%
54 ○ 50 to <75%
55 ○ ≥75%
56
57
58
59
60

- 1
2
3 ○ Don't know
4
5
6 ○ [Q10-PC] In the past 12 months, have any of your medical journals had to print a retraction as
7 a result of misconduct?
8 ○ Yes
9 ○ No
10 ○ Don't Know
11
12
13 ○ [Q10a-PC] If yes, please specify if the research was
14 ▪ Industry-sponsored
15 ▪ Academic research only
16 ▪ Other (please specify – including if there was more than one retraction
17 relating to your journals)
18 ▪ Don't know
19
20
21
22 • [Q11-PC] What authorship criteria do your medical journals apply?
23 ○ ICMJE guidelines
24 ○ Specific journal criteria (modified ICMJE)
25 ○ Specific journal criteria
26 ○ Contributor model
27 ○ Other (please specify)
28 ○ Don't know
29
30
31
32 • [Q12-PC] In the last 12 months, have any of your medical journals refused to accept an
33 author on a manuscript or abstract because he/she has not fulfilled your specified authorship
34 criteria?
35 ○ No
36 ○ Yes
37 ▪ Was this as a result of your own review? Yes/No
38 ▪ Was this as a result of concerns raised by others? Yes/No
39 ○ We don't check authorship criteria – authors are responsible for their own
40 submissions
41 ○ Other (please specify)
42 ○ Don't know
43
44
45
46
47 • [Q13-PC]: What conflict of interest guidelines are used at your medical journals?
48 ○ ICMJE
49 ○ Journal's own
50 ○ Other (please specify)
51 ○ Don't know
52
53
54 ○ [Q13a-PC] Over what duration of time do your journals require authors to disclose
55 COI information?
56 ▪ Current relationships and activities
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Activities within the last 2 years
 - Activities within the last 4 years
 - Activities within the last 5 years
 - More than 5 years
- [Q13b-PC] Do you require disclosures on
 - Solely in relation to drugs/devices that are the subject of the manuscript (Y/N)
 - All industry COI regardless of whether they are discussed in the manuscript (Y/N)
- [Q14-PC] What is your journals' position on professional medical writing support? (tick all that apply)
 - Medical writers are acceptable as long as their contribution is appropriately acknowledged and they are authors if they fulfil the criteria for authorship.
 - All medical writers involved in drafting a manuscript should be authors
 - We follow a contributor model
 - Only where the authors need help for language and grammar
 - We do not accept manuscripts that have had professional medical writing support
 - Other (please specify)
 - Don't know
- [Q15-PC]. Do professional medical writers improve the quality of a manuscript?
 - Yes
 - Sometimes
 - No
 - Don't know
- [Q16-PC] Do you ensure authors acknowledge medical writing support according to your journal's current guidelines?
 - Yes - In our guidance for authors, we provide relevant information (such as a checklist) on acknowledging contributions and support
 - No, This is the responsibility of the authors.
 - Don't know
 - Other (please specify)
- [Q17-PC] Do your medical journals always publish the full acknowledgments submitted by the authors?
 - Yes – both online and in print
 - Yes – in print only
 - Yes – online only
 - No
 - Other (please specify)

- 1
2
3 ○ Don't know
4
5
6 • [Q18-PC] In the past 12 months, how often have you heard of an author refusing to
7 acknowledge professional writing support on a manuscript they submitted to your journal?
8 ○ Never
9 ○ Once
10 ○ More than once
11 ○ Don't know
12
13 ▪ [Q18a-PC] In your opinion, is refusal happening more or less frequently than
14 2 years ago?
15 • More frequently
16 • About the same
17 • Less frequently
18 • Don't know
19
20
21
22
23 • [Q19-PC] What are your medical journal's policies on review articles? (tick all that apply)
24 ○ We review all submissions on merit provided all appropriate acknowledgements and
25 COIs are disclosed and journal guidelines are met
26 ○ We only accept review articles from academia
27 ○ We do not publish review articles
28 ○ Other (please specify)
29 ○ Don't know
30
31
32
33 • [Q20 – PC] What is your philosophy and/or policy on publishing pharmaceutical industry
34 sponsored research? (tick all that apply)
35 ○ We consider all well-conducted research regardless of the funding source
36 ○ We accept industry sponsored research only if they allow full access to the original
37 data
38 ○ We accept industry sponsored research if they allow analysis of the data to be
39 conducted by an independent academic statistician
40 ○ We do a more rigorous review of industry sponsored research
41 ○ We don't accept publications on industry sponsored research
42 ○ Other (please specify)
43 ○ Don't know
44
45
46
47
48 • [Q21-PC] In the past 12 months, has your journal rejected a paper primarily because you
49 believed the content was biased because it was associated with the pharmaceutical industry?
50 ○ No
51 ○ No, we don't publish industry sponsored research
52 ○ Yes, once
53 ○ Yes, more than once.
54 ○ Don't know
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- [Q22-PC] Do your journals accept advertising from industry?
 - Yes
 - No
 - Don't know
 - If yes, do you have an in-house or affiliated sales department that contacts industry regarding potential advertising?
 - Yes
 - No
 - Don't know

 - [Q23-PC] Do your journals sell reprints of individual papers?
 - Yes
 - No
 - Don't know
 - If yes, do you have an in-house or affiliated sales department that contacts industry regarding potential reprints?
 - Yes
 - No
 - Don't know

Section 8 – ACADEMIC, RESEARCH and/or MEDICAL Institution or Association

- [Q1-ARM] Please select the category that best describes the geographic remit of your role
 - Global
 - Regional
 - Please specify which region
 - National
 - Please specify which country [TGaS to add drop down list of countries]
 - Other (please specify)

- [Q2-ARM] Please select the category that best describes your role in the institution/association
 - Executive/Department or Function Head
 - Director/Team Leader
 - Researcher
 - Educator
 - Other (please specify)

- [Q3-ARM] Does your institution/association have a role in publication of medical research in peer-reviewed journals? (tick all that apply)
 - Yes – we conduct and publish our own research
 - Yes – we conduct and publish research in collaboration with academic partners
 - Yes – we conduct and publish medical research in collaboration with pharmaceutical/Biotechnology/Devices industry partners
 - No – we do not publish medical research papers
 - Don't know

- [Q4-ARM] As there are guidelines in place to publish all medical research regardless of outcome, how do you address the challenge of publishing everything? (tick all that apply)
 - Our academics author all of the papers themselves
 - We have dedicated writing resource at our institution
 - We contract with freelancers to support development of the publications
 - Our industry partners fund professional medical writing support for us
 - We prioritise publications of most relevance and interest to the field
 - We don't publish all of the studies that we conduct
 - Don't know

- [Q5-ARM] Do you work with professional medical writers (Check all that apply)?
 - Yes
 - If yes are they
 - Independent freelancers? Y/N
 - Agency professionals? Y/N
 - In-house writing team? Y/N
 - No
 - Don't know

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- [Q6-ARM] If yes to Q5 Who pays for professional medical writing support for your academics?
 - Our institution pays
 - Industry partners pay
 - We don't use paid medical writing support
 - Other (please specify)
 - Don't know

 - [Q7-ARM] How do you ensure that you have acknowledged professional medical writing support according to the current/journal guidelines? (tick all that apply)
 - We expect authors to follow the specific journal requirements
 - We provide training to all of our researchers regarding publication of medical research in journals
 - We leave this up to the journals to determine
 - It is up to the medical writers to ensure they are appropriately acknowledged
 - Other (please specify)
 - Don't know

 - [Q8-ARM] What are your institution policies on review articles?
 - We don't have a policy on this
 - Review articles are allowable
 - We follow journal guidelines on review articles
 - We only support systematic reviews papers
 - Other (please specify)
 - Don't know

 - [Q8a-ARM] If you support review articles, do you work with industry collaborators?
 - We don't work with industry on review papers
 - Yes
 - They pay for the research to be done
 - They pay for a medical writer to support development of the paper once the research has been done
 - They provide an unrestricted grant and have no input into the paper at all
 - Don't know

 - [Q9-ARM] What are your institution policies on industry sponsored research? That is, are you able to collaborate with industry in relation to clinical research projects, able to author papers with industry authors, able to accept the support of medical publication professionals etc?
 - [Free text]

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- [Q10-ARM] Who provides you with advice regarding proper disclosure of potential conflicts of interest when publishing medical research?
 - Our institution provides guidance
 - My colleagues
 - Journal requirements
 - Medical writers
 - Industry personnel
 - We don't get advice
 - Other (please specify)
 - Don't know

 - [Q11-ARM] What guidelines do you follow for conflict of interest disclosures?
 - My institution's
 - The journal's
 - Depends on who's guidelines are strongest
 - Other (please specify)
 - Don't know

 - [Q12-ARM] Please outline your perceptions and attitudes towards pharmaceutical industry involvement in medical publications
 - I think there is a role for industry as authors and collaborators in medical publications as they have internal research and development departments and relevant expertise
 - I think there is a role for industry in supporting medical publications, but not as authors
 - I think industry should hand over the research and allow academia to analyse the data
 - I'm not sure what role industry should have in medical publications
 - Other (please specify)
 - Don't know

 - [Q13-ARM] In the last 12 months, have you been refused authorship on a manuscript or abstract because you did not fulfil authorship criteria?
 - Never
 - Once
 - More than once

 - [Q13a-ARM] If once or more, please indicate why you were refused authorship.
 - Disagreed with the interpretation of the data
 - Disagreed with the order of authorship
 - Left the organisation where I did the work
 - Did not meet authorship criteria
 - Did not agree to adhere to ethical publication practises
 - Did not agree to disclose medical writing support

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Other (please specify)
 - Don't know

 - [Q14-ARM] In the past 12 months, have you refused professional writing support based on concerns about the perception of 'ghost-writing'?
 - No
 - Yes – I prefer to do all my own writing
 - Yes – my institution does not allow the use of any medical writers
 - Yes, but I did not understand the role of the professional medical writer and accepted their support once I understood how this would be disclosed

 - [Q15-ARM] In the last 12 months have you used unacknowledged, professional medical writing support?
 - No
 - Yes (please explain)

 - [Q16-ARM] Do you feel that the pharmaceutical industry influences the content of industry sponsored publications?
 - No
 - Yes - inappropriately influences the selection of data for inclusion, discussion and conclusions

 - Yes - provides appropriate contributions that are acknowledged
 - Yes - provides appropriate contributions that are unacknowledged
 - Other (please specify)
 - Don't know

 - [Q17-ARM] When you are working on a paper relating to an industry sponsored study, do you have full access to the relevant data if you request it?
 - Yes
 - Yes, but I rarely look at the raw data
 - No
 - I have never asked
 - Other (please specify)
 - Don't know

 - [Q18-ARM] When developing a paper with industry partners and other authors, how much input do you have on the choice of journal?
 - The authors decide as a team
 - The lead author usually decides
 - Industry partners decide
 - The agency decides
 - Don't know
 - Other

 - [Q19-ARM] In the past 12 months, to your knowledge, has your department been involved in the development of a peer-reviewed publication for a study (or studies) that did not meet the

1
2
3 primary endpoint or could otherwise be construed as inconclusive or negative? Yes/No/Don't
4 know

- 5 ○ If yes, has the paper(s) been accepted or published in a peer-reviewed journal?
6 Yes/No/Don't know
7
8 ▪ If no (tick all that apply)
9 • The paper(s) has not yet been submitted for peer review
10 • The paper(s) was rejected
11 • The paper(s) was published, but not in a peer-reviewed journal
12 • Other (please specify)
13 • Don't know
14
15
16
17 • [Q20-AG] In the past 12 months, are you aware of any results from a study (or studies) that
18 did not meet the primary endpoint, or could otherwise be construed as inconclusive or
19 negative, for which publication is not planned? Yes/No/Don't know
20
21 ○ If yes, what reason is given for non-publication? (tick all that apply)
22 ▪ Study did not meet primary endpoint
23 ▪ Study was not conducted in humans
24 ▪ Drug development has been discontinued
25 ▪ Study was not well designed
26 ▪ Study did not complete
27 ▪ Additional studies are required to verify the findings
28 ▪ Company did not like the results
29 ▪ Other (please specify)
30 ▪ Don't know
31
32
33
34 • [Q21-ARM] Is number of academic publications a requirement for progression in your
35 department?
36 ○ Yes – they are very important
37 ○ Yes – they are very important, but only if listed as lead or last author
38 ○ Somewhat important
39 ○ Not really
40 ○ Other (please specify)
41 ○ Don't know
42
43
44
45 • [Q22-ARM] Who do you think should provide training about ethical medical publication
46 practises and standards to academia?
47 ○ Our institution
48 ○ The journals
49 ○ Industry
50 ○ Professional associations
51 ○ Training during qualifications
52 ○ Other (please specify)
53 ○ Don't know
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
- [Q23-ARM] What method do you use most when looking for up-to-date information in peer-reviewed publications?
 - PubMed
 - Google
 - Google scholar
 - My institution's library
 - Open access journals only
 - Print journals delivered to me
 - Online journals only
 - Other (please specify)

OPTIONAL QUESTIONS AND CLOSING COMMENTS

Email address to opt-in for receiving results

- 16
17
18
19
20
21
22
23
24
25
26
27
28
- Please state where you obtained the link to this survey
 - Email from an association that I am a member of
 - From my organization
 - GPS LinkedIn site
 - From a colleague
 - Other (please specify)

29
30
31
32
33

Please provide your email address if you would like to receive the summary results once available

IF you have time we would welcome any additional thoughts around:

- 34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- What educational needs remain regarding ethical publication practices? (free text)
 - How best might these be addressed? (free text)
 - Are there any additional questions you think would be useful to ask in future surveys? (free text)

BMJ Open

Awareness and enforcement of guidelines for publishing industry-sponsored medical research among publication professionals: the Global Publication Survey

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004780.R1
Article Type:	Research
Date Submitted by the Author:	31-Mar-2014
Complete List of Authors:	Wager, Elizabeth; Sideview Woolley, Karen; ProScribe Medical Communications, Adshead, Viv; KnowledgePoint 360, Cairns, Angela; KnowledgePoint 360, Fullam, Josh; TGaS Advisors, Gonzalez, John; AstraZeneca, Grant, Tom; AstraZeneca, Tortell, Stephanie; KnowledgePoint 360,
Primary Subject Heading:	Medical publishing and peer review
Secondary Subject Heading:	Ethics
Keywords:	MEDICAL JOURNALISM, MEDICAL ETHICS, MEDICAL EDUCATION & TRAINING

SCHOLARONE™
Manuscripts

Only

1
2
3 **Awareness and enforcement of guidelines for publishing industry-sponsored medical**
4 **research among publication professionals: the Global Publication Survey**
5
6
7
8

9
10 Elizabeth Wager

11 Sideview, Princes Risborough, UK

12
13
14 Karen Woolley

15 ProScribe Medical Communications, Noosaville, Australia; Faculty of Health

16 Sciences, University of Queensland, Brisbane, Australia; Faculty of Science, Health,

17 Education and Engineering, Sunshine Coast, Australia
18
19
20

21
22
23 Viv Adshead

24 KnowledgePoint360 Group, Macclesfield, Cheshire, UK

25
26
27 Angela Cairns

28 KnowledgePoint360 Group, Macclesfield, Cheshire, UK

29
30
31
32 Josh Fullam

33 TGaS Advisors, East Norriton, Pennsylvania, USA

34
35
36 John Gonzalez

37 AstraZeneca, Alderley Park, Cheshire, UK

38
39
40 Tom Grant

41 AstraZeneca, Alderley Park, Cheshire, UK *

42
43
44
45 Stephanie Tortell

46 Complete Medical Communications, Macclesfield, Cheshire, UK **

47
48
49 * now at Complete HealthVizion, Macclesfield, Cheshire, UK

50
51
52 ** now at: KnowledgePoint360 Group, Macclesfield, Cheshire, UK
53
54
55
56
57
58
59
60

1
2
3 **Corresponding author:** Dr Elizabeth Wager

4 Sideview, 19 Station Road, Princes Risborough, HP27 9DE, UK

5
6
7 email: liz@sideview.demon.co.uk

8
9
10 phone (+44) (0)1844 275814

11
12 fax (+44) (0)1844 275034

13
14
15
16 **Keywords**

17
18 publications, guidelines, drug industry, ethics, data reporting

19
20
21
22
23 **Word count**

24
25 5451 words (excluding abstract, refs, figures, and tables)

26
27
28
29
30 I, Dr Elizabeth Wager, the Corresponding Author of this article contained within the original
31 manuscript which includes any diagrams & photographs, other illustrative material, video,
32 film or any other material howsoever submitted by the Contributor(s) at any time and related
33 to the Contribution ("the Contribution") have the right to grant on behalf of all authors and do
34 grant on behalf of all authors, a licence to the BMJ Publishing Group Ltd and its licensees, to
35 permit this Contribution (if accepted) to be published in BMJ Open and any other BMJ Group
36 products and to exploit all subsidiary rights, as set out in the licence at:
37 http://group.bmj.com/products/journals/instructions-for-authors/BMJOpen_licence.pdf
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: To gather information about current practices and implementation of publication guidelines among publication professionals working in or for the pharmaceutical industry.

Design/ Setting: Web-based survey publicised via email and social media to members of the International Society for Medical Publication Professionals (ISMPP) and other organizations November 2012 to February 2013.

Participants: 469 individuals involved in publishing industry-sponsored research in peer-reviewed journals, mainly working in pharmaceutical or device companies ('industry', n=144), communication agencies ('agency', n=238), contract research organizations (CRO, n=15), or as freelancers (n=34). Most respondents (78%) had worked on medical publications for ≥ 5 years and 62% had a PhD/MD.

Results: Over 90% of industry, agency, and CRO respondents routinely refer to Good Publication Practice (GPP2) and the International Committee of Medical Journal Editors' Uniform Requirements. Most respondents (78% industry, 79% agency) received mandatory training on ethical publication practices. Over 90% of respondents' companies had publication guidelines or policies and required medical writing support to be acknowledged in publications (96% industry, 99% agency). Many industry respondents used publication management tools to monitor compliance with company guidelines and about half (46%) stated that their company had formal publication audits. Fewer agencies audited adherence to guidelines but 20% of agency respondents reported audits of employees and 6% audits of freelancers. Of concern, 37% of agency respondents reported requests from authors or sponsors that they believed were unethical, although 93% of these requests were withdrawn after respondents explained the need for compliance with guidelines. Most respondents'

1
2
3 departments (63% industry, 58% agency, 60% CRO) had been involved in publishing studies
4
5 with negative or inconclusive results.
6
7

8 **Conclusions:** Within this sample, most publication professionals working in or for industry
9
10 were aware of, and applying, major publication guidelines. However, the survey also
11
12 identified specific areas where education and promotion of guidelines is needed to ensure
13
14 ethical publication practices.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article summary

Strengths of this study

- Large-scale, international survey of publication professionals (n=469)
- Focused on awareness and implementation of guidelines relating to responsible publication practice, providing insight into current industry practices
- Included publication professionals (e.g. writers, planners, and managers) working in pharmaceutical and medical device companies, medical communication agencies, contract research organizations, or as freelancers
- Survey allowed anonymous responses

Limitations of this study

- Limited response from freelancers (n=34), journal editors, publishers, and academics (n=38)
- Self-selection bias may mean that respondents were not representative of the total population if those with a particular interest in, or concerns about, ethical publication practices were more likely to complete the survey than those with less knowledge, interest or concerns
- Methods used for publicising the survey (via websites, social media, etc.) meant it was impossible to calculate a precise response rate.

INTRODUCTION

Misleading, inaccurate, or incomplete reporting of clinical trial findings can have serious consequences, since doctors and policy-makers rely on publications when developing treatment guidelines and making decisions affecting patients. The involvement of medical writers and other publication professionals, such as planners and managers, in developing peer-reviewed publications reporting clinical trials has been criticised by some,[1, 2] but defended by others.[3, 4] Similarly, while some studies have shown that publications funded by pharmaceutical companies are of equal or higher quality than publications from academia,[5-7] others have shown that they are more likely to be biased.[8, 9] Concern about irresponsible publication practices, from both within and outside the industry, has led to the creation and evolution of several guidelines.[4, 10-13] These guidelines seek to establish responsible publication practices, increase transparency, and prevent bias and commercial influence in reporting medical research. While many have welcomed such guidelines, critics of the pharmaceutical industry remain unconvinced, for example, commenting “Publicly, they insist that everything has changed.... But my concern is this. Having seen so many codes openly ignored and broken, it’s hard to take any set of voluntary ideals seriously.”[14] Given this concern about whether voluntary guidelines are effective, and because there was little evidence available to show whether continuing concerns about industry publication practices were justified, we sought to generate ‘real world’ evidence about current practices in the medical publications profession.

We therefore carried out a large-scale, international, survey (the Global Publication Survey) to obtain information about the ways in which medical writers and other publication professionals work and, in particular, their awareness of current publication guidelines. We also sought to learn about the processes adopted by pharmaceutical and communications

1
2
3 companies to encourage responsible practices and to implement published guidelines. The
4
5 aim of this survey was to identify areas in which guidelines were understood and enforced,
6
7 areas for improvement, and targets for education and training.
8
9

10 11 12 **METHODS**

13
14 The survey questionnaire (Appendix 1) was developed by an international team including
15
16 professional writers and publication managers with experience of working in pharmaceutical
17
18 and communications companies and in a freelance capacity. Several team members had been
19
20 involved in developing publication guidelines (see the author list and acknowledgements for
21
22 details). Question topics were based on results of a previous survey of members of the
23
24 International Society for Medical Publication Professionals (ISMPP). Question and answer
25
26 options were discussed, drafted, and refined by the team. Question types included multiple
27
28 choice (check one/check all), matrix table, rating (1-5 scale), ranking (top 3), dropdown
29
30 selection, and free text. Logic checks limited the number of questions respondents saw based
31
32 on 'skip logic' (i.e. some questions only appeared if the respondent answered 'yes' to an
33
34 earlier question). 'Not applicable', 'Don't know', and 'Other (specify)' responses were
35
36 offered to capture the full range of possible responses.
37
38
39

40
41
42 The questionnaire was transcribed to an online data capture tool hosted by Qualtrics
43
44 (www.qualtrics.com) survey technology. Pilot testing for question content, flow, and logic
45
46 was performed by team members, and the survey was revised as necessary.
47
48
49

50
51
52 Respondents saw a different selection of questions depending on their work sector
53
54 (categorised as: pharmaceutical or medical device company, agency, contract research
55
56 organization [CRO], freelance, journal editor, publisher, or academic) and their previous
57
58
59
60

1
2
3 answers. A response was required for each question before the next screen was displayed but
4
5 users had the option to revisit previously completed questions. Optional questions were
6
7 included at the end of the core survey allowing participants to offer additional comments.
8
9

10
11 The survey was announced on 28th November 2012 via email to all members of ISMPP
12
13 (n=1105). A link included in the email provided individual access to the survey (so each
14
15 recipient could respond only once and reminders could be sent to non-responders). ISMPP
16
17 members were also encouraged to share an unrestricted link to the survey with individual
18
19 colleagues or via their company intranet. The survey was also promoted via social media
20
21 (LinkedIn and Twitter). Several organizations and companies (including the American
22
23 Medical Writers Association, the European Medical Writers Association, the European
24
25 Association of Science Editors, the Committee on Publication Ethics, McCann Complete
26
27 Medical, and Excerpta Medica) publicised the survey to their members or on their websites
28
29 through December 2012. The survey closed on 18th February 2012.
30
31
32
33
34
35

36 Respondents could complete the survey anonymously but, to encourage participation, had the
37
38 option of supplying an email address to enter a draw for one of two iPad tablet computers.
39
40 Participants were informed that their personal information would not be shared beyond those
41
42 administering the survey. Respondent-level data was available only to TGaS Advisors (the
43
44 company responsible for all aspects of survey administration and data aggregation), and was
45
46 not shared with the survey organizers or sponsors. Descriptive statistics using frequencies and
47
48 percentages were used. Funding for the incentive prizes was provided by ISMPP. The team
49
50 members who developed the questionnaire and executed the survey, interpreted the data, and
51
52 developed this publication, worked in their own time or during work time with permission
53
54 from their various employers but without specific funding or payment.
55
56
57
58
59
60

1
2
3
4
5 Research Ethics Committee (Internal Review Board) approval was not required for this
6
7 survey, as it did not relate to personal medical information, did not involve patients or
8
9 healthcare professionals (other than in their role as journal editors), was not carried out by an
10
11 academic institution, and participation was entirely voluntary. Participants were given the
12
13 option of supplying an email address if they wanted to enter a prize draw, but could remain
14
15 completely anonymous if they preferred. We considered that provision of an email address
16
17 does not necessarily identify an individual (since email addresses do not necessarily indicate
18
19 name or workplace) and participants were assured that only two people would be contacted to
20
21 supply the incentive prize. Email details were stored securely by TGas Advisors and were not
22
23 revealed to anybody else involved with the survey. Following the guidelines of University
24
25 College London (although this study was entirely independent of any academic institution)
26
27 and of the National Research Ethics Service of the UK, such a questionnaire is exempt from
28
29 requiring Research Ethics Committee approval.
30
31
32
33
34
35

36 **RESULTS**

37 **Respondents**

38
39
40 The survey reached the intended international target audience with responses from 23
41
42 countries. The largest responses came from the USA (44%) and UK (39%). Of the 490 who
43
44 opened the survey invitation, 469 confirmed that they were involved in publishing industry-
45
46 sponsored research in peer-reviewed medical journals and completed the survey (Table 1).
47
48 Most respondents (92%), worked in pharmaceutical or medical device companies (termed
49
50 'industry' respondents; 31%), medical communications agencies (termed 'agency'
51
52 respondents; 51%), or contract research organizations (CROs 3%) providing publication
53
54 services to drug and device manufacturers, or as freelancers (7%). The survey was also
55
56
57
58
59
60

1
2
3 completed by 5 journal editors, 17 publishers, 9 academics and 7 people working in other
4
5 roles – results from these categories (total = 8%) are not reported in the text due to the low
6
7 response rate and small numbers but may be viewed at [http://www.ismpp.org/gps-raw-
10
11 data](http://www.ismpp.org/gps-raw-
8
9 data). Because of the responsive design, the numbers answering each question varied but
12
13 respondents generally answered about 40 questions. Most respondents took 20-30 minutes to
14
15 complete the survey. The full data tables are available at [http://www.ismpp.org/gps-raw-
18
19 data](http://www.ismpp.org/gps-raw-
16
17 data).

20
21 Because of the methods used to promote the survey (including websites and social media), it
22
23 was not possible to calculate a precise response rate or assess differences between
24
25 respondents and non-respondents. However, the membership of ISMPP at the time of the
26
27 survey was 1105 and the response rate from ISMPP members was 20% (i.e. 221 of the
28
29 respondents responded via the individual links sent out to ISMPP members).

30
31
32
33
34 Most respondents were highly educated (56% had a doctorate) and experienced (79% had
35
36 worked with medical publications for at least 5 years) (Table 1). Half of the respondents
37
38 worked in departments that had been involved with over 30 manuscripts in the last year.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Respondent characteristics

Characteristic	Number	Percentage
Workplace:		
industry ¹	144	31
agency or CRO ²	238	51
CRO ³	15	3
freelance	34	7
other	38	8
Experience of working with peer-reviewed publications:		
<2 years	36	8
2-4 years	66	14
5-9 years	111	24
10 years or more	256	55
Qualification: ⁴		
Masters degree	111	24
Doctorate	263	56
MD / medical qualification	26	6
Other	26	6
Certified Medical Publication	161	34
Professional (CMPP)		

¹Pharmaceutical, biotech or medical device company

²Communications company

³Contract research organization

⁴ Respondents were asked to tick all that applied

Awareness of guidelines

Almost all industry and agency respondents reported being aware of international guidelines on responsible publication practices (Fig 1). Overall, 91% stated that they routinely referred to Good Publication Practice (GPP2) and 93% to the International Committee of Medical Journal Editors' Uniform Requirements for guidance on ethical practice. Other sources of guidance consulted routinely by respondents in all sectors included ISMPP (71%), medical writers associations (e.g. AMWA and EMWA: 39%), and the Committee on Publication Ethics (COPE: 34%).

Training

Regular training on ethical publication practices was compulsory for most respondents in industry and agencies. Mandatory training for employees was reported by 78% of industry, 79% of agency, and 93% of CRO respondents. In addition, 68% of agency respondents reported that their industry customers provided mandatory training for agency personnel. Training at least once a year was reported by 70%, 68% and 71% for industry, agency and CRO respondents respectively. Just over half the industry respondents (55%) reported that their companies provided training for agency staff or freelancers but only 17% of agency and 20% of CRO respondents reported that their organization provided training for freelancers (while 43% and 53% respectively didn't know if freelancers were trained). Similarly, 24% of the freelancers (5/21) reported that they received mandatory training from industry or agency customers.

Respondents kept up-to-date on current guidelines primarily via training provided by their organization (64%), from professional associations (68%), and monitoring the literature (70%).

Company codes of conduct and publication policies

In addition to their awareness of external guidelines on ethical publication practices (e.g., GPP2), most respondents reported being aware of internal guidelines governing publication practices. Overall, 78% of respondents worked in an organization that had a Code of Conduct governing ethical publication practices. Nearly all the industry (94%) and agency (94%) respondents and all the CRO respondents (15/15) stated that their company had guidelines or a policy on ethical publication practices (5 industry and 8 agency respondents stated their company did not have such a policy while 3 and 7, respectively, did not know) (Fig 1).

Most company guidelines and policies are not publicly available: only 38% of industry, 35% of agency, and 33% of CRO respondents reported that these documents were publicly accessible (e.g. posted online) (Figure 2).

Of the industry respondents, 67% stated that their company was committed to peer-reviewed publication of results of all studies in humans. Exceptions to this commitment were studies for which companies did not have control (e.g. investigator-initiated studies) (reported by 21) and Phase 1 studies (i.e. early-phase drug development) (reported by 14).

Public disclosure of trial results was reported, by those working within the industry, to be fulfilled by: posting results on a public register (92%), publishing in a peer-reviewed journal (73%), publishing a conference abstract (51%), posting results on a company website (28%), or a combination of these. When asked about the timing of journal publications, most industry respondents reported that their company policy was to submit a manuscript within 12 or 18 months of study completion (last subject, last visit) (43% and 18% respectively).

1
2
3 Nevertheless, 24% of industry respondents reported that their company did not have a target
4
5 deadline for submitting a manuscript after trial completion (Figure 2).
6
7

8
9
10 Similar proportions of industry and agency respondents (80% and 81% respectively) reported
11
12 that authorship obligations were set out in formal agreements before manuscript development
13
14 (Fig 1). Almost all industry (96%) and agency (99%) respondents, and 100% of CRO
15
16 respondents, reported that their department ensured that authors acknowledge professional
17
18 medical writing support in every publication (Fig 1). Only one respondent from each of the
19
20 industry and agency groups answered no to this question. However, 11% of respondents from
21
22 both industry and agency, and 13% from CROs, were aware of academic authors initially
23
24 refusing to acknowledge professional writing support in the last 12 months.
25
26
27
28

29 **Compliance with codes**

30
31 Respondents from industry, and to a lesser extent from agencies, reported that their
32
33 publication practices were subjected to compliance checks. Of the industry respondents, 61%
34
35 stated that their company had a formal process for monitoring adherence to company
36
37 standards and 66 of these (46% of the total) carried out publication audits. A very similar
38
39 response was obtained from those working in CROs (60% and 47% respectively). However,
40
41 of the agency respondents, 44% reported that their company had formal compliance
42
43 monitoring for internal standards and only 20% carried out publication audits. In addition,
44
45 about half the industry respondents (47%) reported that their company had a formal process
46
47 for monitoring third-party providers' adherence with company standards and 75% of these
48
49 reported that this involved an audit. Agency and CRO respondents stated that some (43%,
50
51 47% respectively), most (19%, 0%), or none (6%, 13%) of their customers had formal,
52
53
54
55
56
57
58
59
60 regular processes such as knowledge tests or audits for monitoring suppliers' adherence to the

1
2
3 customer's standards, while 27% of agency and 40% of CRO respondents did not know if
4
5 their customers did this. Agency and CRO respondents also reported that their customers
6
7 used publication management tools to assess compliance (only 6% and 13% respectively
8
9 reported that no customers did this).
10

11
12
13
14 Of the industry respondents, 52% worked in a company operating under a US Government
15
16 'Corporate Integrity Agreement' (CIA: see [https://oig.hhs.gov/compliance/corporate-](https://oig.hhs.gov/compliance/corporate-integrity-agreements/index.asp)
17
18 [integrity-agreements/index.asp](https://oig.hhs.gov/compliance/corporate-integrity-agreements/index.asp)), which typically requires formal compliance checking.
19
20

21 22 23 **Organization of publication activities**

24
25 Publication activities were primarily governed by medical departments; publications were
26
27 rarely funded, or approved, by commercial departments (Fig 1). According to the industry
28
29 respondents, the budget for peer-reviewed publications was usually held by the medical
30
31 affairs (72%) or clinical development (24%) departments. Nevertheless, seven respondents
32
33 (5%) stated that the publications budget was held by a commercial department (e.g. sales or
34
35 marketing) (Fig 2). Involvement of members of commercial departments in developing
36
37 publications varied, with industry respondents stating that they were: not involved (27%),
38
39 provided with information only (48%), members of the publication team (44%), allowed to
40
41 suggest target journals for author consideration (22%), involved in reviewing manuscripts for
42
43 accuracy (19%), or part of a formal approval process (5%).
44
45
46
47
48

49 50 **Agency response to requests for perceived unethical practices**

51
52 Respondents were often, but not always, successful in preventing publication practices they
53
54 considered unethical. Of the agency respondents, 38% were aware, in the past 12 months, of
55
56 their company being asked by an author or a sponsor to do something that they believed
57
58
59
60

1
2
3 contravened ethical practices (10% once and 28% more than once) while 2/15 CRO
4
5 respondents (13%) reported such requests. Respondents reported that their agency's response
6
7 was to explain the need for compliance, resulting in the request being withdrawn or amended
8
9 (92% and both CRO cases), or to refuse to accept the work (1%); however, 3% (3/90) stated
10
11 that the agency ultimately complied with the request.
12
13

14
15
16 Although a slightly higher proportion of freelancers (17/34, 50%) reported requests which
17
18 they believed constituted unethical practices, this should not be over-interpreted due to the
19
20 small group size; 12% (2/17) of freelancers accepted such work.
21
22

23 24 25 **Information provided to authors**

26
27 Authors were routinely provided with various documents and data sources to facilitate
28
29 manuscript preparation. These documents included (for agency and industry respondents
30
31 respectively): clinical study report (81%, 79%), study protocol (79%, 83%), summarized data
32
33 (67%, 66%), statistical report (58%, 62%), manuscript outline (58%, 56%), statistical
34
35 analysis plan (42%, 54%), and raw data/data tables (42%, 42%).
36
37
38
39

40 41 **Enforcement of authorship criteria**

42
43 Respondents actively enforced compliance with authorship criteria (Table 2).
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2

Responses to the question “In the last 12 months, to your knowledge, how often has your department recommended to the lead author the removal of a co-author from a manuscript or abstract that was in development?”

	Never	Once	More than once	Other	Don't know
Industry (n=144)	44% (64)	10% (15)	22% (32)	2% (3)	21% (30)
Agency (n=238)	24% (58)	11% (26)	35% (84)	3% (6)	27% (64)
CRO* (n=15)	27% (4)	33% (5)	7% (1)	7% (1)	27% (4)
Freelance (n=34)	74% (25)	9% (3)	15% (5)	3% (1)	0

*Contract Research Organization

Of the industry respondents, 33% were aware of an author being removed from a manuscript within the last 12 months and 94% stated that this was due to the individual not meeting authorship criteria. Other reasons for recommending removal of an author included individuals leaving the company (28%) or not agreeing to adhere to ethical publication practices (13%) (respondents could select more than one reason). Three respondents from industry and two from agencies reported authors being removed because they disagreed with

1
2
3 the interpretation of the data. Eight freelancers reported recommending the removal of an
4
5 author, in all cases because the individual did not meet authorship criteria.
6
7

8 9 10 **Publishing negative findings**

11 Most industry respondents' companies attempted to publish negative or inconclusive results.
12
13 Of the industry respondents, 63% reported that their department had supported the
14
15 publication of a study with negative or inconclusive results (17% stated that this had not
16
17 happened and 19% did not know). Only six respondents (4%) were aware of a negative or
18
19 inconclusive study for which publication was not planned, in three cases this was due to the
20
21 discontinuation of product development. Responses were similar in the agency (and CRO)
22
23 groups, with 58% (60%) aware of the publication of negative findings and 6% (13%) being
24
25 aware of negative findings for which publication was not planned. Of the freelancers, 38%
26
27 had been involved with the publication of negative findings in the last 12 months.
28
29
30
31
32
33

34 **Freelance responses**

35
36 Only 34 freelance publication professionals responded to the survey and some of these did
37
38 not answer all questions, therefore the results may not be representative and should not be
39
40 over-interpreted. However, the following findings were noteworthy: 12/34 (35%) did not
41
42 know whether their customers had publication guidelines; 15/21 (71%) stated that they did
43
44 not receive mandatory training; and 21/34 (62%) stated that their clients did not have formal,
45
46 regular processes to monitor their adherence to standards. However, freelancers reported
47
48 routinely consulting published guidelines (100% for ICMJE, 91% for GPP2) on ethical
49
50 issues.
51
52
53
54
55
56
57
58
59
60

DISCUSSION

This is one of the largest, international surveys designed to capture information about current knowledge and implementation of publication guidelines within the pharmaceutical, medical device, and medical communications industries. Our survey showed high reported levels of knowledge of the various publication guidelines among publication professionals, with over 90% of respondents stating that they routinely referred to them. Although these published guidelines (such as GPP2) are not generally enforced by legislation, according to our survey most companies have codes of conduct, policies, or internal guidelines that reflect and enforce them. Similarly, most companies (industry and agencies) provide mandatory training to internal staff, while many pharmaceutical and medical device companies also train agency personnel who develop publications on their behalf. The relatively low rates of training and auditing of freelancers suggested in this survey (albeit from a small number of respondents), however, may represent a problem that companies, agencies, and authors who work with freelancers should address.

Many pharmaceutical companies in the USA currently operate under Corporate Integrity Agreements (CIAs). For such companies, many aspects of good publication practice are legally enforced. An analysis of 12 such agreements issued from 2009 to mid-2012 showed that they included requirements for author agreements, publication plans, and the posting of study results.[15] The CIA requirements were consistent with GPP2 and the ICMJE guidelines and also mandated training and reporting. CIA requirements apply not only to the pharmaceutical company but also to their management of any third-party suppliers, therefore, they will also affect many agencies, freelancers, and CROs. Similarly, even companies without a CIA often require suppliers to follow their policies. Therefore, for many agencies

1
2
3 and freelancers, failure to follow a customer's policy could mean loss of future business, thus
4
5 the underlying guidelines are viewed as compulsory rather than optional.
6
7

8
9
10 The importance with which guidelines are viewed is reflected in the effort (and therefore time
11 and money) companies invest in monitoring compliance. Our survey found that many
12 pharmaceutical and device companies have formal monitoring processes including
13 publication audits. Since our survey may have included several respondents from the same
14 company, the results cannot indicate precisely what proportion of companies have such
15 processes but it is probably well over half. The fact that fewer agencies appear to audit to
16 their own internal standards is not surprising, since many reported being regularly audited by
17 their customers. However, rates of training and auditing of freelancers (by pharmaceutical
18 companies and agencies) is less reassuring and suggests room for improvement.
19
20
21
22
23
24
25
26
27
28
29

30
31
32 Many companies use specialist publication planning software (such as Datavision™ or
33 PubSTRAT™). Our survey shows that such tools are used not only for publication project
34 management but also to monitor and demonstrate compliance with company procedures, for
35 example, by ensuring that all authors have approved a manuscript outline, drafts, and the final
36 version.
37
38
39
40
41
42
43
44

45 Lack of transparency surrounding company involvement, non-disclosure of competing
46 interests, and misleading authorship have been causes for concern in industry-sponsored
47 publications in the past.[16] In particular, the occurrence of 'ghost-writing' (i.e.
48 unacknowledged use of medical writers) and guest or honorary authorship (i.e. named authors
49 not fulfilling journal authorship criteria) were spurs for the development of both general and
50 specific guidelines.[3, 4, 11, 17] It is therefore encouraging that 96-100% of respondents
51
52
53
54
55
56
57
58
59
60

1
2
3 (working in pharmaceutical and medical device companies, agencies, and CROs) stated that
4
5 their department ensured that medical writers were acknowledged (thus preventing the
6
7 medical writers from being 'ghost writers'). Of concern, however, is the fact that some
8
9 academic authors apparently continue to be reluctant to acknowledge writing support.
10
11 Although publication professionals can alert authors about the need for disclosure, academic
12
13 institutions clearly have an educational role to play.
14
15

16
17
18 The ICMJE authorship criteria (which are widely endorsed by medical journals and which
19
20 were revised after the survey) state that listed authors should have made substantial
21
22 contributions to both the research and its publication. Therefore authorship cannot be
23
24 determined until a publication is developed. Individuals involved with the research being
25
26 reported may be invited to become authors, but will not qualify unless they also take an
27
28 active role in the publication. It is therefore encouraging that our survey found that not only
29
30 industry sponsors of research, but also publication agencies and freelancers working for them,
31
32 actively enforce authorship criteria by suggesting that individuals should be removed from
33
34 author listings if they fail to meet the ICMJE or other agreed criteria (see Table 2). It can take
35
36 considerable courage for a freelancer or agency employee to suggest that a proposed author
37
38 has not contributed sufficiently to merit being listed, especially if that person is a senior
39
40 academic or well-known expert. Being the one to identify a guest author carries the risk of
41
42 damaging relationships and possibly work prospects. However, arguably there is an even
43
44 greater and more serious risk of damaged relations, reputations, and work prospects if a
45
46 publication professional fails to raise authorship concerns which are later raised by a journal.
47
48 Early clarification of authorship obligations should reduce the risk of guest authorship and it
49
50 was encouraging that most respondents reported that authorship agreements were confirmed
51
52 before manuscript preparation started.
53
54
55
56
57
58
59
60

1
2
3
4
5 As we cannot tell how often proposed authors fail to contribute to publications, our survey
6
7 cannot show how often this is overlooked, but the fact that almost one-third of industry
8
9 respondents were aware of instances of authors being removed because they did not meet
10
11 authorship criteria suggests that guidelines are being enforced. However, this question also
12
13 revealed that three industry (2%) and two agency (0.8%) respondents were aware of authors
14
15 being removed from publications because they disagreed with the interpretation of the
16
17 findings. We cannot tell how many cases these represent, since several respondents may have
18
19 reported the same case, nor can we tell whether the disagreements about interpretation were
20
21 with the sponsor (which would be concerning) or between co-authors, but this issue needs
22
23 further scrutiny.
24
25
26
27
28

29
30 The difficulties of interpreting the ICMJE authorship criteria in some situations have been
31
32 examined in a study coordinated by the Medical Publishing Insights and Practices (MPIP)
33
34 Initiative.[18] Using vignettes presenting ‘challenging real-world authorship scenarios’ this
35
36 study found that journal editors, clinical investigators, medical writers, and publication
37
38 planners had different views about who qualified for authorship and suggested that additional
39
40 guidance might be helpful.
41
42
43
44

45 **Limitations**

46
47 We had originally hoped to compare or confirm responses from publication professionals
48
49 with those from journal editors and academic investigators, however, we were less successful
50
51 in promoting the survey among these groups than among publication professionals and
52
53 consider the response from these sectors too small to be reliable. The number of responses
54
55 from freelance publication professionals was also disappointing and it is therefore important
56
57
58
59
60

1
2
3 not to over-interpret the findings from this group. Care should also be taken in extrapolating
4 proportions of respondents to proportions of companies or agencies, since we had no way of
5 measuring the numbers of respondents per company.
6
7
8
9

10
11 We also recognise that our survey, like many others, carried the risk of self-selection bias.

12
13 Our survey was promoted mainly via professional organizations such as ISMPP and
14 AMWA/EMWA which promote ethical publication practices. Those choosing to respond to a
15 survey supported by these associations may be more likely to follow and report ethical
16 publication practices. Also, those who chose to complete the survey may have had a special
17 interest in, or concerns about, the issues covered. Our respondents therefore may not be
18 representative of all publication professionals and may be better informed about the topics
19 covered by this survey and more aware of guidelines (e.g. from attending professional
20 meetings or taking part in educational activities). However, due to the methods used to
21 publicise the survey (including websites and social media rather than to a clearly defined
22 population) it was not possible to compare characteristics of respondents and non-
23 respondents. We also acknowledge that our respondents came primarily from higher-income
24 countries. Our findings may not be applicable to publication practices in lower-income
25 countries, particularly given the significant influence of country income on publication
26 practices. [5, 19]
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 Another problem with any survey is if respondents give 'socially desirable' rather than
48 truthful answers. One reason we have confidence in our findings is that responses were not
49 uniform, e.g. only 34% reported referring to the COPE guidelines compared with 91% for the
50 ICMJE guidelines. The fact that the survey highlighted weaknesses as well as strengths (e.g.
51 the proportion of freelancers who receive training) also suggests that responses were factual.
52
53
54
55
56
57
58
59
60

Comparison with other surveys

Journal editors' awareness of various guidelines was measured in 2007 in an international survey to which 111 editors of biomedical journals responded.[20] This survey noted that "awareness and use of guidelines and other resources on publication ethics was generally low". Over half the editors (55%) reported being unaware of the ICMJE Uniform Requirements and two-thirds (67%) were unaware of the GPP guidelines, while the proportion of editors reporting that they had used these guidelines were just 24% and 9% respectively. This represents a marked contrast to the publication professionals responding to our survey, over 90% of whom reported that they routinely referred to these two guidelines.

Another survey of 183 editors of high-impact medical journals in 2009 found that, although 76% had received training in medical editing, they performed poorly when answering questions about: authorship (only 30% gave 'correct' answers, i.e. consistent with commonly cited guidelines), plagiarism (17% correct), peer review (16% correct), and conflicts of interest (15% correct).[21]

A 2012 survey of 294 healthcare professionals found that 42% were unaware of the GPP guidelines.[22] This survey also found that the doctors (69% of whom were authors on peer-reviewed articles) were unfamiliar with, or disagreed with, the ICMJE authorship criteria, since a considerable proportion considered that data collection (51%) or general supervision of a laboratory (33%) alone were criteria for authorship. Nevertheless, 66% of respondents in the healthcare practitioners survey stated that they would be concerned about 'the involvement of pharmaceutical employees as authors or reviewers of a draft manuscript'. A smaller survey of surgeons in Croatia (in 2011) found that only 54% (31/57) were aware of

1
2
3 the ICMJE guidelines although 74% (43/58) of the respondents had worked on at least 2
4
5 manuscripts for publication in the last 2 years.[23]
6
7

8
9
10 A large-scale, repeated survey of medical writers (who were nearly all members of AMWA
11 or EMWA),[24] which attracted 746 responses in 2005, and 662 in 2008, found lower levels
12
13 of familiarity with guidelines than the current survey (carried out in 2012) but showed that
14
15 awareness had risen between 2005 and 2008. For example, the proportion of respondents
16
17 claiming to be familiar with ICMJE guidelines rose from 54% in 2005 to 75% in 2008. The
18
19 figures for GPP were 43% and 58%, and for the EMWA guidelines (published in 2005) 27%
20
21 and 46% respectively in 2005 and 2008. The AMWA/EMWA survey also asked writers
22
23 about their experience of being involved with unacknowledged writing work (i.e.
24
25 ghostwriting). In 2005, 39% stated that this practice had decreased in the last 5 years (52%
26
27 stated that it was unchanged and 8% that it had increased). In 2008, 63% considered that
28
29 ghostwriting had decreased, 30% stated that it was unchanged and 6% that it had increased in
30
31 the last 5 years. The proportion of professional writers reporting that they always requested
32
33 acknowledgement for a substantial contribution to a manuscript also rose from 25% in 2005
34
35 to 43% in 2008. The survey was repeated in 2011 (with 620 respondents)[25] and responses
36
37 showed a clear decrease in the proportion of manuscripts (not necessarily all for peer-
38
39 reviewed journals) with undisclosed contributions (i.e. ghostwriting) which fell from 62% in
40
41 2005, to 42% in 2008, and 33% in 2011.
42
43
44
45
46
47
48

49
50 Ghostwriting of review articles commissioned by pharmaceutical companies was a particular
51
52 concern when the first GPP guidelines were developed.[26] A survey of authors published in
53
54 six, high impact general medical journals found a decline in ghost authorship between 1996
55
56 and 2008, and a significant decrease (from 26% to 15%) in honorary authorship (which often
57
58
59
60

1
2
3 accompanies ghostwriting) for review articles and editorials (although not for other types of
4
5 article).[27]
6
7

8
9
10 Our survey did not get sufficient response from academics to draw any conclusions about
11
12 their understanding of their role as authors of medical publications. We hope that the full
13
14 report of the MPIP authorship project will cast more light on this.[18]
15
16

17 18 **RECOMMENDATIONS** 19

20 While many of our findings are heartening (Fig 1), some indicate a need for further action
21
22 (Fig 2). We hope that the professional organizations who were involved with this survey (in
23
24 particular, ISMPP, AMWA, and EMWA) along with pharmaceutical and medical device
25
26 companies will use the findings to identify topics for future training or discussion. We
27
28 suggest they might focus on the following areas.
29
30

- 31
32 • Although many companies and agencies had publication policies, it is disappointing
33
34 that so few of these policies were made public. We encourage companies to post their
35
36 publication policies on their websites. Companies might also consider publishing the
37
38 results of publication audits to indicate how closely they comply with guidelines (for
39
40 example, what proportion of clinical trials are published) and to help identify
41
42 obstacles to compliance.
43
44
- 45
46 • While our survey suggests that most pharmaceutical companies and agencies have a
47
48 code of conduct and provide mandatory training on responsible publication practices
49
50 to relevant staff, this is not always the case, and there is room for improvement,
51
52 especially for those that sub-contract work to freelancers. We therefore recommend
53
54 that companies, agencies, and professional groups (such as ISMPP, EMWA, and
55
56 AMWA) put renewed effort into ensuring that all publication professionals receive
57
58
59
60

1
2
3 effective training. Freelancers should be accountable for their own training, or ensure
4 they receive sufficient training from their customers. We also recommend that
5
6 individuals involved less directly in publications should be made aware of the relevant
7
8 guidelines.
9

- 10
11 • Although pharmaceutical companies generally provide invited authors with study
12 reports and protocols, this was not universal. Named authors should always have
13 access to study results to ensure they can understand and interpret the findings.
14
15
- 16 • The reported requests from authors or companies for agency staff to do something
17 that the publication professionals considered unethical warrants further investigation.
18 Our survey did not ask about reporting mechanisms for perceived unethical practices,
19 or how strongly these are communicated and used. We encourage agencies to develop
20 systems for handling such situations. Further education of authors and industry staff,
21 particularly those who are not familiar with the stringency of current guidelines,
22 should help reduce such requests.
23
24
- 25 • The number of freelancers responding to the survey was small (<50), but some of
26 their responses suggested differences from publication professionals working in
27 companies. We therefore hope a similar survey might be undertaken focusing on the
28 needs of this community and their publication practices to better understand areas
29 where they may need support.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 These suggested actions focus primarily on pharmaceutical companies and communications
48 agencies. However, clinical trials and their publication involve many players, and other
49 surveys suggest that both healthcare professionals (investigators and academics) and journal
50 editors would benefit from greater knowledge of published guidelines and may, in fact, be
51 less familiar with such guidelines than publication professionals. Given the financial and
52
53
54
55
56
57
58
59
60

1
2
3 human resources required to ensure timely, accurate, and complete reporting of research
4
5 results,[28] it is likely that the demand for, and use of, publication professionals will increase.
6
7 Our survey findings indicate that further involvement of knowledgeable and experienced
8
9 medical publication professionals, who are familiar with guidelines on reporting clinical trials
10
11 and publication ethics, should be viewed as a positive step in achieving timely and reliable
12
13 reporting. Our survey findings also complement evidence which shows that manuscripts
14
15 prepared with professional writing or editing support are more likely to comply with
16
17 reporting requirements,[29] less likely to be retracted for misconduct,[5] and are accepted for
18
19 publication more quickly,[30] than those prepared without such support.
20
21
22
23
24

25 Authorship of research publications is not straightforward and the ICMJE criteria have
26
27 recently been revised. Our survey did not examine views on existing criteria or problems with
28
29 their implementation, although others have done so.[31, 32] We are aware of current
30
31 initiatives aimed at deepening understanding and developing consensus around authorship
32
33 and the transparency of contributions and we welcome these. We would also welcome
34
35 surveys that test how well non-industry authors and editors comply with voluntary guidelines
36
37 issued by their professional associations and how such compliance is checked.
38
39
40
41
42

43 CONCLUSIONS

44
45 Despite criticism that most publication guidelines are voluntary, our survey suggests that the
46
47 major guidelines are widely known and implemented by publication professionals working in
48
49 pharmaceutical and medical device companies, communication agencies, CROs, and as
50
51 freelancers. Many companies enforce these guidelines through policies, codes of conduct,
52
53 standard operating procedures, and audits. For companies operating under a CIA, many of the
54
55 GPP and ICMJE recommendations are mandated and audited by the Office of the Inspector
56
57
58
59
60

1
2
3 General via independent auditors. When the GPP guidelines were first developed (in the late
4
5 1990s), publication audits were unheard of, yet many companies now regularly audit their
6
7 practices against guidelines such as GPP2, and CIAs mean that many of the GPP
8
9 recommendations are now legally enforced and monitored.
10

11
12
13
14 While there is no room for complacency, and we make no claim that all problems with the
15
16 publication of industry-funded research have disappeared, this survey, taken together with
17
18 others showing improved acknowledgement of medical writers, and reductions in guest
19
20 authorship, suggest that guidelines such as GPP (published in 2003) and GPP2 (2010) have
21
22 had a definite, positive effect on publication practices and that most companies and individual
23
24 publication professionals are striving to do the right thing.
25
26
27
28

29 **Acknowledgements**

30
31 We thank the organizations and individuals that helped publicise and execute the survey, in
32
33 particular Mike Smith (Alphabiocom) and Fiona Steinkamp (NovoNordisk). We also thank
34
35 Dr Serina Stretton (ProScribe Medical Communications) for her assistance with the figures.
36
37
38
39
40
41
42

43 **Contributions**

44
45 All authors were involved in developing the questionnaire and analysing or interpreting the
46
47 data. All authors reviewed the manuscript and discussed it critically over several revisions,
48
49 and agreed to submit it for publication. In addition, EW wrote the first draft of the paper, JF
50
51 was responsible for data management and analysis, and KW presented initial findings at the
52
53 2013 ISMPP meeting and prepared the figures.
54
55
56
57
58
59
60

Competing interests

EW is an author of the original GPP guidelines, the anti-ghostwriting checklist, the EMWA guidelines on the role of medical writers in publications, and several COPE guidelines. She works as a freelance publications consultant and has provided training to many pharmaceutical companies and communication agencies and receives fees and expenses for talks and workshops on publication guidelines.

KW conducts and publishes research on ethical medical writing practices. She is actively involved in not-for-profit associations that advocate for ethical publication practices. She is paid to provide ethical medical writing training courses and services for not-for-profit and for-profit clients, particularly in the Asia-Pacific region.

AC has served on the ISMPP Certification Board of Trustees.

ST is the chair of the ISMPP Advocacy and Outreach Committee.

AC, VA, TG and ST are employed by medical communications companies that provide publications services to authors and industry sponsors.

JG is on the Board of Trustees of ISMPP and is a steering committee member of the MPIP (Medical Publications Insights and Practices) Initiative.

JG and TG are/were employees of AstraZeneca and own shares in the company.

JF is an employee of TGaS Advisors, a division of the KnowledgePoint360 Group.

All authors (except JF) are members of ISMPP. None of the authors received any specific remuneration for working on this project.

Funding

Funding for the incentive prizes was provided by ISMPP. Data collection and analysis was provided (free of charge) by KnowledgePoint360 via TGaS Advisors.

Data sharing statement

The full questionnaire and raw data aggregated by sector (industry, agency, freelance) are available at <http://www.ismpp.org/gps-raw-data>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Fig 1. Percentage of survey respondents from industry and agency groups responding ‘yes’ to selected questions.

Fig 2. Percentage of survey respondents from industry and agency groups responding ‘yes’ to selected questions. (Asterisks indicate that question was only relevant to one group.)

For peer review only

References

1. Sismondo S. Ghosts in the machine: publication planning in the medical sciences. *Social Studies of Science* 2009;**39**:171.
2. Fugh-Berman A. The haunting of medical journals: how ghostwriting sold "HRT". *PLoS ONE* 2010;**7**(9):e1000335.
3. WAME Policy Statement: Ghost writing initiated by commercial companies. <http://www.wame.org/resources/policies#ghost>
4. Jacobs A, Wager E. EMWA guidelines on the role of medical writers in developing peer-reviewed publications. *Curr Med Res Opin* 2005;**21**:317-321.
5. Woolley K, Lew R, Stretton S et al. Lack of involvement of medical writers and the pharmaceutical industry in publications retracted for misconduct: a systematic, controlled, retrospective study. *Current Medical Research & Opinion* 2011;**27**:1175-1182.
6. Kaiser K, Cofield S, Fontaine K et al. Is funding source related to study reporting quality in obesity or nutrition randomized control trials in top-tier medical journals? *Int J Obesity* 2013;**36**:977-981.
7. Smith SM, Wang AT, Katz NP et al. Adverse event assessment, analysis, and reporting in recent published analgesic trials: ACTION systematic review and recommendations. *Pain* 2013;**154**:997-1008.
8. Lundh A, Sismondo S, Lexchin J et al. Industry sponsorship and research outcome. *Cochrane Database Syst Rev* 2012;**12**:MR000033.

- 1
2
3 9. Als-Nielsen B, Chen W, Gluud C et al. Association of funding and conclusions in
4
5 randomized drug trials: a reflection of treatment effect or adverse events? JAMA
6
7 2003;**290**:981-988.
8
9
- 10 10. Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical
11
12 companies. Curr Med Research Opinion 2003;**19**:149-154.
13
14
- 15 11. Graf C, Battisti WP, Bridges D et al. Good publication practice for communicating
16
17 company sponsored medical research: the GPP2 guidelines. BMJ 2010;**339**:b4330.
18
19
- 20 12. Norris R, Bowman A, Fagan JM et al. International Society for Medical Publication
21
22 Professionals (ISMPP) position statement: the role of the professional medical writer.
23
24 Curr Med Research Opinion 2007;**23**:1837-1840.
25
26
- 27 13. AMWA Code of Ethics. http://www.amwa.org/amwa_ethics
28
29 http://www.amwa.org/amwa_ethics.
30
31
32
33
- 34 14. Goldacre B. Bad Pharma. London: Fourth Estate: 2012.
35
36
- 37 15. Rodino FJ. Corporate Integrity Agreements. What they say about publications,
38
39 publication planning, transparency, and ICMJE. Therapeutic Innovation & Regulatory
40
41 Science 2013;**47**(1):50-56.
42
43
44
- 45 16. Laine C, Mulrow CD. Exorcising ghosts and unwelcome guests. Annals of Internal
46
47 Medicine 2005;**143**:611-612.
48
49
- 50 17. Gøtzsche PC, Kassirer JP, Woolley KL et al. What should be done to tackle
51
52 ghostwriting in the medical literature? PLoS Medicine 2009;**6**(2):e1000023.
53
54
55
56
57
58
59
60

- 1
2
3 18. Marusic A, Hren D, Bhattacharya A et al. Deciding authorship: survey findings from
4 clinical investigators, journal editors, publication planners, and medical writers. 2013.
5
6 Chicago. 7th International Congress on Peer Review and Biomedical Publication. 8-9-
7
8 2013.
9
10
11
12 19. Stretton S, Bramich NJ, Keys J et al. Publication misconduct and plagiarism
13 retractions: a systematic, retrospective study. *Curr Med Res Opin* 2012;**28**:1575-1583.
14
15
16 20. Wager E, Fiack S, Graf C et al. Science journal editors' views on publication ethics:
17 results on an international survey. *Journal of Medical Ethics* 2009;**35**:348-353.
18
19
20 21. Wong V, Callahan ML. Medical journal editors lacked familiarity with scientific
21 publication issues despite training and regular exposure. *J Clin Epidemiol* 2012;**65**:247-
22 252.
23
24
25 22. Good Publication Practice: The awareness and views of healthcare professionals.
26 <http://www.epghealthmedia.com/industry-reports/HCP-views-on-GPP/>
27
28
29 23. De Faoite D, Bakota B, Staresinic M et al. Awareness, attitudes, and perceptions of
30 Croatian-based orthopedic and trauma surgeons toward scientific manuscripts,
31 publishing internationally and medical writing. Results of an online questionnaire. *Coll*
32 *Antropol* 2013;**1**:165-168.
33
34
35 24. Jacobs A, Hamilton CW. Decreased evidence of ghostwriting in a 2008 vs 2005
36 survey of medical writers. *The Write Stuff* 2009;**18**(2):118-123.
37
38
39 25. Hamilton CW, Jacobs A. Evidence of decreased ghostwriting in a series of three
40 surveys of medical communicators conducted between 2005 and 2011. *AMWA Journal*
41 2012;**27**:115.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 26. Wager E. Publication ethics: the shift from philosophy to compliance. *Regulatory*
4 *Affairs Journal* 2011;(2 Feb 2011):18-19.
5
6
7
8 27. Wislar JS, Flanagan A, Fontanarosa PB et al. Honorary and ghost authorship in high
9 impact biomedical journals: a cross sectional survey. *BMJ* 2011;**343**:d6128.
10
11
12
13 28. Woolley KL, Gertel A, Hamilton C et al. Poor compliance with reporting research
14 results -- we know it's a problem ... how do we fix it? *Curr Med Research Opinion*
15 2012;**28**:1857-1860.
16
17
18
19 29. Jacobs A. Adherence to the CONSORT guideline in papers written by professional
20 medical writers. *The Write Stuff* 2010;**19**:196-200.
21
22
23
24 30. Bailey M. Science editing and its effect on manuscript acceptance time. *AMWA*
25 *Journal* 2011;**26**:147-152.
26
27
28
29 31. Pignatelli B, Maisonneuve H, Chapuis F. Authorship ignorance: views of researchers
30 in French clinical settings. *J Med Ethics* 2005;**31**:578-581.
31
32
33
34 32. Bhopal R, Rankin J, McColl E et al. The vexed question of authorship: views of
35 researchers in a British medical faculty. *BMJ* 1997;**314**:1009-1012.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 **Awareness and enforcement of guidelines for publishing industry-sponsored medical**
8 **research among publication professionals: the Global Publication Survey**
9

10
11
12 Elizabeth Wager

13
14 Sideview, Princes Risborough, UK

15
16 Karen Woolley

17
18 ProScribe Medical Communications, Noosaville, Australia; Faculty of Health

19
20 Sciences, University of Queensland, Brisbane, Australia; Faculty of Science, Health,

21
22 Education and Engineering, Sunshine Coast, Australia

23
24 Viv Adshead

25
26 KnowledgePoint360 Group, Macclesfield, Cheshire, UK

27
28 Angela Cairns

29
30 KnowledgePoint360 Group, Macclesfield, Cheshire, UK

31
32 Josh Fullam

33
34 TGaS Advisors, East Norriton, Pennsylvania, USA

35
36 John Gonzalez

37
38 AstraZeneca, Alderley Park, Cheshire, UK

39
40 Tom Grant

41
42 AstraZeneca, Alderley Park, Cheshire, UK *

43
44 Stephanie Tortell

45
46 Complete Medical Communications, Macclesfield, Cheshire, UK **

47
48 * now at Complete HealthVizion, Macclesfield, Cheshire, UK

49
50 ** now at: KnowledgePoint360 Group, Macclesfield, Cheshire, UK

1
2
3
4
5
6
7 **Corresponding author:** Dr Elizabeth Wager

8 Sideview, 19 Station Road, Princes Risborough, HP27 9DE, UK

9
10 email: liz@sideview.demon.co.uk

11
12 phone (+44) (0)1844 275814

13
14 fax (+44) (0)1844 275034

15
16
17
18 **Keywords**

19 publications, guidelines, drug industry, ethics, data reporting

20
21
22
23
24 **Word count**

25 5451 words (excluding abstract, refs, figures, and tables)

26
27
28
29
30 I, Dr Elizabeth Wager, the Corresponding Author of this article contained within the original
31 manuscript which includes any diagrams & photographs, other illustrative material, video,
32 film or any other material howsoever submitted by the Contributor(s) at any time and related
33 to the Contribution ("the Contribution") have the right to grant on behalf of all authors and do
34 grant on behalf of all authors, a licence to the BMJ Publishing Group Ltd and its licensees, to
35 permit this Contribution (if accepted) to be published in BMJ Open and any other BMJ Group
36 products and to exploit all subsidiary rights, as set out in the licence at:
37 http://group.bmj.com/products/journals/instructions-for-authors/BMJOpen_licence.pdf

Abstract

Objectives: To gather information about current practices and implementation of publication guidelines among publication professionals working in or for the pharmaceutical industry.

Design/ Setting: Web-based survey publicised [via email and social media](#) to members of the International Society for Medical Publication Professionals (ISMPP) and other **relevant** organizations, November 2012 to February 2013.

Participants: 469 individuals involved in publishing industry-sponsored research in peer-reviewed journals, mainly working in pharmaceutical or device companies ('industry', n=144), communication agencies ('agency', n=238), ~~or~~ contract research organizations (CRO, n=15), or as freelancers (n=34). Most respondents (78%) had worked on medical publications for ≥ 5 years and 62% had a PhD/MD.

Results: Over 90% of industry, agency, and CRO respondents routinely refer to Good Publication Practice (GPP2) and the International Committee of Medical Journal Editors' Uniform Requirements. Most respondents (78% industry, 79% agency) received mandatory training on ethical publication practices. Over 90% of respondents' companies had publication guidelines or policies and required medical writing support to be acknowledged in publications (96% industry, 99% agency). Many industry respondents used publication management tools to monitor compliance with company guidelines and about half (46%) stated that their company had formal publication audits. Fewer agencies audited adherence to guidelines but 20% of agency respondents reported audits of employees and 6% audits of freelancers. Of concern, 37% of agency respondents reported requests from authors or sponsors that they believed were unethical, although 93% of these requests were withdrawn after respondents explained the need for compliance with guidelines. Most respondents'

1
2
3
4
5
6 departments (63% industry, 58% agency, 60% CRO) had been involved in publishing studies
7
8 with negative or inconclusive results.
9

10
11 **Conclusions:** Within this ~~survey~~ sample, most publication professionals working in or for
12 industry were aware of, and applying, major publication guidelines. However, the survey
13 also identified specific areas where education and promotion of guidelines is needed to
14
15 ensure ethical publication practices.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article summary

Strengths of this study

- Large-scale, international survey of publication professionals (n=469)
- Focused on awareness and implementation of guidelines relating to responsible publication practice, providing insight into current industry practices
- Included publication professionals (e.g. writers, planners, and managers) working in pharmaceutical and medical device companies, medical communication agencies, contract research organizations, or as freelancers
- Survey allowed anonymous responses

Limitations of this study

- Limited response from freelancers (n=34), journal editors, publishers, and academics (n=38)
- Self-selection bias may mean that respondents were not representative of the total population if those with a particular interest in, or concerns about, ethical publication practices were more likely to complete the survey than those with less knowledge, or interest or concerns
- Methods used for publicising the survey (via websites, social media, etc.) meant it was impossible to calculate a precise response rate.

INTRODUCTION

Misleading, inaccurate, or incomplete reporting of clinical trial findings can have serious consequences, since doctors and policy-makers rely on publications when developing treatment guidelines and making decisions affecting patients. The involvement of medical writers and other publication professionals, such as planners and managers, in developing peer-reviewed publications reporting clinical trials has been criticised by some,[1, 2] but defended by others.[3, 4] Similarly, while some studies have shown that publications funded by pharmaceutical companies are of equal or higher quality than publications from academia,[5-7] others have shown that they are more likely to be biased.[8, 9] Concern about irresponsible publication practices, from both within and outside the industry, has led to the creation and evolution of several guidelines.[4, 10-13] These guidelines seek to establish responsible publication practices, increase transparency, and prevent bias and commercial influence in reporting medical research. While many have welcomed such guidelines, critics of the pharmaceutical industry remain unconvinced, for example, commenting “Publicly, they insist that everything has changed.... But my concern is this. Having seen so many codes openly ignored and broken, it’s hard to take any set of voluntary ideals seriously.”[14] Given this concern about whether voluntary guidelines are effective, and because there was little evidence available to show whether continuing concerns about industry publication practices were justified, we sought to generate ‘real world’ evidence about current practices in the medical publications profession.

We therefore carried out a large-scale, international, survey (the Global Publication Survey) to obtain information about the ways in which medical writers and other publication professionals work and, in particular, their awareness of current publication guidelines. We also sought to learn about the processes adopted by pharmaceutical and communications

1
2
3
4
5
6
7 companies to encourage responsible practices and to implement published guidelines. The
8 aim of this survey was to identify areas in which guidelines were understood and enforced,
9 areas for improvement, and targets for education and training.
10
11

12 13 14 **METHODS**

15
16 The survey questionnaire (Appendix 1) was developed by an international team including
17 professional writers and publication managers with experience of working in pharmaceutical
18 and communications companies and in a freelance capacity. Several team members had been
19 involved in developing publication guidelines (see the author list and acknowledgements for
20 details). Question topics were based on results of a previous survey of members of the
21 International Society for Medical Publication Professionals (ISMPP). Question and answer
22 options were discussed, drafted, and refined by the team. Question types included multiple
23 choice (check one/check all), matrix table, rating (1-5 scale), ranking (top 3), dropdown
24 selection, and free text. Logic checks limited the number of questions respondents saw based
25 on 'skip logic' (i.e. some questions only appeared if the respondent answered 'yes' to an
26 earlier question). 'Not applicable', 'Don't know', and 'Other (specify)' responses were
27 offered to capture the full range of possible responses.
28
29
30
31
32
33
34
35
36
37
38

39
40
41 The questionnaire was transcribed to an online data capture tool hosted by Qualtrics
42 (www.qualtrics.com) survey technology. Pilot testing for question content, flow, and logic
43 was performed by team members, and the survey was revised as necessary.
44
45
46
47

48
49 Respondents saw a different selection of questions depending on their work sector
50 (categorised as: pharmaceutical or medical device company, agency, contract research
51 organization [CRO], freelance, journal editor, publisher, or academic) and their previous
52
53
54

1
2
3
4
5
6
7 answers. ~~Respondents answered, on average, about 40 questions.~~ A response was required for
8 each question before the next screen was displayed but users had the option to revisit
9 previously completed questions. Optional questions were included at the end of the core
10 survey allowing participants to offer additional comments.
11
12
13

14
15
16 The survey was announced on 28th November 2012 via email to all members of ISMPP
17 (n=1105). A link included in the email provided individual access to the survey (so each
18 recipient could respond only once and reminders could be sent to non-responders). ISMPP
19 members were also encouraged to share an unrestricted link to the survey with individual
20 colleagues or via their company intranet. The survey was also promoted via social media
21 (LinkedIn and Twitter). Several organizations and companies (including the American
22 Medical Writers Association, the European Medical Writers Association, the European
23 Association of Science Editors, the Committee on Publication Ethics, McCann Complete
24 Medical, and Excerpta Medica) publicised the survey to their members or on their websites
25 through December 2012. The survey closed on 18th February 2012.
26
27
28
29
30
31
32
33
34
35

36
37 Respondents could complete the survey anonymously but, to encourage participation, had the
38 option of supplying an email address to enter a draw for one of two iPad tablet computers.
39

40 Participants were informed that their personal information would not be shared beyond those
41 administering the survey. Respondent-level data was available only to TGaS Advisors (the
42 company who were responsible for all aspects of survey administration and data aggregation),
43 and was not shared with the survey organizers or sponsors. Descriptive statistics using
44 frequencies and percentages were used. Funding for the incentive prizes was provided by
45 ISMPP. The team members who developed the questionnaire and executed the survey,
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 interpreted the data, and developed this publication, worked in their own time or during work
8 time with permission from their various employers but without specific funding or payment.
9

10
11
12 Research Ethics Committee (Internal Review Board) approval was not required for this
13 survey, as it did not relate to personal medical information, did not involve patients or
14 healthcare professionals (other than in their role as journal editors), was not carried out by an
15 academic institution, and participation was entirely voluntary. Participants were given the
16 option of supplying an email address if they wanted to enter a prize draw, but could remain
17 completely anonymous if they preferred. We considered that provision of an email address
18 does not necessarily identify an individual (since email addresses do not necessarily indicate
19 name or workplace) and participants were assured that only two people would be contacted to
20 supply the incentive prize. Email details were stored securely by TGas Advisors and were not
21 revealed to anybody else involved with the survey. Following the guidelines of University
22 College London (although this study was entirely independent of any academic institution)
23 and of the National Research Ethics Service of the UK, such a questionnaire is exempt from
24 requiring Research Ethics Committee approval.
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 RESULTS

40 Respondents

41
42 The survey reached the intended international target audience with responses from 23
43 countries. The largest responses came from the USA (44%) and UK (39%). Of the 490 who
44 opened the survey invitation, 469 confirmed that they were involved in publishing industry-
45 sponsored research in peer-reviewed medical journals and completed the survey (Table 1).
46
47 Most respondents (92%), worked in pharmaceutical or medical device companies (termed
48 'industry' respondents; 31%), medical communications agencies (termed 'agency'
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 respondents; 51%), or contract research organizations (CROs 3%) providing publication
8 services to drug and device manufacturers, or as freelancers (7%). The survey was also
9 completed by 5 journal editors, 17 publishers, 9 academics and 7 people working in other
10 roles – results from these categories (total = 8%) are not reported in the text due to the low
11 response rate and small numbers but may be viewed at [http://www.ismpp.org/gps-raw-
13 data](http://www.ismpp.org/gps-raw-
12 data)QQQ. Because of the responsive design, the numbers answering each question varied
14 [but respondents generally answered about 40 questions. – Most respondents took 20-30
15 minutes to complete the survey.](#)†The full data tables are available at
16 <http://www.ismpp.org/gps-raw-data>QQQ. ~~Most respondents took 20-30 minutes to
17 complete the survey.~~

18
19
20
21
22
23
24
25
26
27
28 Because of the methods used to promote the survey ([including websites and social media](#)), it
29 was not possible to calculate a [precise](#) response rate [or assess differences between
30 respondents and non-respondents](#). However, the membership of ISMPP at the time of the
31 survey was 1105 and the response rate from ISMPP members was 20% (i.e. 221 of the
32 respondents responded via the individual links sent out to ISMPP members).
33
34
35
36
37
38

39 Most respondents were highly educated (56% had a doctorate) and experienced (79% had
40 worked with medical publications for at least 5 years) (Table 1). Half of the respondents
41 worked in departments that had been involved with over 30 manuscripts in the last year.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Respondent characteristics

Characteristic	Number	Percentage
Workplace:		
industry ¹	144	31
agency or CRO ²	238	51
CRO ³	15	3
freelance	34	7
other	38	8
Experience of working with peer-reviewed publications:		
<2 years	36	8
2-4 years	66	14
5-9 years	111	24
10 years or more	256	55
Qualification: ⁴		
Masters degree	111	24
Doctorate	263	56
MD / medical qualification	26	6
Other	26	6
Certified Medical Publication	161	34
Professional (CMPP)		

¹Pharmaceutical, biotech or medical device company

² Communications company

³ Contract research organization

⁴ Respondents were asked to tick all that applied

Awareness of guidelines

Almost all industry and agency respondents ~~reported being~~ were aware of international guidelines on responsible publication practices (Fig 1). Overall, 91% stated that they routinely referred to Good Publication Practice (GPP2) and 93% to the International Committee of Medical Journal Editors' Uniform Requirements for guidance on ethical practice. Other sources of guidance consulted routinely by respondents in all sectors included ISMPP (71%), medical writers associations (e.g. AMWA and EMWA: 39%), and the Committee on Publication Ethics (COPE: 34%).

Training

Regular training on ethical publication practices was compulsory for most respondents in industry and agencies. Mandatory training for employees was reported by 78% of industry, 79% of agency, and 93% of CRO respondents. In addition, 68% of agency respondents reported that their industry customers provided mandatory training for agency personnel. Training at least once a year was reported by 70%, 68% and 71% for industry, agency and CRO respondents respectively. Just over half the industry respondents (55%) reported that their companies provided training for agency staff or freelancers but only 17% of agency and 20% of CRO respondents reported that their organization provided training for freelancers (while 43% and 53% respectively didn't know if freelancers were trained). Similarly, 24% of the freelancers (5/21) reported that they received mandatory training from industry or agency customers.

Respondents kept up-to-date on current guidelines primarily via training provided by their organization (64%), from professional associations (68%), and monitoring the literature (70%).

Company codes of conduct and publication policies

In addition to their awareness of external guidelines on ethical publication practices (e.g., GPP2), most respondents ~~reported being~~ were aware of internal guidelines governing publication practices. Overall, 78% of respondents worked in an organization that had a Code of Conduct governing ethical publication practices. Nearly all the industry (94%) and agency (94%) respondents and all the CRO respondents (15/15) stated that their company had guidelines or a policy on ethical publication practices (5 industry and 8 agency respondents stated their company did not have such a policy while 3 and 7, respectively, did not know) (Fig 1).

Most company guidelines and policies are not publicly available: only 38% of industry, 35% of agency, and 33% of CRO respondents reported that these documents were publicly accessible (e.g. posted online) (Figure 2).

Of the industry respondents, 67% stated that their company was committed to peer-reviewed publication of results of all studies in humans. Exceptions to this commitment were studies for which companies did not have control (e.g. investigator-initiated studies) (reported by 21) and Phase 1 studies (i.e. early-phase drug development) (reported by 14).

Public disclosure of trial results was reported, by those working within the industry, to be fulfilled by: posting results on a public register (92%), publishing in a peer-reviewed journal (73%), publishing a conference abstract (51%), posting results on a company website (28%), or a combination of these. When asked about the timing of journal publications, most industry respondents reported that their company policy was to submit a manuscript within

1
2
3
4
5
6
7 12 or 18 months of study completion (last subject, last visit) (43% and 18% respectively).

8
9 Nevertheless, 24% of industry respondents reported that their company did not have a target
10 deadline for submitting a manuscript after trial completion (Figure 2).

11
12
13
14 Similar proportions of industry and agency respondents (80% and 81% respectively) reported
15 that authorship obligations were set out in formal agreements before manuscript development
16 (Fig 1). Almost all industry (96%) and agency (99%) respondents, and 100% of CRO
17 respondents, reported that their department ensured that authors acknowledge professional
18 medical writing support in every publication (Fig 1). Only one respondent from each of the
19 industry and agency groups answered no to this question. However, 11% of respondents from
20 both industry and agency, and 13% from CROs, were aware of academic authors initially
21 refusing to acknowledge professional writing support in the last 12 months.
22
23
24
25
26
27
28
29
30
31

32 **Compliance with codes**

33
34 Respondents from industry, and to a lesser extent from agencies, ~~reported that had~~ their
35 publication practices were subjected to compliance checks. Of the industry respondents, 61%
36 stated that their company had a formal process for monitoring adherence to company
37 standards and 66 of these (46% of the total) carried out publication audits. A very similar
38 response was obtained from those working in CROs (60% and 47% respectively). However,
39 of the agency respondents, 44% reported that their company had formal compliance
40 monitoring for internal standards and only 20% carried out publication audits. In addition,
41 about half the industry respondents (47%) reported that their company had a formal process
42 for monitoring third-party providers' adherence with company standards and 75% of these
43 reported that this involved an audit. Agency and CRO respondents stated that some (43%,
44 47% respectively), most (19%, 0%), or none (6%, 13%) of their customers had formal,
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 regular processes such as knowledge tests or audits for monitoring suppliers' adherence to the
8 customer's standards, while 27% of agency and 40% of CRO respondents did not know if
9 their customers did this. Agency and CRO respondents also reported that their customers
10 used publication management tools to assess compliance (only 6% and 13% respectively
11 reported that no customers did this).
12
13
14
15

16
17
18 Of the industry respondents, 52% worked in a company operating under a US Government
19 'Corporate Integrity Agreement' (CIA: see [https://oig.hhs.gov/compliance/corporate-](https://oig.hhs.gov/compliance/corporate-integrity-agreements/index.asp)
20 integrity-agreements/index.asp), which typically requires formal compliance checking.
21
22
23
24

25 26 **Organization of publication activities**

27
28 Publication activities were primarily governed by medical departments; publications were
29 rarely funded, or approved, by commercial departments (Fig 1). According to the industry
30 respondents, the budget for peer-reviewed publications was usually held by the medical
31 affairs (72%) or clinical development (24%) departments. Nevertheless, seven respondents
32 (5%) stated that the publications budget was held by a commercial department (e.g. sales or
33 marketing) (Fig 2). Involvement of members of commercial departments in developing
34 publications varied, with industry respondents stating that they were: not involved (27%),
35 provided with information only (48%), members of the publication team (44%), allowed to
36 suggest target journals for author consideration (22%), involved in reviewing manuscripts for
37 accuracy (19%), or part of a formal approval process (5%).
38
39
40
41
42
43
44
45
46
47
48

49 **Agency response to requests for perceived unethical practices**

50
51 Respondents were often, but not always, successful in preventing publication practices they
52 considered unethical. Of the agency respondents, 38% were aware, in the past 12 months, of
53
54
55

1
2
3
4
5
6
7 their company being asked by an author or a sponsor to do something that they believed
8 contravened ethical practices (10% once and 28% more than once) while 2/15 CRO
9 respondents (13%) reported such requests. Respondents reported that their agency's response
10 was to explain the need for compliance, resulting in the request being withdrawn or amended
11 (92% and both CRO cases), or to refuse to accept the work (1%); however, 3% (3/90) stated
12 that the agency ultimately complied with the request.
13
14
15
16
17
18
19

20 Although a slightly higher proportion of freelancers (17/34, 50%) reported requests which
21 they believed constituted unethical practices, this should not be over-interpreted due to the
22 small group size; 12% (2/17) of freelancers accepted such work.
23
24
25
26
27

28 **Information provided to authors**

29 Authors were routinely provided with various documents and data sources to facilitate
30 manuscript preparation. These documents included (for agency and industry respondents
31 respectively): clinical study report (81%, 79%), study protocol (79%, 83%), summarized data
32 (67%, 66%), statistical report (58%, 62%), manuscript outline (58%, 56%), statistical
33 analysis plan (42%, 54%), and raw data/data tables (42%, 42%).
34
35
36
37
38
39
40

41 **Enforcement of authorship criteria**

42 Respondents actively enforced compliance with authorship criteria (Table 2).
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2

Responses to the question “In the last 12 months, to your knowledge, how often has your department recommended to the lead author the removal of a co-author from a manuscript or abstract that was in development?”

	Never	Once	More than once	Other	Don't know
Industry (n=144)	44% (64)	10% (15)	22% (32)	2% (3)	21% (30)
Agency (n=238)	24% (58)	11% (26)	35% (84)	3% (6)	27% (64)
CRO* (n=15)	27% (4)	33% (5)	7% (1)	7% (1)	27% (4)
Freelance (n=34)	74% (25)	9% (3)	15% (5)	3% (1)	0

*Contract Research Organization

Of the industry respondents, 33% were aware of an author being removed from a manuscript within the last 12 months and 94% stated that this was due to the individual not meeting authorship criteria. Other reasons for recommending removal of an author included individuals leaving the company (28%) or not agreeing to adhere to ethical publication practices (13%) (respondents could select more than one reason). Three respondents from industry and two from agencies reported authors being removed because they disagreed with

1
2
3
4
5
6
7 the interpretation of the data. Eight freelancers reported recommending the removal of an
8 author, in all cases because the individual did not meet authorship criteria.
9

10 11 12 **Publishing negative findings**

13
14 Most industry respondents' companies attempted to publish negative or inconclusive results.
15
16 Of the industry respondents, 63% reported that their department had supported the
17
18 publication of a study with negative or inconclusive results (17% stated that this had not
19
20 happened and 19% did not know). Only six respondents (4%) were aware of a negative or
21
22 inconclusive study for which publication was not planned, in three cases this was due to the
23
24 discontinuation of product development. Responses were similar in the agency (and CRO)
25
26 groups, with 58% (60%) aware of the publication of negative findings and 6% (13%) being
27
28 aware of negative findings for which publication was not planned. Of the freelancers, 38%
29
30 had been involved with the publication of negative findings in the last 12 months.
31
32

33 34 **Freelance responses**

35
36 Only 34 freelance publication professionals responded to the survey and some of these did
37
38 not answer all questions, therefore the results may not be representative and should not be
39
40 over-interpreted. However, the following findings were noteworthy: 12/34 (35%) did not
41
42 know whether their customers had publication guidelines; 15/21 (71%) stated that they did
43
44 not receive mandatory training; and 21/34 (62%) stated that their clients did not have formal,
45
46 regular processes to monitor their adherence to standards. However, freelancers reported
47
48 routinely consulting published guidelines (100% for ICMJE, 91% for GPP2) on ethical
49
50 issues.
51
52
53
54
55
56
57
58
59
60

DISCUSSION

This is one of the largest, international surveys designed to capture information about current knowledge and implementation of publication guidelines within the pharmaceutical, medical device, and medical communications industries. Our survey showed high reported levels of knowledge of the various publication guidelines among publication professionals, with over 90% of respondents stating that they routinely referred to them. Although these published guidelines (such as GPP2) are not generally enforced by legislation, according to our survey most companies have codes of conduct, policies, or internal guidelines that reflect and enforce them. Similarly, most companies (industry and agencies) provide mandatory training to internal staff, while many pharmaceutical and medical device companies also train agency personnel who develop publications on their behalf. The relatively low rates of training and auditing of freelancers suggested in this survey (albeit from a small number of respondents), however, may represent a problem that companies, agencies, and authors who work with freelancers should address.

Many pharmaceutical companies in the USA currently operate under Corporate Integrity Agreements (CIAs). For such companies, many aspects of good publication practice are legally enforced. An analysis of 12 such agreements issued from 2009 to mid-2012 showed that they included requirements for author agreements, publication plans, and the posting of study results.[15] The CIA requirements were consistent with GPP2 and the ICMJE guidelines and also mandated training and reporting. CIA requirements apply not only to the pharmaceutical company but also to their management of any third-party suppliers, therefore, they will also affect many agencies, freelancers, and CROs. Similarly, even companies without a CIA often require suppliers to follow their policies. Therefore, for many agencies

1
2
3
4
5
6
7 and freelancers, failure to follow a customer's policy could mean loss of future business, thus
8
9 the underlying guidelines are viewed as compulsory rather than optional.

10
11
12 The importance with which guidelines are viewed is reflected in the effort (and therefore time
13
14 and money) companies invest in monitoring compliance. Our survey found that many
15
16 pharmaceutical and device companies have formal monitoring processes including
17
18 publication audits. Since our survey may have included several respondents from the same
19
20 company, the results cannot indicate precisely what proportion of companies have such
21
22 processes but it is probably well over half. The fact that fewer agencies appear to audit to
23
24 their own internal standards is not surprising, since many reported being regularly audited by
25
26 their customers. However, rates of training and auditing of freelancers (by pharmaceutical
27
28 companies and agencies) is less reassuring and suggests room for improvement.

29
30
31 Many companies use specialist publication planning software (such as DatavisionTM or
32
33 PubSTRATTM). Our survey shows that such tools are used not only for publication project
34
35 management but also to monitor and demonstrate compliance with company procedures, for
36
37 example, by ensuring that all authors have approved a manuscript outline, drafts, and the final
38
39 version.

40
41
42
43 Lack of transparency surrounding company involvement, non-disclosure of competing
44
45 interests, and misleading authorship have been causes for concern in industry-sponsored
46
47 publications in the past.[16] In particular, the occurrence of 'ghost-writing' (i.e.
48
49 unacknowledged use of medical writers) and guest or honorary authorship (i.e. named authors
50
51 not fulfilling journal authorship criteria) were spurs for the development of both general and
52
53 specific guidelines.[3, 4, 11, 17] It is therefore encouraging that 96-100% of respondents
54
55

1
2
3
4
5
6
7 (working in pharmaceutical and medical device companies, agencies, and CROs) stated that
8 their department ensured that medical writers were acknowledged (thus preventing the
9 medical writers from being 'ghost writers'). Of concern, however, is the fact that some
10 academic authors apparently continue to be reluctant to acknowledge writing support.
11

12
13
14 Although publication professionals can alert authors about the need for disclosure, academic
15 institutions clearly have an educational role to play.
16
17

18
19
20 The ICMJE authorship criteria (which are widely endorsed by medical journals and which
21 were revised after the survey) state that listed authors should have made substantial
22 contributions to both the research and its publication. Therefore authorship cannot be
23 determined until a publication is developed. Individuals involved with the research being
24 reported may be invited to become authors, but will not qualify unless they also take an
25 active role in the publication. It is therefore encouraging that our survey found that not only
26 industry sponsors of research, but also publication agencies and freelancers working for them,
27 actively enforce authorship criteria by suggesting that individuals should be removed from
28 author listings if they fail to meet the ICMJE or other agreed criteria (see Table 2). It can take
29 considerable courage for a freelancer or agency employee to suggest that a proposed author
30 has not contributed sufficiently to merit being listed, especially if that person is a senior
31 academic or well-known expert. Being the one to identify a guest author carries the risk of
32 damaging relationships and possibly work prospects. However, arguably there is an even
33 greater and more serious risk of damaged relations, reputations, and work prospects if a
34 publication professional fails to raise authorship concerns which are later raised by a journal.
35
36 Early clarification of authorship obligations should reduce the risk of guest authorship and it
37 was encouraging that most respondents reported that authorship agreements were confirmed
38 before manuscript preparation started.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

1
2
3
4
5
6
7
8
9 As we cannot tell how often proposed authors fail to contribute to publications, our survey
10 cannot show how often this is overlooked, but the fact that almost one-third of industry
11 respondents were aware of instances of authors being removed because they did not meet
12 authorship criteria suggests that guidelines are being enforced. However, this question also
13 revealed that three industry (2%) and two agency (0.8%) respondents were aware of authors
14 being removed from publications because they disagreed with the interpretation of the
15 findings. We cannot tell how many cases these represent, since several respondents may have
16 reported the same case, nor can we tell whether the disagreements about interpretation were
17 with the sponsor (which would be concerning) or between co-authors, but this issue needs
18 further scrutiny.
19
20
21
22
23
24
25
26
27
28

29
30 The difficulties of interpreting the ICMJE authorship criteria in some situations have been
31 examined in a study coordinated by the Medical Publishing Insights and Practices (MPIP)
32 Initiative.[18] Using vignettes presenting 'challenging real-world authorship scenarios' this
33 study found that journal editors, clinical investigators, medical writers, and publication
34 planners had different views about who qualified for authorship and suggested that additional
35 guidance might be helpful.
36
37
38
39
40
41
42

43 **Limitations**

44
45 We had originally hoped to compare or confirm responses from publication professionals
46 with those from journal editors and academic investigators, however, we were less successful
47 in promoting the survey among these groups than among publication professionals and
48 consider the response from these sectors too small to be reliable. The number of responses
49 from freelance publication professionals was also disappointing and it is therefore important
50
51
52
53
54
55

1
2
3
4
5
6
7 not to over-interpret the findings from this group. Care should also be taken in extrapolating
8 proportions of respondents to proportions of companies or agencies, since we had no way of
9 measuring the numbers of respondents per company.
10

11
12
13
14 We also recognise that our survey, like many others, carried the risk of self-selection bias.
15
16 Our survey was promoted mainly via professional organizations such as ISMPP and
17 AMWA/EMWA which promote ethical publication practices. Those choosing to respond to a
18 survey supported by these associations may be more likely to follow and report ethical
19 publication practices. Also, those who chose to complete the survey may have had a special
20 interest in, or concerns about, the issues covered. Our respondents therefore may not be
21 representative of all publication professionals and may be better informed about the topics
22 covered by this survey and more aware of guidelines (e.g. from attending professional
23 meetings or taking part in educational activities). However, due to the methods used to
24 publicise the survey (including websites and social media rather than to a clearly defined
25 population) it was not possible to compare characteristics of respondents and non-
26 respondents. We also acknowledge that our respondents came primarily from higher-income
27 countries. Our findings may not be applicable to publication practices in lower-income
28 countries, particularly given the significant influence of country income on publication
29 practices. [5, 19]
30
31
32
33
34
35
36
37
38
39
40
41
42

43
44
45 Another problem with any survey is if respondents give 'socially desirable' rather than
46 truthful answers. One reason we have confidence in our findings is that responses were not
47 uniform, e.g. only 34% reported referring to the COPE guidelines compared with 91% for the
48 ICMJE guidelines. The fact that the survey highlighted weaknesses as well as strengths (e.g.
49 the proportion of freelancers who receive training) also suggests that responses were factual.
50
51
52
53
54

Comparison with other surveys

Journal editors' awareness of various guidelines was measured in 2007 in an international survey to which 111 editors of biomedical journals responded.[20] This survey noted that "awareness and use of guidelines and other resources on publication ethics was generally low". Over half the editors (55%) reported being unaware of the ICMJE Uniform Requirements and two-thirds (67%) were unaware of the GPP guidelines, while the proportion of editors reporting that they had used these guidelines were just 24% and 9% respectively. This represents a marked contrast to the publication professionals responding to our survey, over 90% of whom reported that they routinely referred to these two guidelines.

Another survey of 183 editors of high-impact medical journals in 2009 found that, although 76% had received training in medical editing, they performed poorly when answering questions about: authorship (only 30% gave 'correct' answers, i.e. consistent with commonly cited guidelines), plagiarism (17% correct), peer review (16% correct), and conflicts of interest (15% correct).[21]

A 2012 survey of 294 healthcare professionals found that 42% were unaware of the GPP guidelines.[22] This survey also found that the doctors (69% of whom were authors on peer-reviewed articles) were unfamiliar with, or disagreed with, the ICMJE authorship criteria, since a considerable proportion considered that data collection (51%) or general supervision of a laboratory (33%) alone were criteria for authorship. Nevertheless, 66% of respondents in the healthcare practitioners survey stated that they would be concerned about 'the involvement of pharmaceutical employees as authors or reviewers of a draft manuscript'. A smaller survey of surgeons in Croatia (in 2011) found that only 54% (31/57) were aware of

1
2
3
4
5
6
7 the ICMJE guidelines although 74% (43/58) of the respondents had worked on at least 2
8 manuscripts for publication in the last 2 years.[23]
9

10
11
12 A large-scale, repeated survey of medical writers (who were nearly all members of AMWA
13 or EMWA),[24] which attracted 746 responses in 2005, and 662 in 2008, found lower levels
14 of familiarity with guidelines than the current survey (carried out in 2012) but showed that
15 awareness had risen between 2005 and 2008. For example, the proportion of respondents
16 claiming to be familiar with ICMJE guidelines rose from 54% in 2005 to 75% in 2008. The
17 figures for GPP were 43% and 58%, and for the EMWA guidelines (published in 2005) 27%
18 and 46% respectively in 2005 and 2008. The AMWA/EMWA survey also asked writers
19 about their experience of being involved with unacknowledged writing work (i.e.
20 ghostwriting). In 2005, 39% stated that this practice had decreased in the last 5 years (52%
21 stated that it was unchanged and 8% that it had increased). In 2008, 63% considered that
22 ghostwriting had decreased, 30% stated that it was unchanged and 6% that it had increased in
23 the last 5 years. The proportion of professional writers reporting that they always requested
24 acknowledgement for a substantial contribution to a manuscript also rose from 25% in 2005
25 to 43% in 2008. The survey was repeated in 2011 (with 620 respondents)[25] and responses
26 showed a clear decrease in the proportion of manuscripts (not necessarily all for peer-
27 reviewed journals) with undisclosed contributions (i.e. ghostwriting) which fell from 62% in
28 2005, to 42% in 2008, and 33% in 2011.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46
47 Ghostwriting of review articles commissioned by pharmaceutical companies was a particular
48 concern when the first GPP guidelines were developed.[26] A survey of authors published in
49 six, high impact general medical journals found a decline in ghost authorship between 1996
50 and 2008, and a significant decrease (from 26% to 15%) in honorary authorship (which often
51
52
53
54
55

1
2
3
4
5
6
7 accompanies ghostwriting) for review articles and editorials (although not for other types of
8 article).[27]
9

10
11
12 Our survey did not get sufficient response from academics to draw any conclusions about
13 their understanding of their role as authors of medical publications. We hope that the full
14 report of the MPIP authorship project will cast more light on this.[18]
15
16
17
18

19 20 **RECOMMENDATIONS**

21
22 While many of our findings are heartening (Fig 1), some indicate a need for further action
23 (Fig 2). We hope that the professional organizations who were involved with this survey (in
24 particular, ISMPP, AMWA, and EMWA) along with pharmaceutical and medical device
25 companies will use the findings to identify topics for future training or discussion. We
26 suggest they might focus on the following areas.
27
28
29

- 30
31
32 • Although many companies and agencies had publication policies, it is disappointing
33 that so few of these policies were made public. We encourage companies to post their
34 publication policies on their websites. Companies might also consider publishing the
35 results of publication audits to indicate how closely they comply with guidelines (for
36 example, what proportion of clinical trials are published) and to help identify
37 obstacles to compliance.
38
39
- 40
41
42 • While our survey suggests that most pharmaceutical companies and agencies have a
43 code of conduct and provide mandatory training on responsible publication practices
44 to relevant staff, this is not always the case, and there is room for improvement,
45 especially for those that sub-contract work to freelancers. We therefore recommend
46 that companies, agencies, and professional groups (such as ISMPP, EMWA, and
47 AMWA) put renewed effort into ensuring that all publication professionals receive
48
49
50
51
52
53
54

1
2
3
4
5
6
7 effective training. Freelancers should be accountable for their own training, or ensure
8 they receive sufficient training from their customers. We also recommend that
9 individuals involved less directly in publications should be made aware of the relevant
10 guidelines.
11
12
13

- 14 • Although pharmaceutical companies generally provide invited authors with study
15 reports and protocols, this was not universal. Named authors should always have
16 access to study results to ensure they can understand and interpret the findings.
17
18
- 19 • The reported requests from authors or companies for agency staff to do something
20 that the publication professionals considered unethical warrants further investigation.
21
22 Our survey did not ask about reporting mechanisms for perceived unethical practices,
23 or how strongly these are communicated and used. We encourage agencies to develop
24 systems for handling such situations. Further education of authors and industry staff,
25 particularly those who are not familiar with the stringency of current guidelines,
26 should help reduce such requests.
27
28
- 29 • The number of freelancers responding to the survey was small (<50), but some of
30 their responses suggested differences from publication professionals working in
31 companies. We therefore hope a similar survey might be undertaken focusing on the
32 needs of this community and their publication practices to better understand areas
33 where they may need support.
34
35
36
37
38
39
40
41
42
43
44

45 These suggested actions focus primarily on pharmaceutical companies and communications
46 agencies. However, clinical trials and their publication involve many players, and other
47 surveys suggest that both healthcare professionals (investigators and academics) and journal
48 editors would benefit from greater knowledge of published guidelines and may, in fact, be
49 less familiar with such guidelines than publication professionals. Given the financial and
50
51
52
53
54

1
2
3
4
5
6
7 human resources required to ensure timely, accurate, and complete reporting of research
8 results,[28] it is likely that the demand for, and use of, publication professionals will increase.
9
10 Our survey findings indicate that further involvement of knowledgeable and experienced
11 medical publication professionals, who are familiar with guidelines on reporting clinical trials
12 and publication ethics, should be viewed as a positive step in achieving timely and reliable
13 reporting. Our survey findings also complement evidence which shows that manuscripts
14 prepared with professional writing or editing support are more likely to comply with
15 reporting requirements,[29] less likely to be retracted for misconduct,[5] and are accepted for
16 publication more quickly,[30] than those prepared without such support.
17
18
19
20
21
22
23
24
25

26 Authorship of research publications is not straightforward and the ICMJE criteria have
27 recently been revised. Our survey did not examine views on existing criteria or problems with
28 their implementation, although others have done so.[31, 32] We are aware of current
29 initiatives aimed at deepening understanding and developing consensus around authorship
30 and the transparency of contributions and we welcome these. We would also welcome
31 surveys that test how well non-industry authors and editors comply with voluntary guidelines
32 issued by their professional associations and how such compliance is checked.
33
34
35
36
37
38
39
40

41 **CONCLUSIONS**

42
43 Despite criticism that most publication guidelines are voluntary, our survey suggests that the
44 major guidelines are widely known and implemented by publication professionals working in
45 pharmaceutical and medical device companies, communication agencies, CROs, and as
46 freelancers. Many companies enforce these guidelines through policies, codes of conduct,
47 standard operating procedures, and audits. For companies operating under a CIA, many of the
48 GPP and ICMJE recommendations are mandated and audited by the Office of the Inspector
49
50
51
52
53
54

1
2
3
4
5
6
7 General via independent auditors. When the GPP guidelines were first developed (in the late
8 1990s), publication audits were unheard of, yet many companies now regularly audit their
9 practices against guidelines such as GPP2, and CIAs mean that many of the GPP
10 recommendations are now legally enforced and monitored.
11
12
13
14

15
16 While there is no room for complacency, and we make no claim that all problems with the
17 publication of industry-funded research have disappeared, this survey, taken together with
18 others showing improved acknowledgement of medical writers, and reductions in guest
19 authorship, suggest that guidelines such as GPP (published in 2003) and GPP2 (2010) have
20 had a definite, positive effect on publication practices and that most companies and individual
21 publication professionals are striving to do the right thing.
22
23
24
25
26
27
28

29 **Acknowledgements**

30 We thank the organizations and individuals that helped publicise and execute the survey, in
31 particular Mike Smith (Alphabiocom) and Fiona Steinkamp (NovoNordisk). We also thank
32 Dr Serina Stretton (ProScribe Medical Communications) for her assistance with the figures.
33
34
35
36
37
38
39
40

41 **Contributions**

42 All authors were involved in developing the questionnaire and analysing or interpreting the
43 data. All authors reviewed the manuscript and discussed it critically over several revisions,
44 and agreed to submit it for publication. In addition, EW wrote the first draft of the paper, JF
45 was responsible for data management and analysis, and KW presented initial findings at the
46 2013 ISMPP meeting and prepared the figures.
47
48
49
50
51
52
53
54
55

Competing interests

EW is an author of the original GPP guidelines, the anti-ghostwriting checklist, the EMWA guidelines on the role of medical writers in publications, and several COPE guidelines. She works as a freelance publications consultant and has provided training to many pharmaceutical companies and communication agencies and receives fees and expenses for talks and workshops on publication guidelines.

KW conducts and publishes research on ethical medical writing practices. She is actively involved in not-for-profit associations that advocate for ethical publication practices. She is paid to provide ethical medical writing training courses and services for not-for-profit and for-profit clients, particularly in the Asia-Pacific region.

AC has served on the ISMPP Certification Board of Trustees.

ST is the chair of the ISMPP Advocacy and Outreach Committee.

AC, VA, TG and ST are employed by a medical communications company that provides publications services to authors and industry sponsors.

JG is on the Board of Trustees of ISMPP and is a steering committee member of the MPIP (Medical Publications Insights and Practices) Initiative.

JG and TG are/were employees of AstraZeneca and own shares in the company.

JF is an employee of TGaS Advisors, a division of the KnowledgePoint360 Group.

All authors (except JF) are members of ISMPP. None of the authors received any specific remuneration for working on this project.

Funding

Funding for the incentive prizes was provided by ISMPP. Data collection and analysis was provided (free of charge) by KnowledgePoint360 via TGaS Advisors.

Data sharing statement

The full questionnaire and raw data aggregated by sector (industry, agency, freelance) are available at ~~XXX~~ <http://www.ismpp.org/gps-raw-data>

1
2
3
4
5
6
7 **Figure legends:**

Formatted: Font: Bold

8 Fig 1. Percentage of survey respondents from industry and agency groups responding 'yes' to
9 selected questions.

10
11
12
13
14 Fig 2. Percentage of survey respondents from industry and agency groups responding 'yes' to
15 selected questions. (Asterisks indicate that question was only relevant to one group.)
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Sismondo S. Ghosts in the machine: publication planning in the medical sciences. *Social Studies of Science* 2009;**39**:171.
2. Fugh-Berman A. The haunting of medical journals: how ghostwriting sold "HRT". *PLoS ONE* 2010;**7**(9):e1000335.
3. WAME Policy Statement: Ghost writing initiated by commercial companies. <http://www.wame.org/resources/policies#ghost>
4. Jacobs A, Wager E. EMWA guidelines on the role of medical writers in developing peer-reviewed publications. *Curr Med Res Opin* 2005;**21**:317-321.
5. Woolley K, Lew R, Stretton S et al. Lack of involvement of medical writers and the pharmaceutical industry in publications retracted for misconduct: a systematic, controlled, retrospective study. *Current Medical Research & Opinion* 2011;**27**:1175-1182.
6. Kaiser K, Cofield S, Fontaine K et al. Is funding source related to study reporting quality in obesity or nutrition randomized control trials in top-tier medical journals? *Int J Obesity* 2013;**36**:977-981.
7. Smith SM, Wang AT, Katz NP et al. Adverse event assessment, analysis, and reporting in recent published analgesic trials: ACTION systematic review and recommendations. *Pain* 2013;**154**:997-1008.
8. Lundh A, Sismondo S, Lexchin J et al. Industry sponsorship and research outcome. *Cochrane Database Syst Rev* 2012;**12**:MR000033.

- 1
2
3
4
5
6
7 | 9. Als-Nielsen B, Chen W, Gluud C et al. Association of funding and conclusions in
8 randomized drug trials: a reflection of treatment effect or adverse events? JAMA
9 2003;**290**:981-988.
- 10
11
12
13 | 10. Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical
14 companies. Curr Med Research Opinion 2003;**19**:149-154.
- 15
16
17
18 | 11. Graf C, Battisti WP, Bridges D et al. Good publication practice for communicating
19 company sponsored medical research: the GPP2 guidelines. BMJ 2010;**339**:b4330.
- 20
21
22
23 | 12. Norris R, Bowman A, Fagan JM et al. International Society for Medical Publication
24 Professionals (ISMPP) position statement: the role of the professional medical writer.
25 Curr Med Research Opinion 2007;**23**:1837-1840.
- 26
27
28
29 | 13. AMWA Code of Ethics. http://www.amwa.org/amwa_ethics
30 http://www.amwa.org/amwa_ethics.
- 31
32
33
34 | 14. Goldacre B. Bad Pharma. London: Fourth Estate: 2012.
- 35
36
37 | 15. Rodino FJ. Corporate Integrity Agreements. What they say about publications,
38 publication planning, transparency, and ICMJE. Therapeutic Innovation & Regulatory
39 Science 2013;**47**(1):50-56.
- 40
41
42
43 | 16. Laine C, Mulrow CD. Exorcising ghosts and unwelcome guests. Annals of Internal
44 Medicine 2005;**143**:611-612.
- 45
46
47
48 | 17. Gøtzsche PC, Kassirer JP, Woolley KL et al. What should be done to tackle
49 ghostwriting in the medical literature? PLoS Medicine 2009;**6**(2):e1000023.
- 50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 18. Marusic A, Hren D, Bhattacharya A et al. Deciding authorship: survey findings from
8 clinical investigators, journal editors, publication planners, and medical writers. 2013.
9 Chicago. 7th International Congress on Peer Review and Biomedical Publication. 8-9-
10 2013.
11
12
13
14
15 19. Stretton S, Bramich NJ, Keys J et al. Publication misconduct and plagiarism
16 retractions: a systematic, retrospective study. *Curr Med Res Opin* 2012;**28**:1575-1583.
17
18
19
20 20. Wager E, Fiack S, Graf C et al. Science journal editors' views on publication ethics:
21 results on an international survey. *Journal of Medical Ethics* 2009;**35**:348-353.
22
23
24 21. Wong V, Callaham ML. Medical journal editors lacked familiarity with scientific
25 publication issues despite training and regular exposure. *J Clin Epidemiol* 2012;**65**:247-
26 252.
27
28
29
30
31 22. Good Publication Practice: The awareness and views of healthcare professionals.
32 <http://www.epghealthmedia.com/industry-reports/HCP-views-on-GPP/>
33
34
35
36 23. De Faoite D, Bakota B, Staresinic M et al. Awareness, attitudes, and perceptions of
37 Croatian-based orthopedic and trauma surgeons toward scientific manuscripts,
38 publishing internationally and medical writing. Results of an online questionnaire. *Coll*
39 *Antropol* 2013;**1**:165-168.
40
41
42
43
44 24. Jacobs A, Hamilton CW. Decreased evidence of ghostwriting in a 2008 vs 2005
45 survey of medical writers. *The Write Stuff* 2009;**18**(2):118-123.
46
47
48
49 25. Hamilton CW, Jacobs A. Evidence of decreased ghostwriting in a series of three
50 surveys of medical communicators conducted between 2005 and 2011. *AMWA Journal*
51 2012;**27**:115.
52
53
54
55
56
57
58
59
60


- 1
2
3
4
5
6
7 26. Wager E. Publication ethics: the shift from philosophy to compliance. *Regulatory*
8 *Affairs Journal* 2011;(2 Feb 2011):18-19.
9
- 10
11 27. Wislar JS, Flanagin A, Fontanarosa PB et al. Honorary and ghost authorship in high
12 impact biomedical journals: a cross sectional survey. *BMJ* 2011;**343**:d6128.
13
14
- 15
16 28. Woolley KL, Gertel A, Hamilton C et al. Poor compliance with reporting research
17 results -- we know it's a problem ... how do we fix it? *Curr Med Research Opinion*
18 2012;**28**:1857-1860.
19
20
- 21
22 29. Jacobs A. Adherence to the CONSORT guideline in papers written by professional
23 medical writers. *The Write Stuff* 2010;**19**:196-200.
24
25
- 26
27 30. Bailey M. Science editing and its effect on manuscript acceptance time. *AMWA*
28 *Journal* 2011;**26**:147-152.
29
30
- 31
32 31. Pignatelli B, Maisonneuve H, Chapuis F. Authorship ignorance: views of researchers
33 in French clinical settings. *J Med Ethics* 2005;**31**:578-581.
34
35
- 36
37 32. Bhopal R, Rankin J, McColl E et al. The vexed question of authorship: views of
38 researchers in a British medical faculty. *BMJ* 1997;**314**:1009-1012.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



155x61mm (300 x 300 DPI)

Peer review only



161x61mm (300 x 300 DPI)

Peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60